world parkinson congress - cdn.ymaws.com€¦ · national institutes of neurological disorders and...

2 0 0 6 O N S I T E P R O G R A M

A UNIQUE INTERNATIONAL EVENT

BRINGING THE

PARKINSON’S

COMMUNITY

TOGETHER

WORLDPARKINSON

CONGRESS

WORLDPARKINSON

CONGRESS

Organized by the World Parkinson Congress, Inc.

Supported by:

The Movement Disorder Society

The National Institutes of Health

U.S. Army Medical Research Acquisition Activity

Professional and patient voluntary organizations

Congress Dates: February 22-26, 2006

Washington Convention Center • Washington, D.C., USA

ORGANIZATIONAL PARTNERS

The organizers of the Congress wish to thank the following organizations, associations and foundations for endorsing the Congress.

Agrupacion Amigos de Parkinson, ChileAlbanian Society of Neurology, AlbaniaAllliance for Aging Research, USAAmerican Academy of Neurology, USAAmerican Academy of Physical Medicine & Rehabilitation, USAAmerican Association of Neuroscience Nurses, USAAmerican Brain Coalition, USAAmerican Neurological Association, USAAmerican Occupational Therapy Association, USAAmerican Parkinson Disease Association, Inc., USAAmerican Physical Therapy Association, USAAmerican Speech-Language-Hearing Association, USAAsociacion Peruana Para la Enfermedad de Parkinson, PeruAssociation of Physiotherapists in Parkinson’s Disease Europe,

LuxembourgAssociazione Italiana Disordini Del Movimento e Malattia Di

Parkinson, ItalyAtlantic-Euro-Mediterranean Academy of Medical Sciences,

BulgariaAustrian PD Society, AustriaAustrian Society of Neurology, AustriaBelgian Neurological Society, BelgiumBulgarian Neurological Society, BulgariaCroatian Association of Patients with Movement Disorders, CroatiaCyprus Neurological Society, CyprusCyprus Parkinson’s Disease Association, CyprusDallas Area Parkinsonism Society, USADepartment of Veterans Affairs Parkinson’s Disease Research,

Education & Clinical Centers, USAEdmond J. Safra Philanthropic Foundation, USAEstonian Ludvig Puusepp Society of Neurologists and

Neurosurgeons, EstoniaEstonian Parkinson’s Society, EstoniaEuropean Neurological SocietyEuropean Parkinson’s Disease Association, UKFamily Caregiver Alliance/National Center on Caregiving, USAFondazia Parkinsonism, BulgariaFondazione Grigioni per Il Morbo Di Parkinson, ItalyGerman Parkinson’s Society, Germany Georgian International Union of Parkinson’s Disease Patients, GeorgiaHope for a Cure Foundation, USAHouston Area Parkinson Society, USAIsrael Parkinson Association, IsraelIsraeli Neurological Association, IsraelJapan Parkinson’s Disease Association, JapanLithuanian Parkinson’s Disease Society, LithuaniaLSVT Foundation, USAMelvin D. Yahr International Parkinson’s Disease FoundationMichigan Parkinson Foundation, USAMovement Disorders Caring Society of Sweden, SwedenMovers & Shakers, USAMuhammad Ali Parkinson Center, USANational Alliance for Caregiving, USANational Institutes of Neurological Disorders and Stroke-NIH, USANational Parkinson Foundation, USANational VA Parkinson’s Disease Consortium, USA

New Rhythms Foundation, USANortheast Parkinson’s and Caregivers, Inc., USANorthwest Parkinson’s Foundation, USAParkinson Association of Minnesota, USAParkinson Association of Northern California, USAParkinson Association of the Carolinas, USAParkinson Association of the Rockies, USAParkinson Awareness Association of Central Indiana, USAParkinson Education Program of Greater Cleveland, USAParkinson Foundation of the Heartland, USAParkinson Foundation of the National Capital Area, USAParkinson Patiënten Verenging, The NetherlandsParkinson Pipeline Project, USAParkinson Society of British Columbia, CanadaParkinson Society of Canada, CanadaParkinson Society of Ottawa, CanadaParkinson Study Group, USA/CanadaParkinson’s Action Network, USAParkinson’s Association of Louisiana, USAParkinson’s Disease and Movement Disorder Society, IndiaParkinson’s Disease Foundation, USAParkinson’s Disease Society, UKParkinson’s Resources of Oregon, USAParkinson’s Society of Alberta, CanadaParkinson’s Society of New Zealand, New ZealandParkinson’s Society of Southern Alberta, CanadaParkinson’s Victoria, Inc., AustraliaPeople Living With Parkinson’s, USAPortuguese Neurological Society, PortugalSlovenian PD Society, SloveniaSociedad Latino Americana de Movimentos Anormales, PeruSociété Française de Neurologie, FranceSociété Luxembourgeoise De Neurologie, LuxembourgSociety of Hungarian Neurologists and Psychiatrists, HungarySoutheast Parkinson Disease Association, USASwedish Parkinson’s Disease Association, SwedenSwiss Parkinson Association, SwitzerlandTaiwan Neurological Society, TaiwanTaiwan Parkinson Association, TaiwanTake Charge! Cure Parkinson, Inc., USAThe Cure Parkinson’s Trust, UKThe Michael J. Fox Foundation for Parkinson’s Research, USAThe Movement Disorder SocietyThe Parkinson Alliance, USAThe Parkinson’s Institute, USAThe Swedish Neurological Society, SwedenTurkish Neurological Society, TurkeyVictoria Epilepsy & Parkinson’s Centre, CanadaWE MOVE, USAWorld Federation of NeurologyWorld Federation of Neurology Research Group on

Parkinsonism and Related DisordersWorld Federation of Neuroscience NursesYoung Onset Parkinson’s Association, USAYoung Parkinson’s of Indiana, USA

3

Welcome Addresses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

General Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

Registration Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

Media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Speaker Ready Room. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

First Aid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Transportation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

Tour Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

Medical History Exhibit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

Creativity and Parkinson’s Exhibit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

Renewal Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

CME/CEU Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

Program

Wednesday, February 22, Educational Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

Opening Ceremony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

Welcome Reception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

How to Read Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Thursday, February 23, Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Friday, February 24, Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Saturday, February 25, Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

Sunday, February 26, Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44

Guided Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52

Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68

Exhibitor Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72

Exhibitor Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81

Convention Center Map. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82

Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

TABLE OF CONTENTS

4

Dear Attendees:

On behalf of the Steering Committee, I would like to take this opportunity to welcomeyou to the first World Parkinson Congress and to Washington, D.C.

The Congress brings together leading researchers and clinicians in the field ofParkinson’s disease, allied health professionals and especially those who suffer fromParkinson’s and their caregivers. People from around the world who affect and areaffected by this disease are joining together and sharing the latest availableinformation in order to help us move more quickly towards better treatment options,and ultimately a cure for Parkinson’s. The Program Committee has organized a variedand extensive program. There is something of interest for all attendees at all timesduring the Congress. It is truly an event like no other.

Be sure to see the exhibit on the history of Parkinson’s, join a tour of the scientificposter presentations, take in the exhibition of art created by people with Parkinson’sand be sure to visit the Exhibit Hall for products that serve the needs of Parkinsonpatients and their support team.

The World Parkinson Congress is the first event of this design and magnitude to beoffered anywhere in the world. We hope, at its conclusion, that we will have created astronger, closer community and a better understanding of this disease and thetreatment options available as we move closer to a cure.

Sincerely,

Stanley Fahn, M.D.Chair, Steering Committee

WELCOME

5

Dear Attendees:

It has been a remarkable process that led to the creation of the first WorldParkinson Congress. The Program Committee, comprised of a stellar group ofindividuals, undertook a bold mission to construct a vibrant and rigorous programthat would appeal to patients, caregivers, clinicians, allied health professionals andscientists. We sought to attract the best people from the international community toshare their knowledge and experience with our attendees. We intended the WPC tobe a forum for information exchange across disciplines and interests. Through theefforts of many, we have arrived at the current program. I hope it meets yourindividual needs.

We organized each day by theme and endeavored to maximize opportunity for cross-fertilization amongst participants by varying program elements. We cast eachmorning and late afternoon plenary session with the goal of appealing to allparticipants. The remainder of each day is structured to address specific interests.Moreover, we programmed different formats (symposia, community sessions andinteractive workshops) in the hope of bringing the presenters and audience togetherin the most optimal manner. Lastly, we sought to include other interesting featuresreflecting on historical and cultural aspects of Parkinson’s disease.

The success of the WPC depends on your participation. I anticipate meeting many ofyou during the meeting and welcome your feedback.

Most importantly, I extend my personal welcome to all participants of this unique event.

Sincerely,

Howard Federoff, M.D., Ph.D.Chair, Program Committee

WELCOME

6

Dear Attendees:

I am pleased to welcome you to the World Parkinson Congress on behalf of theNational Institutes of Health (NIH). By your participation in this historic event—aninternational exchange that will allow us to share the latest scientific findings,consolidate information about treatment and care and spark new ideas for futureresearch—you are contributing to the collective knowledge of Parkinson’s disease. The partnerships forged at this conference will go far toward ensuring that the global dialogue initiated this week will continue for years to come.

The NIH has a long-standing research interest in Parkinson’s disease, and wewelcome the opportunity for information sharing and collaboration that thisinternational forum provides. We remain firm in our commitment to fund a broadspectrum of research to understand the biology of the disease, explore the role ofgenetics and environmental factors and investigate a variety of promising therapies.Through a multifaceted approach of basic, translational and clinical research, we aimto find ways to prevent, treat and cure Parkinson’s disease and improve the quality oflife for patients and their caregivers.

May you come away from the World Parkinson Congress with a renewed sense ofhope and purpose, and valuable partnerships in the fight against Parkinson’s disease.

Elias A. Zerhouni, M.D.Director, National Institutes of Health

WELCOME

7

Steering Committee

Stanley Fahn, M.D. (Chair)Mary Baker, M.B.E.Judith Blazer, M.S. Donald Calne, M.D.Katherine Clarence-Smith, M.D.Amy Comstock, Esq.Ariel Deutch, Ph.D.Robin Elliott Marian EmrHoward Federoff, M.D., Ph.D.Ruth Hagestuen, R.N.Franz Hefti, Ph.D.J. William Langston, M.D.Andrew Lees, M.D. Yoshikuni Mizuno, M.D.Diane Murphy, Ph.D.C. Warren Olanow, M.D.Gianni Pezzoli, M.D.Ira Shoulson, M.D.G. Frederick Wooten, M.D.

CommunicationCommittee

Marian Emr (Chair)Robin ElliottChristiana EversBen KirbyMichelle Schwartz

Finance Committee

C. Warren Olanow, M.D. (Chair)Robert Burke, M.D.Werner Poewe, M.D.Matthew Stern, M.D.

Audit Committee

Amy Comstock, Esq. (Chair)Patric DonaghueJose Garcia-Pedrosa, Esq.

Industry AdvisoryCommittee

Chris Fibiger, Ph.D. (Chair)Stephen Grate, D.V.M.Eric Siemers, M.D.

Program Committee --Science & Research

Howard Federoff, M.D., Ph.D. (Chair)M. Flint Beal, M.D.Nancy Bonini, Ph.D.Robert Burke, M.D.Ted Dawson, M.D., Ph.D.Ariel Deutch, Ph.D.Col. Karl Friedl, Ph.D.Ruth Hagestuen, R.N. Peter Heutink, Ph.D.Etienne Hirsch, Ph.D.Russell Katz, M.D.Annette Kirshner, Ph.D.Cindy Lawler, Ph.D.Col. Brian Lukey, Ph.D.Ronald McKay, Ph.D.Yoshikuni Mizuno, M.D.Diane Murphy, Ph.D.C. Warren Olanow, M.D.Tony Phelps, Ph.D.Serge Przedborski, M.D., Ph.D.Ira Shoulson, M.D.

Program Subcommittee -- CareDelivery & Quality of Life

Ruth Hagestuen, R.N. (Chair)Mary Baker, M.B.E.Judith Blazer, M.S.Alba Bonetti, R.N.Julie Carter, R.N.Alessandro Di Rocco, M.D.Howard Federoff, M.D., Ph.D.Leslie Findley, Ph.D.Oscar Gershanik, M.D.Nir Giladi, M.D.Gladys González-Ramos, Ph.D.Peter Hagell, R.N., Ph.D.Robert Iansek, Ph.D., FRACPAllan Kroland, D.C.Zvezdan Pirtosek, M.D., Ph.D.Lisa Shulman, M.D.Sharon Stone

Organization andGovernmental RelationsCommittee

Judith Blazer, M.S. (Chair)Amy Comstock, Esq.Robin Elliott

Program Subcommittee -- Creativity& Parkinson’s

Oliver Sacks, M.D. (Honorary Chair)Sharon Stone (Chair)David AignerMary Baker, M.B.E.Karyn Boyar, R.N.Lucien Cote, M.D.Steven Frucht, M.D.Lizzie GrahamRuth Hagestuen, R.N.Marti Haykin, M.D.David Hardesty, M.D.Sharon KleinIsobel Robins KoneckyArlene LevineAnn LoebMarshall LoebSheree Loftus, Ph.D.Melanie MaarLaura Marsh, M.D.Michael Pourfar, M.D.Elizabeth SchaafMichele TorrecillaBonnie WangJane Baum WachslerPeggy Willocks

Scholarship Committee --Junior Scholar Awards

Lisa Schulman, M.D. (Chair)Robert Burke, M.D. Ted Dawson, M.D., Ph.D.Michael Zigmond, M.D.Alesandro Di Rocco, M.D.

Scholarship Committee --People with Parkinson’s

Ruth Hagestuen, R.N. (Chair)Adolpho DiazSharon MetzSharon StoneMichele Torrecilla

COMMITTEES

8

Congress Venue

The three-year-old Convention Center in Washington, D.C., is host to the first World Parkinson Congress. Conveniently located near theMt. Vernon Square Metro (subway) stop, the Convention Center sits between the historic Shaw/U Street district and the revitalizeddistrict of downtown Washington, D.C. A short distance to the National Mall and within walking distance of shopping, museums andrestaurants, the Convention Center provides a convenient location to enjoy all that Washington, D.C. has to offer.

Registration Information

Registration for the Congress will take place in the L Street Bridge. This can be found by entering the Washington Convention Centerfrom the Mount Vernon Place entrance and proceeding through the Grand Lobby and up the escalators.

Registration Times:Tuesday, February 21 4:00 p.m.–7:00 p.m.Wednesday, February 22 7:00 a.m.–8:00 p.m.Thursday, February 23 8:00 a.m.–5:00 p.m.Friday, February 24 8:00 a.m.–5:00 p.m.Saturday, February 25 8:00 a.m.–5:00 p.m.Sunday, February 26 8:00 a.m.–1:00 p.m.

Audio Recordings

Audio Recordings of various courses will be available for purchase during the conference. The sales desk is located near the registrationarea. Following the conference, CDs will be available on www.aven.com.

Smoking Policy

The Convention Center is a non-smoking facility.

Congress Language

The official language of the Congress is English.

Name Badges

Color coding will designate each attendee group as follows:Medical Professionals………………………………………………….BluePatients, Caregivers, Media and Others………………….RedExhibitors………………………………………………………………………..Black

Certificate of Attendance

Certificates of Attendance will be available at the registration counters on the L Street Bridge.

Abstract Volume

Poster presentations have been published in an abstract supplement to the Movement Disorders journal. Each delegate should havereceived one copy with their registration materials. Members of The Movement Disorder Society received a copy with their Januaryissue of the journal.

Abstracts-On-Disk

All abstracts published in the supplement to the Movement Disorders journal are available on disk by Abstracts2View and have beenplaced in Congress bags.

GENERAL INFORMATION

9

GENERAL INFORMATION

Internet Service Center (Exhibit Hall D)

Ten kiosks with Internet access are available for use by the Congress attendees. They are located in Hall D and are open duringCongress hours.

Media (Room 302)

All members of the media assigned to cover the Congress must have pre-registered or register as soon as they arrive at theConvention Center. Members of the media will be clearly identified by name badges and are subject to the same rules and regulations asall other Congress attendees.

The media room will be open daily. Only credentialed and registered media are allowed in the media room at any time.

Press Briefings (Room 301)

Check the media room for press briefing times.

Photography and Videotaping

All photography and videotaping is strictly prohibited at the Congress without prior permission.

Speaker Ready Room (Room 204A)

All speakers and chairs for the Congress will be admitted to the speaker ready room. In the room, speakers will find a phone, Internetaccess, a computer and an LCD projector to prepare for each presentation. The room will be available each day of the Congress from8:00 a.m. to 6:00 p.m.

Kiosks for Snacks and Beverages

Breakfast items are available for sale at two places in the Convention Center: Starbucks in the Grand Lobby has pastries and coffee andFoggy Bottom restaurant also serves breakfast items on the 2nd level outside Exhibit Hall D.

Lunch will be available for purchase at Foggy Bottom, Wolfgang Puck and Quizno’s. Restaurants are on the 2nd level outside Exhibit Hall D.

Cloakroom

The coat and baggage check will be available on the L Street Bridge, across from the registration area.

First Aid

If a situation arises where first aid is needed, please see the registration desk for further assistance.

Parking

Parking in garages near the Convention Center is available on a first-come, first-served basis. If driving, exhibitors and attendees areencouraged to use the public parking facilities. For a more detailed map of area garages, please seewww.dcconvention.com/directions/parking.asp. There also are six handicap spaces located on the 9th Street side of the building.

Americans with Disabilities Act

If you have requirements that meet the regulations of the Americans with Disabilities Act, please notify a WPC staff member orvolunteer for assistance.

10

Transportation/Shuttle Service

Public TransportationEfficient and easy to use, the Metrorail system provides quick and easy access to the DC metropolitan area. Base fare is $1.35 per tripand increases during rush hour and for longer trips. Rail farecards can be purchased at vending machines located outside theturnstiles. For more information call (202) 637-7000 or go to www.wmata.com.

Hotel Shuttle InformationThe World Parkinson Congress will provide complimentary shuttle bus service between conference hotels and the WashingtonConvention Center during the Congress dates. The shuttle bus is available to guests staying in the official WPC hotels.

TaxisTaxi stands are located outside the Washington Convention Center at the Mount Vernon Place entrance.

Tours

USA Hosts is the tour company chosen by WPC for local tours of Washington, D.C. A tour desk will be available on the L Street Bridge.

Welcome to Washington TourThursday, February 23, 20069:30 a.m.–12:30 p.m.

U.S. Holocaust Museum TourThursday, February 23, 20061:00 p.m.–4:00 p.m.

Illuminated DC (at night) TourThursday, February 23, 20067:30 p.m.–10:30 p.m.

Inside the Smithsonian TourFriday, February 24, 20061:00 p.m.–4:00 p.m.

Illuminated DC (at night) TourFriday, February 24, 20067:30 p.m.–10:30 p.m.

Welcome to Washington TourSaturday, February 25, 20069:30 a.m.–12:30 p.m.

Magnificent Mansions TourSaturday, February 25, 20061:00 p.m.–4:00 p.m.

GENERAL INFORMATION

11

GENERAL INFORMATION

Guided Poster Tours

Guided Poster Tours will be available throughout the Congress.Tours will begin at 6:00 p.m. on the below dates during the listedhours.

Thursday, February 23 6:00 p.m.–7:30 p.m.Friday, February 24 6:00 p.m.–7:30 p.m.Saturday, February 25 6:00 p.m.–7:30 p.m.

For more information see program section.

Poster PresentationsAbstracts with even-numbered publication numbers will berepresented on Thursday and Saturday from 12:00 p.m.–2:00 p.m. Abstracts with odd-numbered publication numbers will be represented on Friday and Sunday also from 12:00 p.m.–2:00 p.m.

Evaluations

Please take time to complete the evaluation form provided foreach session you attend. Your input and comments are essentialin planning future educational programs for the WPC.

Exhibition Location: Hall D

Please allow adequate time in your daily schedule to visit theexhibitors located in Hall D of the Convention Center. The exhibitionis an integral component of your WPC experience, offering you theopportunity to speak with representatives of companies thatprovide services and market products directly related toParkinson’s disease. Representatives will be available to discussthese services and products during the following hours:

Wednesday, February 22 7:30 p.m.–9:00 p.m.

Thursday, February 23 11:00 a.m.–2:00 p.m. &4:00 p.m.–7:00 p.m.

Friday, February 24 11:00 a.m.–2:00 p.m. &4:00 p.m.–7:00 p.m.

Saturday, February 25 11:00 a.m.–2:00 p.m. &4:00 p.m.–7:00 p.m.

12

Creativity and Parkinson’s

Creativity and Parkinson’s, a museum-quality exhibition of artwork created by persons living with PD, willshowcase art selections from 14 countries throughout the world. “Meet-the-artist” tours — nightly from6:00 p.m.–7:30 p.m., performances (a schedule will be posted at the exhibition site) and demonstrationsduring the Congress, will offer opportunities to peek into the dynamic and important role that thecreative process plays in personal expression and quality of life. Artists will talk about the creativeprocess, their own work and how Parkinson’s impacts their creativity as well as how creativity impactstheir Parkinson’s.

As Dr. Oliver Sacks, the Honorary Chair of theCreativity and Parkinson’s Committee, has written:“…knowing that they can be ‘liberated’, if only for awhile, and respond to music, or perform it, or act, orpaint, and in so doing reclaim, for a while, theirhealthy selves, their powers, is itself profoundlyencouraging and therapeutic for patients withparkinsonism.”

Many will come to this exhibition out of curiosity orsupport for one of the artists. We believe that mostwill leave this exhibition with a renewed awe of thehuman spirit and perhaps a renewed respect for therole that creativity plays in dealing with Parkinson’s

head on. We hope you too will experience the awakening of the spirit and share this renewal with yourcolleagues, loved ones and friends. We believe that this exhibition will not only be enjoyed by those whoview it but will provide fuel for further investigation into the creative process and its relationship withindividuals who are coping with Parkinson’s.

The Creativity and Parkinson’s exhibition is supported by: VSA arts who have generously contributed thewalls and display cases for the History as well as the Creativity and Parkinson’s exhibition; unrestrictededucational and personal grants from: The Medtronic Foundation, GlaxoSmithKline, Society forNeuroscience, The Mary Duke Biddle Foundation, the Takako Asakawa Richards & Paul RichardsFoundation, the National Parkinson Foundation and Bob and Jane Wachsler; in-kind contributions fromthe volunteer members of the Creativity and Parkinson’s Committee; and is underwritten and managedby the Parkinson’s Disease Foundation, Inc.

Medical Historical Exhibition

A Short History of Parkinson’s Disease—A Historical Overview of Major Achievements in Therapy, presents acomprehensive history of Parkinson’s disease, honors major therapeutic contributions and puts new light on theevolution of treatment substances linking the researchers and developers behind these advances. The exhibitionwill be open daily and will present a unique collection of artifacts and medical historical documents.

Visitors will be guided through the exhibition along six thematic fields.

The exhibition is also devoted to stimulate scientific discussion and should help tocomplete the knowledge about Parkinson’s disease and its treatment strategies.

This exhibit is supported by: MERZ, NeuroBiotec, F. Hoffman La Roche, SchwarzPharma and VSA arts.

CREATIVITY AND PARKINSON’S

Elena TueroFreehold, NJ, USA

Bill BakerWoking, England

Anneliese SchmitzBalve, Germany

13

Renewal Room (Room 205)

Restore and revitalize yourself at the free soul-nurturing RENEWAL ROOM. Drop in to nourish mind, body and spirit with a variety ofprograms focused on the sharing of engaging experiences, providing enrichment, entertainment, fun and fulfillment. Rejuvenate withyoga, meditation, singing, dancing, drumming, movement, stories, laughter and more!

Thursday, February 23 10:00 a.m.–10:45a.m. Yoga – Mobility & Tranquility – Experience calming, stabilizing effects of yoga through breath-work and

meditation, Melanie Maar11:00 a.m.–11:45 a.m. Imagine Your Perfect Self – Guided imagery with music, an emotional and spiritual meditation, Nancy Hahn12:00 p.m.–12:45 pm. Tremble Clefs – Therapeutic group singing for people with Parkinson’s disease, Karen Hesley1:00 p.m.–1:45 p.m. What’s a Joint Like You Doing in a Place Like This? – Playing with joints, movement & vocal expression,

Pnina Isseroff 2:00 p.m.–2:45 p.m. Rhythmic Release & Renewal – Experience healthy heart beats with drum beats, Heather Mac Tavish, Lori

Fithian, Nancy Hahn3:00 p.m.–3:45 p.m. PD & the Art of Moving – Flexibility, strength, balance, coordination and speech exercises, John Argue 3:55 p.m.–4:15 p.m. On Your Mark, Get Set, Goal! – Goal-setting for the WPC & beyond, John Ball

Friday, February 247:45 a.m.–8:15 a.m. Walk and Roll – Work in a work out with the captain of Team Parkinson, John Ball10:00 a.m.–10:45a.m. Yoga – Mobility & Tranquility – Increase strength, flexibility and mobility of the body, Melanie Maar11:00 a.m.–11:45 a.m. Motivating Moves – Exercise to an award-winning video, Janet Hamburg 12:00 p.m.–12:45 pm. Awkward Dancer, Awesome Singer – Original songs, inspiration & fun, Charlie Nimovitz 1:00 p.m.–1:45 p.m. Drumming, Dopamine & Delight – Participate in a drum circle (instruments provided), Barry Wakefield &

Paul Bennett 2:00 p.m.–2:45 p.m. Artplay – Gymnastics for the Brain – Art therapist sparks synapses with art, Gail Edwards3:00 p.m.–3:45 p.m. A Session with the Wowee PT of PD – Everyday habits of movement & alignment, Marilyn Basham, RPT

Parkinson Institute 3:55 p.m.–4:15 p.m. Be Scene & Heard on Film & Radio – Share your story & spirit with a neurologist & professional

interviewer, (by appointment only), Samay Jain, M.D. & Susan Epps

Saturday, February 257:45 a.m.–8:15 a.m. Walk and Roll – Work in a work out with the captain of Team Parkinson, John Ball 10:00 a.m.–10:45a.m. Special Guest11:00 a.m.–11:45 a.m. Sound Bytes – Speak your truth with radio interviewer, Susan Epps12:00 p.m.–12:45 pm. Talk About Shaking a Leg! – Let’s all laugh about PD, Lucy Roucis1:00 p.m.–1:45 p.m. Community Collaboration – A community brain-storming session: creative solutions to practical PD

problems, Marilyn Basham, RPT, Nancy Hahn, Heather Mac Tavish, and guests2:00 p.m.–2:45 p.m. Beating Out the Dol-drums – Stuart Needle3:00 p.m.–3:45 p.m. Grace Notes – Singing, interwoven with guided imagery and musical accompaniments, Grace Griffith &

Charlie Nimovitz

Sunday, February 267:45 a.m.–8:15 a.m. Walk and Roll – Work in a work out with the captain of Team Parkinson, John Ball 10:00 a.m.–10:45a.m. Qi – Gong of the Seven Lotus – Enhance your personal energy, Pnina Isseroff 11:00 a.m.–11:45 a.m. Create Your Own Drum~Story~Song – Learn how to create a Drum~Story~Song using songs from all

cultures and countries, Heather Mac Tavish , Nancy Hahn and Koaru Sasaki 12:00 p.m.–12:45 pm. Ping Pong Proscribes Parkinson’s – Practice eye-hand coordination and fine motor skills. Have fun with

percussive ping pong!, Danny Newman 2:00 p.m.–4:00 p.m. Rally with the Rhythm; Beat on the Drum; Revel in the Fun to Come!, Jonathan Murray, Ken Crampton,

Jaqui MacMillan, Cheryl Wu, Lori Fithian, Kaoru Sasaki, Elizabeth Mitchell, Katy Gaughan, Nellie Hill, BarryWakefield, Paul Bennett, Mark Barkman and Ann O’Neill

The organizers of the Congress thank Heather MacTavish, Nancy Hahn, Jonathan Murray and the volunteers of New Rhythms Foundationfor organizing the Renewal Room. Without their time and effort this unique component of the Congress would not be possible.

RENEWAL ROOM

14

CME/CEU CREDITS

Continuing Medical Education/ContinuingEducational Unit Learning Objectives

As a result of participating in this Congress, the attendee should be betterable to:

1. Discuss the role of genetics and environment as Parkinson’s disease(PD) risk factors;

2. Describe the cell biological, neurochemical, neuropathological andneurophysiological aspects of PD;

3. Identify the contributions of inflammation, protein mishandling andoxidative injury in the pathogenesis of PD;

4. List the spectrum of diseases within which PD fits;

5. List the distinguishing features of PD from Parkinson Plus disorders;

6. Explain conventional medical approaches to the treatment of allstages of PD;

7. Describe surgical approaches and the patients most suitable forthese treatment options;

8. List the non-motor features of PD and their treatment options;

9. Discuss the role of non-pharmacologic, complementary andalternative approaches in the care of PD patients;

10. Explain the complications of medical therapy and approaches to theirmanagement;

11. Discuss the impact of parkinsonism on disability and quality-of-life;

12. Describe the relationship between public policy and health caredelivery;

13. Discuss the various national and international models ofinterdisciplinary team care for persons affected by PD;

14. Discuss the bio-psychosocial changes experienced by persons with PDand caregivers from early diagnosis to advanced stages and end of life;

15. Articulate and understand the role of allied health professionals(occupational, speech and physical therapists as well as nutritionists,mental health experts and social workers) and treatment provided bysuch professionals in the care of those living with PD;

16. Describe the neuro-psychiatric and cognitive changes in PD;

17. Articulate and understand the multiple stressors experienced byfamily caregivers and the ways to provide care and support for this population;

18. Describe the unique role of the R.N. in care and treatment of PD.

15

CME/CEU CREDITS

Target Audience

The target audience of the first World Parkinson Congress includes clinicians, researchers, post-doctoral fellows, allied health professionals,students, caregivers and people with Parkinson’s disease who have an interest in the current research and approaches for the diagnosis andbest care practices of Parkinson’s disease.

Availability of Continuing Medical Education (CME) Credit

The Scientific Program of the first World Parkinson Congress has been reviewed and approved for category 1 credit toward the AmericanMedical Association (AMA) Physician’s Recognition Award.

The Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians. The Movement DisorderSociety designates this educational activity for a maximum of 33 AMA PRA Category 1 CreditsTM. Physicians should only claim creditcommensurate with the extent of their participation in the activity. One credit may be claimed for each hour of participation.

Please see the CME request form in your Congress bag for sessions eligible for CME.

Availability of Continuing Education Units (CEU) Credit

The Congress intends to offer CEU credit to attendees. Details on which professions will have CEU credit offered will be announced prior tothe Congress.

AANNThe American Association of Neuroscience Nurses is accredited as a provider of continuing nursing education credits by the AmericanNurses Credentialing Center’s Commission on Accreditation. The AANN will offer a maximum of 32.8 credits. Attendees should only claimcredits commensurate with the extent of their participation.

Requesting CME/CEU Credit Certificates

In order to receive a CME or CEU certificate authenticating participation in the education activity, Congress participants must complete andsubmit a CME or CEU request form following their participation in the Congress. Completed CME and CEU request forms should be handedto meeting room attendants along with completed evaluation forms.

Alternatively, completed forms can be returned to the CME/CEU desk situated near the registration desk or placed in one of the drop boxeslocated throughout the second floor of the Convention Center. Participants can find CME and CEU request forms for the Congress in theirregistration bags. Participants should pick up their bags at the time of registration. Additional CME and CEU request forms can be obtainedfrom the CME/CEU desk near the registration desk.

16

Faculty Financial Disclosure Information

The World Parkinson Congress aims to ensure balance, independence, objectivity and scientific rigor in all educational activities. To ensurethis, all planning committee and faculty members participating in any WPC activity are required to disclose to the audience all relevantfinancial relationships with any commercial interest. Relevant relationships are defined as financial relationships in any amount occurringwithin the past 12 months. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers or othercorporations whose products or services are related to the subject matter of this Congress.

This disclosure will be provided to all participants prior to the beginning of the activity. The intent of this policy is not to prevent a speaker witha potential conflict of interest from making a presentation; it is merely intended that any potential conflict should be identified and resolvedprior to the activity. Failure by any faculty or planning committee member to disclose all such relationships will result in their inability toparticipate in the activity.

Please see the insert in your Congress registration bag for complete information regarding faculty disclosure of commercial relationships.

Faculty Disclosure of Unlabeled Product/Device Use Discussion

Presentations which provide information in whole or in part related to non-approved uses for drug products and/or devices must clearlyacknowledge the unlabeled indications or the investigative nature of their proposed uses to the audience. Speakers who plan to discuss non-approved uses for commercial products and/or devices must advise the Congress audience of their intent.

Please see the insert in your Congress registration bag for complete information regarding faculty disclosure of unlabeled product/device use discussion.

CME/CEU CREDITS

17

7:00 a.m.–8:00 p.m. Registration on L Street Bridge

8:00 a.m.–4:00 p.m. Set-up for Vendors

8:30 a.m.–6:15 p.m. Educational Sessions

Educational Sessions will provide the latest information regarding research and treatment options for Parkinson’s disease. Admission to these sessions will be by delegate name badge; no tickets will be required.

Educational Sessions are supported through unrestricted educational grants from: Boehringer Ingelheim,Novartis Pharma AG/Orion Pharma; Schwarz Pharma; Kyowa Pharmaceuticals Inc.; GlaxoSmithKline; Teva Neuroscience, Eisai, Teva Pharmaceutical Industries Ltd., Lundbeck; and Valeant Pharmaceuticals.

8:30 a.m.–9:30 a.m. Novel Perspectives on Adjunctive Therapies in Parkinson’s Disease . . . . Ballroom B

Chair: Wolfgang Oertel (Germany)

Novel Perspectives on the Use of Tolcapone – C. Warren Olanow (USA)Novel Delivery of Selegiline – Ray Watts (USA)PanelSupported through an unrestricted education grant from Valeant Pharmaceuticals International.

9:45 a.m.–10:45 a.m. MAO Inhibition: State of the Art. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom B

Chair: Stanley Fahn (USA)

MAO-B Inhibitors: Symptomatic Effects in the Treatment of Early and Advanced PD – Olivier Rascol(France)

MAO-B Inhibitors: Do They Have Disease Modifying Effects – Andrew Siderowf (USA)PanelSupported through an unrestricted education grant from Teva Neuroscience; Eisai; Teva PharmaceuticalIndustries Ltd.; Lundbeck.

11:00 a.m.–12:00 p.m. Drugs in the Pipeline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom B

Chair: Joseph Jankovic (USA)

Non-Dopaminergic Drugs in the Pipeline – Peter Jenner (UK)Clinical Trials With A2A Antagonists – Mark Stacy (USA)PanelSupported through an unrestricted education grant from Kyowa Pharmaceuticals, Inc..

12:15 p.m.–1:15 p.m. Patch Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom B

Chair: Anthony Lang (Canada)

Novel Methods for Drug Delivery – José Obeso (Spain)Rotigotine – Patch Delivery of a Dopamine Agonist – Cheryl Waters (USA)PanelSupported through an unrestricted education grant from Schwarz Pharma.

1:15 p.m.–1:45 p.m. Lunch Break

EDUCATIONAL SESSIONS PROGRAMWednesday, February 22

Wed

nesd

ay, F

ebru

ary

22

, 20

06

18

1:45 p.m.–2:45 p.m. RLS and PD: Is There a Relationship?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom B

Chair: Kapil Sethi (USA)

Treatment of RLS – Eduardo Tolosa (Spain)RLS and PD – Cynthia Comella (USA)PanelSupported through an unrestricted education grant from GlaxoSmithKline.

3:00 p.m.–4:00 p.m. Non-Motor Features of PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom B

Chair: Christopher Goetz (USA)

An Overview of Non-Motor Features of PD – Nir Giladi (Israel)Treatment of Non-Motor Features – Matthew Stern (USA)PanelSupported through an unrestricted education grant from Boehringer Ingelheim.

4:15 p.m.–6:15 p.m. Levodopa – the Past, the Present and the Future . . . . . . . . . . . . . . . . . . . . Ballroom B

Chair: Anthony Lang (Canada)

Levodopa: History, Strengths and Weaknesses – Andrew Lees (UK)Evidence for CDS in PD – C. Warren Olanow (USA)Attempts to Obtain CDS with Levodopa Formulations – Fabrizio Stocchi (Italy)PanelSupported through an unrestricted education grant from Novartis Pharma AG/Orion Pharma.

6:30 p.m.–7:30 p.m. Opening Ceremony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall E

• Stanley Fahn, M.D.• Michael J. Fox• Elias Zerhouni, M.D.• Melanie Maar “Off and On”—a Dance Inspired by Restrictions• Mary Baker, An Introduction to the World Declaration on Parkinson’s Disease

7:30 p.m.–9:00 p.m. Welcome Reception. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D

Please join us for the Welcome Reception in Hall D. During the reception you will have an opportunity tonetwork with other professionals, meet with exhibitors, visit the Medical Historical Exhibit and walk throughthe Creativity and Parkinson’s Exhibition that will showcase selected works of art created by people withParkinson’s disease.

EDUCATIONAL SESSIONS PROGRAMWednesday, February 22

19

PROGRAM

How to Read the Scientific Program

The program has been color-coded for reference and to make it easier to navigate. Please note the color guide below for more details.

Plenary Sessions:

Designed to bring together all Congress attendees each morning and at the close of each day. Morning plenary sessions will offer presentersspeaking about specific topics that will highlight the daily themes. Closing plenary sessions will resemble town hall meetings, with a handful ofspeakers who will summarize the material that was presented during the day, offer insight on how it relates to the daily theme and providesuggestions on where this information might lead.

Science Sessions and Symposia:

Designed to offer in-depth sessions focused on specific cutting-edge research in the field of PD. These sessions will appeal to physicians,researchers, scientists and those who want to understand the basic and clinical science underlying the research conducted to betterunderstand the many facets of Parkinson’s disease.

Community Sessions and Care Delivery/Quality-of-Life Symposia:

Designed to offer concentrated sessions focused on best care delivery practices and quality-of-life topics. Areas covered include speechpathology, physical therapy, occupational therapy, mental health, social work, nutrition, and neuroscience nursing. These sessions will alsoinclude topics that look at the therapeutic value of art and creativity and PD, the power of optimism and hope when dealing with Parkinson’sdisease and the improvement in quality-of-life when exercise is included in the daily routines of those living with the disease.

Policy Sessions:

Designed to highlight domestic and international policy issues surrounding Parkinson’s disease, chronic diseases for our aging society andadvocacy training. Issues range from funding for research in the neurosciences to current stem cell policy. These sessions will appeal toanyone involved in policy making and to those who are interested in better understanding how policy affects research and work in the area ofParkinson’s disease.

Interactive Workshops:

More than 50 different workshops designed to offer intimate settings for smaller groups of attendees ranging from 50 to 100 people.Participants will have opportunities to learn first-hand from experts and have an opportunity to ask questions about specific topics such as:Post-DBS surgery, speech treatment, complementary medicine, depression and anxiety, hope and healing and to participate in actualexercise sessions. Space will be limited in these sessions, so please plan accordingly.

Hot Topics:

Each day, four of the hottest topics from the poster sessions will be selected for presentation to the broader audience. Every afternoon,before the closing plenary in the main hall, presenters will deliver a 15-minute presentation of their research. This is an opportunity for allattendees to get an up-close presentation of some of the most cutting-edge research being done today. Attendees at these hot topicssessions will learn of research yet to be seen in journals and will have a chance to meet some of the up-and-coming researchers in the field.

20

THEME: What causes Parkinson’s disease and how does this knowledgeinfluence approaches to care deliver?

8:15 a.m.–8:30 a.m. MEETING INTRODUCTION AND WELCOME

8:30 a.m.–9:30 a.m. PLENARY SESSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall E

• Stanley Fahn (USA) Overview of PD; Clinical Features and Evolution, Diagnosis and Differential Diagnosis,Imaging, Established and New Treatments.

• Yoshikuni Mizuno (Japan) -- Pathology, Environmental, Epidemiology and Genetics.

At the conclusion of this session, participants should be able to: (1) Develop a clear picture of the definition ofParkinson’s disease; (2) Understand the pathology of Parkinson’s disease; (3) Recognize the number ofgenes causing familial Parkinson’s disease.

9:00 a.m.–7:30 p.m. Creativity & PD and History of Parkinson’s Research Exhibits . . . . . . . . . . . . Hall D

SCIENCE SESSIONS

10:00 a.m.–11:30 a.m. Science 1: PATHOLOGY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom A

• Oleh Hornykiewicz, Chair (Austria)• Maria Spillantini (UK) The Lewy Body & Its Proteins• Etienne Hirsch (France) Inflammatory Pathology of PD• Jean-Paul Vonsattel (USA) Staging: Where Does It Begin?• Kurt Jellinger (Austria) Distinguishing Parkinsonian Disorders Based on Their Pathology

At the conclusion of this session, participants should be able to: (1) Describe cell biological andneuropathological aspects and staging of Parkinson’s disease; (2) Describe the contribution of inflammation,protein misfolding and oxidative injury in the pathogenesis of Parkinson’s disease; (3) Describe the spectrumof diseases within which Parkinson’s disease fits.

Science 2: ENVIRONMENTAL FACTORS/EPIDEMIOLOGY . . . . . . . . . . . . . Ballroom B

• Karen Marder, Chair (USA)• Beate Ritz (USA) Challenges and Progress in Studying Environmental Causes of Parkinson’s Disease• Caroline Tanner (USA) Epidemiology of Parkinson’s Disease• Webster Ross (USA) Preclinical Indicators of Parkinson’s Disease in Honolulu-Asia Aging Study• Harvey Checkoway (USA) Gene-Environmental Interactions in Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Describe the population distribution, riskfactors and methodological issues surrounding gene-environment interactions in Parkinson’s disease;(2) Understand how a geographic information system (GIS) based model of pesticide exposure can be usedto investigate the role of pesticides implicated as risk factors for PD; (3) Identify mid-life risk factors that areassociated with increased risk of pathologically confirmed PD.

PROGRAMThursday, February 23

21


Thur

sday

, Feb

ruar

y 2

3, 2

00

6

10:00 a.m.–11:30 a.m. Science 3: GENETICS: IMPLICATIONS FOR PATHOGENESIS. . . . . . . . . . . . Ballroom C

• Peter Heutink, Chair (The Netherlands)• Valina Dawson (USA) Unraveling the Pathobiology of DJ-1• Vincenzo Bonifati (Italy) DJ-1-related Neurodegeneration: Implications for the Pathogenesis of

Parkinson’s Disease• Enza Maria Valente (Italy) Clinical and Molecular Aspects of PINK1-related Parkinsonism• Thomas Gasser (Germany) LRRK2 Mutations in Autosomal-Dominant Parkinsonism

At the conclusion of this session, participants should be able to: (1) Describe the molecular pathwaysaffected by genetic mutations in different genes; (2) Discuss the impact of finding mutations in Mendelianforms of PD for understanding the etiology of idiopathic PD; (3) Define expectation of progression and clinicalvariability of disease for patients with mutations in distinct genes.

10:15 a.m.–11:30 a.m. COMMUNITY SESSIONS

Community 1: GENETICS AND ENVIRONMENT . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Zbigniew Wszolek, Chair (USA)• Andrew Singleton (USA) Genes, Genetics and PD• J. William Langston (USA) Environment and PD• Joan Samuelson (USA) Looking Towards the Future and the Cure of PD

At the conclusion of this session, participants should be able to: (1) Describe the importance of genetics inParkinson’s disease and related parkinsonian disorders; (2) Describe the importance of environmentalexposures in Parkinson’s disease and related parkinsonian disorders; (3) Describe the emerging approachesof therapeutic interventions in neurodegenerative conditions including Parkinson’s disease.

Community 2: THE CHALLENGES OF DELIVERING COMPREHENSIVE CARE IN PD: U.S. AND INTERNATIONAL PERSPECTIVES. . . . . . . . . . Room 207 A/B

• Peter Hagell, Chair (Sweden)• Mary Baker (UK) The Importance of Listening to European Citizens• Ruth Hagestuen (USA) Challenges in the U.S.

At the conclusion of this session, participants should be able to: (1) Describe common means of measuringperceived health in Parkinson’s disease; (2) Discuss requirements for high-quality health statusmeasurement; (3) Discuss problems and challenges in health status measurement in Parkinson’s disease.

12:00 p.m.–2:00 p.m. POSTER PRESENTATIONS – Even-numbered posters . . . . . . . . . . . . . . . . . . . . . . Hall D

22


SYMPOSIA SESSIONS

12:00 p.m.–1:25 p.m. Symposium 1: EPIDEMIOLOGY, ENVIRONMENTAL-GENE INTERACTIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Katrina Gwinn-Hardy, Chair (USA)• Karen Marder (USA) The Epidemiology of Dementia in Parkinson’s Disease• Nicholas Wood (UK) Can Genetics Help Identify Environmental Risks in PD• Demetrius Maraganore (USA) High-resolution Whole-genome Association Study of Parkinson’s

Disease: Susceptibility Gene Discovery, Unencumbered by the Thought Process• Silvia Mandel (Israel) Gene and Protein Expression Profiling Indicates Homology Between Sporadic and

Familial Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Explain the present state of knowledge ofgene and environment interactions; (2) Identify steps researchers could take and strategies for the study ofgene-environment interactions; (3) Discuss the basis of our understanding of gene discovery, and how thatcan be used to help clarify the epidemiology of disease subtypes.

Symposium 2: PATHOLOGY OF ABNORMAL PROTEINS IN PARKINSONISM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 B

• Jean-Paul Vonsattel, Chair (USA)• John Trojanowski (USA) Parkinson Diseases Linked to Tau Protein Pathologies• Dennis Dickson (USA) The Neuropathology of Familial Parkinson’s Disease: Lessons from LRRK2• Eliezer Masliah (USA) Interactions of alpha-Synuclein with A-Beta in the Pathogenesis of Parkinson’s

Disease

At the conclusion of this session, participants should be able to: (1) Describe the abnormal proteins thataccumulate in Parkinson’s disease; (2) Understand the interaction between alpha-synuclein and A-beta, theprotein seen in Alzheimer disease; (3) Identify the neuropathology of familial Parkinson’s disease that’s due toLRRK2 mutations.

. Symposium 3: DEVELOPMENT OF THE MIDBRAIN AND DOPAMINE NEURONS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 201

• Ronald McKay, Chair (USA)• Horst Simon (Germany) The Role of the Engrailed Transcription Factor in the Survival of Mesencephalic

Dopaminergic Neurons• J. Peter Burbach (The Netherlands) Genes Required for Maturation and Survival of Dopamine Neurons

of the Substantia Nigra• Wolfgang Wurst (Germany) Dissection of the Genetic Network Controlling Midbrain Dopaminergic

Neuron Development

At the conclusion of this session, participants should be able to: (1) Understand how dopamine neurons inthe midbrain develop; (2) Describe the role of transcription factors in the development of dopamine neurons;(3) Explain the genetic network for the midbrain dopamine neurons.

12:00 p.m.–1:25 p.m. Symposium 4: SCIENTIFIC RESEARCH FUNDING IN NEUROSCIENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 206

• Amy Comstock, Chair (USA)• Story Landis (USA) NIH Neuroscience Funding• Remi Quirion (Canada) CIHR Neuroscience Funding• Col. Karl Friedl (USA) U.S. Army Dual Use Research in Parkinson’s Disease and Soldier Neurotoxic

Exposure Protection

23


Thur

sday

, Feb

ruar

y 2

3, 2

00

6

12:00 p.m.–1:25 p.m. Symposium 5: NON-DRUG THERAPY IN EARLY PD: THE ‘HOW TO’ OF DELIVERING THE DIAGNOSIS . . . . . . . . . . . . . . . . . . . . . . Ballroom C

• Eric Ahlskog, Chair (USA)• John Nutt (USA) Setting the Stage• Julie Carter (USA) Non-Drug Therapy in Early PD: The “how to” of Delivering the Diagnosis

At the conclusion of this session, participants should be able to: (1) Recognize the needs of the newly diagnosedPD patient; (2) Discuss the unspoken concerns and fears experienced by someone just diagnosed with PD;(3) Discuss strategies for delivering the diagnosis of PD while conveying appropriate hope and optimism.

Symposium 6: REAWAKENING. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 207 A/B

• Donald Calne, Chair (Canada)• Oliver Sacks (USA) Awakenings Revisited

At the conclusion of this session, participants should be able to: (1) Describe the history of early twentieth-century encephalitis lethargica epidemic; (2) Recognize symptoms of acute encephalitis lethargica;(3) Discuss manifestations of post-encephalitic parkinsonism and its treatment with L-dopa.

SYMPOSIA SESSIONS

1:30 p.m.–2:55 p.m. Symposium 7: THE FUNCTION OF NEW PROTEINS IN FAMILIAL PD . . . Room 202 A

• Anne Young, Chair (USA)• Ted Dawson (USA) The Syns of Parkinson’s Disease• Nobutaka Hattori (Japan) Protein Degradation System in Nigral Degeneration• Robert Nussbaum (USA) Genetics of Non-familial PD

At the conclusion of this session, participants should be able to: (1) Discuss the putative role of alpha-synuclein in PD; (2) Discuss the cellular mechanisms involved in protein degradation in degenerating neurons;(3) Discuss the genetic evidence in nonfamilial PD.

Symposium 8: ALPHA-SYNUCLEIN: BIOCHEMISTRY, CELL BIOLOGY AND FUNCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 201

• Peter Lansbury, Chair (USA)• Michael Schlossmacher (USA) Monitoring Alpha-Synuclein Steady-state Levels in vivo by ELISA• Virginia Lee (USA) Modulation of Alpha-Synuclein Fibril Formation• Leonidas Stefanis (Greece) Alpha-Synuclein and Protein Degradation

At the conclusion of this session, participants should be able to: (1) Describe how a-synuclein may be relatedto PD cell death and describe several potential therapeutic strategies for PD; (2) Describe the state-of-the-art knowledge of the natural function of a-synuclein; (3) Explain how synuclein may promote cell death.

Symposium 9: DOPAMINE: BIOSYNTHESIS, OXIDATIVE METABOLISM AND NEUROMELANIN . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 207 A/B

• Shu-Leong Ho, Chair (Hong Kong)• Marc Caron (USA) Dopamine: Biosynthesis, Oxidative Metabolism and Neuromelanin• Luigi Zecca (Italy) The Role of Neuromelanin in Aging and Parkinson’s Disease• David Sulzer (USA) The Cytosolic Dopamine Hypothesis of Neurodegeneration

At the conclusion of this session, participants should be able to: (1) Describe the biosynthesis of dopamine,its interactions with neuromelanin and its involvement with oxidative metabolism; (2) Explain the role ofneuromelanin in aging and Parkinson’s disease; (3) Discuss the possible role of cystosolic dopamine inneurodegeneration.

24


1:30 p.m.–2:55 p.m. Symposium 10: HOPE, HEALING AND PREVENTION . . . . . . . . . . . . . . . . . . Ballroom C

• Judith Blazer, Chair (USA)• Michael Lerner (USA) Prevention and Hope in the Lives of People with Parkinson’s

At the conclusion of this session, participants should be able to: (1) Describe the state of the research onenvironmental contaminants in PD and other neurological disorders; (2) Discuss the broader relationshipbetween the environment and human health; (3) Discuss the role of integrative medicine and healthpromotion in a wide range of the chronic environmentally related disorders of our time.

Symposium 11: WORLD-WIDE SPEECH TREATMENT FOR PD: LSVT . . . . Room 206

• Cynthia Fox, Chair (USA)• Lorraine Ramig (USA) World-wide speech treatment for PD: LSVT• Deborah Theodoros (Australia) Speech Treatment/LSVT: The Australian Experience• Mara Behlau (Brazil) Speech Treatment/LSVT: The Brazilian Experience

At the conclusion of this session, participants should be able to: (1) Identify key features of speech disordersassociated with Parkinson disease and the progression of these speech disorders over time; (2) Describethe essential concepts of LSVT speech therapy for Parkinson disease and the efficacy data supportingtreatment outcomes; (3) Recognize the impact of delivery of LSVT world-wide and the potential fortechnology to scale up access to efficacious speech therapy.

Symposium 12: COMPLEMENTARY MEDICINE I. . . . . . . . . . . . . . . . . . . . . Room 202 B

• Allan Kroland, Chair (USA)• Melanie Brandabur (USA) Integrating Complementary Medicine in the Clinical Treatment of

Parkinson’s Disease• Nancy Pearson (USA) NCCAM Support of Neurodegenerative Disease Research

At the conclusion of this session, participants should be able to: (1) Define the role of complementarymedicine in the treatment of people with Parkinson’s disease; (2) Recognize the impact of integratingcomplementary medicine with conventional treatments; (3) Identify choices of complementary therapiesuseful for people with PD and the research being conducted by NCCAM (National Center for Complementaryand Alternative Medicine) at the National Institutes of Health.

3:15 p.m.–4:15 p.m. HOT TOPICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall E

1. Duration of Parkinsonism Prior to Dementia is Associated with a Different Pattern ofNeuropathological and Neurochemical Substrates in DLB and PDD, Dag Aarsland (Norway)

2. Silencing of Human Alpha-Synuclein in Vitro and in Rat Brain Using Lentiviral-Mediated RNAi, Moran Sapru (USA)

3. Heterozygous PINK1 Mutations are a Significant Risk Factor in Sporadic PD, Patrick Abou-Sleiman(UK)

4. Neurologic Music Therapy Interventions to Improve Sensorimotor Functioning in People withParkinson’s Disease, Sandra Holten (USA)

INTERACTIVE WORKSHOPS

3:15 p.m.–4:15 p.m. Workshop 1: GUAM PARKINSON-DEMENTIA COMPLEX: AN UPDATE . . . . Room 101

• Oliver Sacks (USA)

At the conclusion of this session, participants should be able to: (1) Describe the history of Guam Parkinson-Dementia Complex; (2) Explain pros and cons of many etiological hypotheses for Guam Parkinson-DementiaComplex; (3) Discuss recent findings on OMAA toxicity and their possible relevance to neurodegenerativedisease.

25


Thur

sday

, Feb

ruar

y 2

3, 2

00

6

3:15 p.m.–4:15 p.m. Workshop 2: DANCE FOR PARKINSON’S DISEASE SYMPTOMS AND MANAGEMENT, A DEMONSTRATION CLASS LED BY MARK MORRIS DANCE GROUP ARTISTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom C

• Olie Westheimer (USA) & Mark Morris Dance group artists

At the conclusion of this session, participants should be able to: (1) Describe how a dance class for personswith PD combines benefits of physical therapy, cognitive-behavioral learning and music therapy; (2) Identify techniques dancers use to promote balance, execute movements, stretch and exercise musclesthat are useful for persons with PD; (3) Recognize motivational and social benefits of dance classes forpersons with PD, caregivers and family members.

Workshop 3: GENETIC COUNSELING IN PD . . . . . . . . . . . . . . . . . . . . . . . . Room 209 A

• Tatiana Foroud (USA)

At the conclusion of this session, participants should be able to: (1) Discuss the role of genetics as PD riskfactors; (2) Describe the key issues in providing genetic counseling to individuals affected or at-risk with PD;(3) Recognize the difference between genes which when mutated cause PD and polymorphisms or geneticvariation which modulate the risk for PD.

Workshop 4: IS BIOLOGIC SURROGACY A REALITY? . . . . . . . . . . . . . . . . Room 208 B

• Kenneth Marek (USA)

Workshop 5: OPPORTUNITIES FOR ACADEME-INDUSTRY COLLABORATION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 201

• Ira Shoulson (USA)• Eric Siemers (USA)• Cheryl Waters (USA)

Workshop 6: THE PLACEBO EFFECT IN PARKINSON’S DISEASE: CONFOUNDING FACTOR OR FRIEND? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Jon Stoessl (Canada)

At the conclusion of this session, participants should be able to: (1) Recognize the importance of the placeboeffect in Parkinson’s disease; (2) Describe the mechanisms that contribute to the placebo effect inParkinson’s, and reasons for thinking that similar mechanisms may apply to other conditions; (3) Discuss theimportance of controlling for placebo effects in assessing new treatments, and how the placebo effect canbe harnessed for benefit, as well as how it might be minimized where appropriate.

Workshop 7: FOR PHYSICAL THERAPISTS: MOBILITY CHANGES IN PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 209 B

• Meg Morris (Australia)

At the conclusion of this session, participants should be able to: (1) Discuss: the scientific evidence for theoutcomes of different physical therapy interventions for people with Parkinson’s disease; the role of thephysical therapist in measuring impairments, activity limitations, participation restrictions and quality of life;and the role of physical therapists within the multi-disciplinary healthcare team; (2) Describe movementdisorders in Parkinson’s disease; the role of the basal ganglia in movement control; and, the UPDRS, 10mwalk, TUG and other outcome measures for Parkinson’s disease; (3) Recognize the signs and symptoms ofParkinson’s disease; responses of patients to physical therapy; and, the effects of PD medication onmovement and function.

26


3:15 p.m.–4:15 p.m. Workshop 8: OCCUPATIONAL THERAPISTS IN 2006: A NEW APPROACH TO AN OLD PROBLEM . . . . . . . . . . . . . . . . . . . . . . . . Room 204 B

• Beth Kirkwood (Australia)

At the conclusion of this session, participants should be able to: (1) Identify the role of the occupationaltherapist in the management of the PLWP and recognize the problems requiring assessment andtreatment; (2) List the 5 rehabilitation guidelines that are used by occupational therapists in theirrehabilitation programs for PLWP; (3) Describe the environmental and other factors that affect the capacityof a PLWP to undertake their ADLs to an optimal level of independence and safety.

Workshop 9: FOR SOCIAL WORKERS: HOW TO WORK WITH PLWP . . . Room 208 A

• Gladys Gonzalez-Ramos (USA) • Margaret Holloway (UK)

At the conclusion of this session, participants should be able to: (1) Describe the role of social workers in thefield of Parkinson’s disease in the U.S. and U.K; (2) Discuss how the role of social workers can be expanded inthe delivery of care for those affected by Parkinson’s disease; (3) Discuss ways to promote internationalnetworking among social workers in the PD field.

Workshop 10: NEWLY DIAGNOSED PD: WHAT SHOULD I DO?. . . . . . . . . Room 206

• Mariann Di Minno (USA)

At the conclusion of this session, participants should be able to: (1) Discuss the biopsychosocial issuesexperienced by persons with PD and their caregivers upon diagnosis; (2) Identify the components ofdeveloping a partnership with your care provider; (3) Identify the components of reporting PD medicationresponse.

Workshop 11: FOR COUPLES: LIVING WITH PARKINSON’S . . . . . . . Room 102 A/B

• Allan and Holly Kroland (USA)

At the conclusion of this session, participants should be able to: (1) Discuss the emotional impact that achronic progressive disorder like PD can have on relationships; (2) Explain how communication has aprofound effect on relationships under stress; (3) List the ground rules for managing stress in relationshipsfor couples living with PD.

Workshop 12: DEBATE: LEVODOPA SHOULD BE USED AS A FIRST LINE TREATMENT FOR NEWLY DIAGNOSED PARKINSON’S CASES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 207 A/B

• Facilitator: Zvezdan Pirtosek (Slovenia)• PRO: William Wiener (USA)• CON: Oscar Gershanik (Argentina)

At the conclusion of this session, participants should be able to: (1) Explain specific clinical, biochemical andprognostic characteristics of ‘de novo’ Parkinson’s disease; (2) Explain disease- and drug-related changes inprogression of PD; (3) Explain benefits and adverse effects of starting PD treatment with levodopa.

27


Thur

sday

, Feb

ruar

y 2

3, 2

00

6

3:15 p.m.–4:15 p.m. Workshop 13: DISCLOSING THE DIAGNOSIS OF PARKINSON’S . . . . . . Room 204 C

• Stephen Reich (USA)

At the conclusion of this session, participants should be able to: (1) Recognize the variable latency betweenindividuals receiving the diagnosis of Parkinson’s disease and disclosing it to others, including family, friendsand in the work place; (2) Identify whether demographic, social, or disease-specific factors influence theduration before the diagnosis is disclosed; (3) Recognize the most common concerns individuals have aboutdisclosing the diagnosis of Parkinson’s disease.

Workshop 14: TRANSLATIONAL APPROACH TO NEUROPROTECTION: POTENTIAL FOR NICOTINE IN PARKINSON’S DISEASE THERAPY . . . . Room 209 C

• Maryka Quik [USA] • Caroline Tanner [USA]• Bernard Ravina [USA]

At the conclusion of this session, participants should be able to: (1) Describe the role of environment as anegative risk factor for PD. This is based on epidemiological studies showing that there is an inverse relationshipbetween smoking and Parkinson’s disease, that is, that there is less Parkinson’s disease in tobacco users;(2) Describe experimental studies which suggest that the nicotine in tobacco products may be the agentresponsible, at least in part, for the protective effect of smoking in Parkinson’s disease; (3) Discuss the possibilityof using nicotine and selective nicotine agonists for use in Parkinson’s disease therapy.

4:30 p.m.–5:30 p.m. PLENARY WRAP-UP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall E

Moderators: Stanley Fahn and Yoshikuni MizunoPanelists: Oleh Hornykiewicz, Karen Marder, Peter Heutink, Zbigniew Wszolek, Peter Hagell, Katrina Gwinn-Hardy, Jean-Paul Vonsattel, Anne Young, Amy Comstock, Eric Ahlskog, Donald Calne,Ronald McKay, Peter Lansbury, Shu-Leong Ho, Judith Blazer, Cynthia Fox, Allan Kroland

6:00 p.m.–7:30 p.m. Meet the Artists. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Creativity and PD Exhibit, Hall D

6:00 p.m.–7:30 p.m. Guided Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D

28

PROGRAMFriday, February 24

THEME: How do brain cells lose their vitality in Parkinson’s disease and howdoes this knowledge influence approaches to care delivery?


• David Brooks (UK) Vignette; PD Evolution• Serge Przedborski (USA) What Makes the Disease Progress?

At the conclusion of this session, participants should be able to: (1) Describe how Parkinson’s diseaseevolves during its course in patients; (2) Understand the mechanisms that cause cells to die in Parkinson’sdisease; (3) Explain changes seen in neuroimaging over the course of Parkinson’s disease.


SCIENCE SESSIONS

10:00 a.m.–11:30 a.m. Science 1: HOW DOES KNOWLEDGE LEAD TO NEUROPROTECTION?. . . Ballroom B

• Peter Riederer, Chair (Germany)• Anthony Schapira (UK) The Scientific Basis for Neuroprotection• Flint Beal (USA) Novel Translational Targets for Development of PD Therapeutics• C. Warren Olanow (USA) Targeting Protein Aggregation• Moussa Youdim (Israel) Polypharmacology or Multifunctional Neuroprotective Drugs with Various

CNS Targets

At the conclusion of this session, participants should be able to: (1) Understand novel aspects of PDpathology; (2) Learn about new therapeutic strategies at variance to dopamine replacement therapy; (3) Getinformation about novel set up of clinical trials to show clinical neuroprotection.

Science 2: NON-DRUG APPROACHES TO SLOW DISEASE . . . . . . . . . . . . . Ballroom A

• Kapil D. Sethi, Chair (USA)• Michael Zigmond (USA) Triggering Endogenous Neuroprotective Processes: Studies with Cellular and

Animal Models of Parkinson’s Disease• James Joseph (USA) Fruit and Vegetable Supplementation in Brain Aging: ‘Priming’ The Brain Against

The Ravages of Time• Erwin Montgomery (USA) Rehabilitation Approaches• Meg Morris (Australia) Attentional Strategies and Cues: Effects on Locomotion in PD

At the conclusion of this session, participants should be able to: (1) Discuss use of non-drug approaches likerehabilitation and natural supplements in slowing Parkinson’s disease; (2) Discuss possible endogenousneuroprotective mechanisms and how to trigger these by non-drug means; (3) Discuss the role ofattentional strategies to improve locomotion and balance.

Science 3: EVIL PROTEINS AND THEIR MISCHIEF . . . . . . . . . . . . . . . . . . . . Ballroom C

• Ted Dawson, Chair (USA)• Peter Lansbury (USA) New Therapeutic Strategies for Parkinson’s Disease• Mark Cookson (USA) Synuclein and Dardarin: Protein Misfolding and Dominant Parkinson’s Disease• Kevin McNaught (USA) Proteasomal Dysfunction in Parkinson’s Disease• Leonard Petrucelli (USA) Ubiquitin, Proteasome or Synuclein: Who is the Culprit in Parkinson’s Disease?

At the conclusion of this session, participants should be able to: (1) Describe new therapeutic strategies forPD; (2) Discuss the role of alpha-synuclein, LRRK2 and protein misfolding in PD; (3) Discuss the role of theUbiquitin Proteasome System in PD.

29


COMMUNITY SESSIONS

10:15 a.m.–11:30 a.m. Community 1: INTERDISCIPLINARY TEAMS DELIVERING CARE: AN INTERNATIONAL PERSPECTIVE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Ruth Hagestuen, Chair (USA)• Nir Giladi, Orna Moore, Jennie Posen & Yale Manor (Israel) The Role of the Interdisciplinary Team in

Increasing the Awareness and Improving the Care of Patients with PD

At the conclusion of this session, participants should be able to: (1) Describe a model program ofinterdisciplinary care delivery designed to respond to the needs of persons affected by Parkinson’s disease;(2) Define the role of at least four allied health professions in this model; (3) Identify strategies to providecare and support for family caregivers through this model of care.

Community 2: UNDERSTANDING AND COPING WITH DEPRESSION AND NEUROPSYCHOLOGICAL CHANGES IN PARKINSON’S . . . . . . Room 207 A/B

• Alessandro Di Rocco, Chair (USA)• Laura Marsh (USA) Identifying and Treating Depressive Disturbances• Ron Pfeiffer (USA) Apathy, Withdrawal and Personality Change• Joe Friedman (USA) Drug Induced Neuropsychiatric Symptoms

At the conclusion of this session, participants should be able to: (1) Recognize the neuropsychologicalmanifestations of Parkinson’s disease with a special emphasis on depression; (2) Identify the instruments totreat depression and other neuropsychological disorders associated with Parkinson’s disease, includingpharmacological treatment, psychotherapy, support groups, and other non-pharmacological interventions;(3) Discuss the effect on quality of life caused by depression and other neuropsychological changesassociated with Parkinson’s disease.

12:00 p.m.–2:00 p.m. POSTER PRESENTATIONS – Odd-numbered posters. . . . . . . . . . . . . . . . . . . . . . . Hall D

SYMPOSIA SESSIONS

12:00 p.m.–1:25 p.m. Symposium 1: ALPHA-SYNUCLEIN: ANIMAL MODELS . . . . . . . . . . . . . . . . . Room 201

• Eliezer Masliah, Chair (USA)• Mel Feany (USA) Defining Pathways Controlling Alpha-synuclein Neurotoxicity in Drosophila• Michael Lee (USA) Alpha-synucleinopathy and Synuclein Metabolism in Transgenic Mice• Kathleen Maguire-Zeiss (USA) Synuclein Overexpression: Presynaptic Dysfunction in a Parkinson’s

Disease Model

At the conclusion of this session, participants should be able to: (1) Describe the various transgenic modelsof Parkinson’s disease; (2) Describe their importance in understanding the pathogenesis of Parkinson’s;(3) Discuss the significance for developing new treatments.

Symposium 2: MODALITIES FOR FOLLOWING DISEASE PROGRESSION. . . . Ballrooom C

• Wolfgang Oertel, Chair (Germany)• Werner Poewe (Austria) The Natural History of PD• Karl Kieburtz (USA) Clinical Measures of Disease Progression• Kenneth Marek (USA) Can We Use Imaging Outcomes to Monitor PD Progression?

At the conclusion of this session, participants should be able to: (1)Recognize the neuropathological stagesof PD and the different alpha-synuclein pathies (PD versus dementia of the Lewy Body type versus Parkinson+ Dimentia); (2) Describe the different scales employed to amem the severity and the development of motorand non-motor (UPDRS, dyskinesia scale, depression scale, scales for cognitive function) in the time courseof PD; (3) Discuss various technical procedures to describe the progression of PD by: dopamine transporteSPECT; Fluoro DOPA-PET; (functional) MRI; MIBG-SPECT; polysomno-proply.

Frid

ay, F

ebru

ary

24

, 20

06

30


12:00 p.m.–1:25 p.m. Symposium 3: DBS: FOR WHOM AND WHAT APPROACHES . . . . . . Room 207 A/B

• Anna Lena Tornqvist, Chair (Sweden)• Alim Benabid (France) Is Deep Brain Stimulation in STN Neuroprotective in Parkinson’s Disease?• Jerrold Vitek (USA) Controversies in DBS for Parkinson’s Disease: Unanswered Questions• Andres Lozano (Canada) Advances and Challenges in Surgery for PD

At the conclusion of this session, participants should be able to: (1) Identify which patients are suitable forDBS surgery and timing of surgery; (2) Discuss which brain target should be the optimal one with respect tosymptoms and needs in the individual patient; (3) Define beneficial effects of DBS as well as possiblecomplications or adverse effects as related to the choice of target and postoperative treatment.

12:00 p.m.–1:25 p.m. Symposium 4: HEALTH POLICY CONSIDERATIONS FOR CHRONIC DISEASE IN OUR AGING SOCIETIES . . . . . . . . . . . . . . . . . . . . . . . . Room 206

• Lisa Shulman, Chair (USA)• Dan Perry (USA) The Longevity Revolution and the Burden of Chronic Disease• Susan Dentzer (USA) Patients and Pitfalls: A Journalist’s Perspective on Health Care and Health

Financing Issues for Chronic Disease Sufferers• Richard Bringewatt (USA) Chronic Illness Care in the 21st Century: Targets for Health

At the conclusion of this session, participants should be able to: (1) Identify key weaknesses in the structureof the Medicare and Medicaid programs for the treatment of chronic illnesses; (2) Describe targetedsolutions and opportunities for improvement of the flaws in the current health policy, financing andhealthcare delivery for chronic illness care; (3) Describe the impact of increasing longevity on the prevalenceand needs for care of chronic diseases.

12:00 p.m.–1:25 p.m. Symposium 5: FAMILY CARE: THE ROLE OF OPTIMISM . . . . . . . . . . . . . . Room 202 A

• Julie Carter, Chair (USA)• Barbara Stewart (USA) Optimism and Pessimism as Early-Warning Signs in Family Care• Kathryn Zerbe (USA) Optimism: 12 Most Important Mental Health Secrets

At the conclusion of this session, participants should be able to: (1) Describe the difference betweenoptimism and pessimism as measurable; (2) Identify the role of optimism in predicting caregiver strain inearly and middle stage Parkinson’s disease; (3) Explain the tenets of “learned optimism” and how this trainingcould be helpful in buffering family caregiver strain.

Symposium 6: THE CHALLENGES OF CARE DELIVERY: INTERNATIONAL PERSPECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 C

• Alessandro D. Rocco, Chair (USA)• Haruko Tanji (Japan) Caregiver Burden in Japan and the Japanese Long-term Care Insurance System• Oscar Gershanik (Argentina) PD Care Delivery in South America• Miguel Nicolelis (Brazil) Building the Future of Brain Research: the International Neuroscience

Network Project


31


SYMPOSIA SESSIONS

1:30 p.m.–2:55p.m. Symposium 7: EXPERIMENTAL MODEL SYSTEMS . . . . . . . . . . . . . . . . Room 207 A/B

• Serge Przedborski, Chair (USA)• Jie Shen (USA) Cellular and Molecular Mechanisms of Familial Parkinsonism Using Genetic

Mouse Models• Tim Greenamyre (USA) Gene-environment Interactions in PD: Lessons from the Rotenone Model• Benjamin Wolozin (USA) Interaction of Disease Associated Proteins with Mitochondria and the

Proteasome in Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Describe/Discuss/Explain cellular andmolecular mechanisms of familial Parkinsonism using genetic mouse models; (2) Describe gene-environmentinteractions in PD lessons from the Rotenone Model; (3) Describe interaction of disease associated proteinswith mitochondria and the proteasome in Parkinson’s disease.

Symposium 8: GLIA AND NEUROINFLAMMATION. . . . . . . . . . . . . . . . . . . Room 202 B

• Etienne Hirsch, Chair (France)• Patrick McGeer (Canada) Factors Sustaining Inflammation in Parkinson’s Disease• Jau-Shyong Hong (USA) Inflammation-mediated Degeneration of Dopaminergic Neurons: Mechanism,

Interventions and Relevance to Parkinson’s Disease• Anna Czlonkowska (Poland) Harmful or Protective Effect of Inflammation in the Animal Model of

Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Discuss the relevance of inflammatoryprocesses in PD; (2) Describe how inflammation is involved in the progression of cell death in PD and animalmodels of PD; (3) Discuss inflammation related therapeutic intervention in PD.

Symposium 9: PROTEIN MISHANDLING IN PD. . . . . . . . . . . . . . . . . . . . . . . . Room 206

• David Sulzer, Chair (USA)• Marta Martinez-Vicente (USA) Chaperone-mediated Autophagy of Modified Synuclein• Ron Kopito (USA) Autophagic Clearance of Aggregated Proteins• Ryosuke Takahashi (Japan) The Role of Pael-R/GPR37 in the Life and Death of Dopaminergic Neurons

At the conclusion of this session, participants should be able to: (1) Discuss the roles of protesomal andautophagic modes of protein degradation; (2) Describe how protein implicated in familial PD may disturbpathways of protein degradation; (3) Describe potential pathogenic roles of protein aggregates andsubsequent neuronal responses.

1:30 p.m.–2:55p.m. Symposium 10: THE ROLE OF NURSES IN THE LIVES OF PLWP . . . . . . . . Room 201

• Lisette Bunting-Perry, Chair (USA)• Susan Heath (USA) Nursing’s Role in the Lives of PLWP• Mariann Di Minno (USA) The Role of the Nurse in Counseling and Support Across Stages of

the Disease• Cathi Thomas (USA) The Role of the Nurse in Medication Management

At the conclusion of this session, participants should be able to: (1) Discuss the benefit of expert nursing care inParkinson’s disease; (2) Describe the stages of Parkinson’s disease and disease trajectory; (3) Identify keyaspects of illness education provided by nurses to patients and families living with Parkinson’s disease.

Frid

ay, F

ebru

ary

24

, 20

06

32


1:30 p.m.–2:55p.m. Symposium 11: EXERCISE AND PARKINSON’S DISEASE . . . . . . . . . . . . . . Ballroom C

• Becky Farley, Chair (USA)• Michael Zigmond (USA) How Exercise Affects the Brain: Toward a Rationale for Exercise-Induced

Protection• Beth Fisher (USA) The Effect of High-Intensity Exercise Using Body-weight Supported Treadmill Training

(BWSTT) on Neuroplasticity and Functional Recovery in Individuals with Parkinson’s Disease• John Argue (USA) People with PD Should Have Weekly Parkinson’s Exercise Classes for the Rest of

Their Lives

At the conclusion of this session, participants should be able to: (1) Describe the current advances in basicscience that suggest exercise may be neuroprotective; (2) Discuss the effects of task-specific high-intensitylocomotor training on disease progression; (3) Recognize the clinical science rationale underlying “The Artof Moving.”

Symposium 12: COMPLEMENTARY MEDICINE II . . . . . . . . . . . . . . . . . . . . Room 202 A

• Allan Kroland, Chair (USA)• Bala Manyam (USA) Can a Botanical Have an Anti-Parkinson Effect Providing Both Symptomatic and

Neuro-Protective Benefits?• Karol Traviss (Canada) Complementary Therapies for PD: A Nutritionist’s Perspective

At the conclusion of this session, participants should be able to: (1) Discuss the role of a botanical agentwhich provides symptomatic relief with neuroprotective benefit in PWP; (2) Explain the value ofcomplementary and alternative approaches in the care of PWP; (3) List nutrients that may play a role inneuroprotection in Parkinson’s disease.


1. Gender Differences in Parkinson’s Disease, Charlotte Haaxma (The Netherlands)2. Striatal Administration of an AAV-2 Vector Encoding Human Neurturin (CERE-120) Reverses the

Age Related Decline in Markers of Nigrostriatal Function in Rhesus Monkeys, Biblob Dass (USA)3. Evaluation of Parkinson’s Disease (PD) Prevalence in Patients with Malignant Melanoma (MM),

D. Rigel (USA)4. Fatigue in Levodopa-Naive Subjects with Early PD, Giovanni Schifitto (USA)


3:15 p.m.–4:15 p.m. Workshop 1: MANAGING YOUR PARKINSON’S: HOW TO BE PROACTIVE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 207 A/B

• David Heydrick (USA)

At the conclusion of this session, participants should be able to: (1) Recognize that all movements andcognition exercises are “reflected” in the brain and are thus important in symptom management;(2) Recognize that nutrition may be an additional way to fight back against Parkinson’s; (3) Explain the currentand proposed rules for Social Security.

Workshop 2: THE ROLE OF PLWP AND ADVOCACY ORGANIZATIONS IN CLINICAL TRIALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 209 A

• Robin Elliott (USA) • Peggy Willocks (USA)• Perry Cohen (USA)

33


3:15 p.m.–4:15 p.m. Workshop 3: FOR HEALTH PROFESSIONALS: BRINGING LITERACY INTO PRACTICE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 208 A

• Gale Kittle (USA)

At the conclusion of this session, participants should be able to: (1) Discuss the issue of limited healthliteracy and the implications on care of PWP and care partners; (2) List three behaviors that suggest limitedhealth literacy; (3) Describe three strategies to enhance health literacy and patient communication in yourcare setting.

Workshop 4: GROWING UP WITH A CHRONICALLY ILL PARENT . . . . . Room 209 B

• David Morley (UK)

At the conclusion of this session, participants should be able to: (1) Identify recurrent themes and issuesarising when children are confronted with parental illness, and also differences in children’s responses tospecific parental conditions; (2) Discuss recent data assessing the impact of parental illness on adolescentand adult children’s quality of life and psychosocial well-being; (3) Discuss implications for service providersfrom data presented, and recognize the importance of developing effective interventions and informationresources for children of parents with a chronic illness.

Workshop 5: DOMESTIC & INTERNATIONAL POLICY ON STEM CELL RESEARCH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Dan Perry (USA) • Amy Comstock (USA)• Bernard Siegel (USA)

Workshop 6: FUNCTIONAL CHANGES: WHAT TO EXPECT . . . . . . . . . . . . . Room 201

• Lisa Shulman (USA)

At the conclusion of this session, participants should be able to: (1) Describe the daily activities that are mostaffected by the symptoms of Parkinson’s Disease; (2) Explain the relationship between the symptoms of PDand daily function; (3) List the basic activities of daily living and the instrumental activities of daily living thatare affected relatively early in PD and those that are generally intact until very advanced stages of PD.

Workshop 7: EMPOWERMENT THROUGH EDUCATION. . . . . . . . . . . . . . Room 208 B

• Joy Leffler (USA)

At the conclusion of this session, participants should be able to: (1) Discuss the role of educationalopportunities and enhanced patient-to-physician communication in improving the quality of life for people livingwith Parkinson’s disease; (2) Identify avenues to access for education activities and materials that are usefuland understandable; (3) Discuss and demonstrate techniques that assist people living with Parkinson’sdisease to best utilize newly acquired knowledge, skills, and abilities to improve their daily activities andexperience of life with PD.

Workshop 8: THE CHANGING OF THE UPDRS: OLD TO NEW . . . . . . Room 102 A/B

• Christopher Goetz (USA)

At the conclusion of this session, participants should be able to: (1) Define the Strengths and Weakness ofthe original UPDRS; (2) Identify the areas of changes that comprise the new version of the scale, termed theMDS-UPDRS; (3) Recognize the testing process that will establish the clinimetric properties of the MDS-UPDRS in relation to the original scale.

Frid

ay, F

ebru

ary

24

, 20

06

34


3:15 p.m.–4:15 p.m. Workshop 9: ENHANCING TRANSLATIONAL RESEARCH . . . . . . . . . . . . Room 204 B

• Kevin Biglan (USA)

At the conclusion of this session, participants should be able to: (1) Define translational research and identifyits necessary components; (2) Identify major barriers to translational research in Parkinson’s disease;(3) Discuss approaches to enhancing the translation of basic science advances to clinically meaningfultreatments in Parkinson’s disease.

Workshop 10: “BIG AND LOUD” PROGRAM: A COMBINED APPROACH TO PD THROUGH SPEECH AND PHYSICAL THERAPY . . . . . . . . . . . . . . . . . . Room 202 B

• Lorraine Ramig (USA)• Becky Farley (USA)• Cynthia Fox (USA) • David McFarland (USA)

At the conclusion of this session, participants should be able to: (1) Describe the essential concepts of acombined speech and physical therapy approach (Training Big and Loud) that targets increased amplitude ofspeech and body movements simultaneously; (2) Explain preliminary outcome data of Training Big and Loudin individuals with Parkinson disease across measures of limb and speech motor functioning; (3) Discusspotential of neuroplasticity associated with amplitude based training (Big and Loud) and early behavioralintervention in PD.

Workshop 11: THERAPY IN ACTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 209 C

• Sheree Loftus (USA) Tai Chi and PD• Pnina Isseroff (Israel)

At the conclusion of this session, participants should be able to: (1) List the benefits of participating inEnergetic Singing Therapy and Energy Exercise, Qi Gong for PD; (2) Describe how these complementarytherapies differ from allopathic treatment; (3) Explain how these therapies may be used in community care.

Workshop 12: THE ROLE OPTIMISM PLAYS IN THE LIFE OF A PERSON LIVING WITH PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 C

• Tom Isaacs (UK) I’m Not Talkin’ ’bout Shakin I’m Talkin’ ’bout Good Vibrations. It’ll Give You Excitations

At the conclusion of this session, participants should be able to: (1) Recognize that a positive mental attitudeand a sense of humor can overcome the pain, anguish and embarrassment of the physical symptoms ofParkinson’s; (2) Identify that the patient is the focal point for everything to do with Parkinson’s; (3) Recognizethat openness, humor and optimism not only help the individual patient and those immediately around thepatient, but also play a huge part in the overall perception of the condition and ultimately the speed at whichscientific progress is made in the search for a cure.

Workshop 13: MOVEMENT NORMALIZATION STRATEGIES IN PARKINSON’S: WHICH, WHEN AND WHY? . . . . . . . . . . . . . . . . . . . . . . . Room 206

• Robert Iansek (Australia) • Beth Kirkwood (Australia)

At the conclusion of this session, participants should be able to: (1) Explain basal ganglia function &malfunction in Parkinson’s; (2) List guidelines for the development of strategies to assist in functional deficitsin everyday activities; (3) Implement common strategies for gait, postural change, bed mobility, speech,swallowing & manipulative tasks.

35


3:15 p.m.–4:15 p.m. Workshop 14: THE POLITICS OF ILLNESS AT WORK . . . . . . . . . . . . . . . . . . Room 101

• Kathleen Reardon (USA)

At the conclusion of this session, participants should be able to: (1) Identify and understand the often subtleinfluences of medical politics on the communication of doctors and medical staff with patients; (2) Recognizehow patients can influence their treatment and sense of wellbeing by working with and around the politics inmedical settings and how physicians and staff can manage their political culture to better serve patients;(3) Discuss examples of politics influencing treatment, and consider how the politics of families andrelationships at work also influence patients coping with illness, especially Parkinson’s Disease.


Moderators: David Brooks and Serge PrzedborskiPanelists: Peter Riederer, Kapil Sethi, Ted Dawson, Ruth Hagestuen, Alessandro Di Rocco,Eliezer Masliah, Wolfgang Oertel, Anna-Lena Tornqvist, Lisa Shulman, Julie Carter, Etienne Hirsch, David Sulzer, Lisette Bunting-Perry, Allan Kroland


6:00 p.m.–7:30 p.m. Guided Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D

Frid

ay, F

ebru

ary

24

, 20

06

36

PROGRAMSaturday, February 25

THEME: How can Parkinson’s disease be identified before clinical onset and how does this knowledge influence experimental approaches to care delivery?


• J. William Langston (USA) Familial PD: Autosomal Dominant and Recessive Genes• David Eidelberg (USA) Biomarkers and Imaging

At the conclusion of this session, participants should be able to: (1) Explain the problems of using imaging as abiomarker; 2) Describe what a biomarker is; 3) Identify dominant and recessive genes in Parkinson’s disease.


SCIENCE SESSIONS

10:00 a.m.–11:30 a.m. Science 1: GENETIC TESTING: WHO, WHEN AND WHAT TO DO WITH THE RESULTS? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom C

• Eng King Tan, Chair (Singapore)• John Hardy (USA) Is There Definitive Evidence for Environmental Modifiers for PD?• Peter Heutink (The Netherlands) Are We Sure that all Published Mutations are Pathogenic?

Which should be Offered for Genetic Testing?• Kimberley Quaid (USA) Genetic Testing for Parkinson’s Disease: Are We There Yet?• Michael Conneally (USA) Testing for Genetic Factors in Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Identify genetic and environment riskfactors in Parkinson’s disease; (2) Recognize the promises and limitations of genetic testing in Parkinson’sdisease; (3) Discuss selection of suitable at-risk Parkinson’s disease patients for genetic testing.

Science 2: THE ROLE OF NEUROIMAGING AND OTHER BIOMARKERS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom A

• Francois Vingerhoets, Chair (Switzerland)• Matt Stern (USA) Sense of Smell• Kirk A. Frey (USA) VMAT2 and Other Neuro-Chemical Imaging Targets as Potential PD Bio-Markers• Joel Perlmutter (USA) Neuroimaging Biomarkers of Parkinson Disease Progression?• Hidenao Fukuyama (Japan) Nicotine Receptor of Acetylcholine in Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Discuss olfactory function in Parkinson’sdisease and its relevance to preclinical diagnosis; (2) Explain cholinergic system implications into thepathogenesis and treatment of Parkinson’s disease; (3) Discuss the use of the current neuroimagingbiomarkers in the estimate of the progression of Parkinson’s disease.

37


Sat

urda

y, F

ebru

ary

25

, 20

06

10:00 a.m.–11:30 a.m. Science 3: CUTTING EDGE TECHNOLOGIES TO UNDERSTAND PD . . . . . Ballroom B

• Ole Isacson, Chair (USA)• Patrick Aebischer (Switzerland) Models of Parkinson’s Disease Based on Lentiviral-mediated Over-

Expression of α-Synuclein as a Tool for Therapeutic Approaches• Howard Federoff (USA) Biomolecular Profiling to Ascertain Molecular Signatures of Disease• Jim Eberwine (USA) RNA Analysis in Individual Neuronal Dendrites: Insights into Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Identify the role of genetics andenvironment as PD risk factors; (2) Recognize the cell biological, neurochemical, neuropathological andneurophysiological aspects of PD; (3) List the non-motor features of PD and their treatment options.

COMMUNITY SESSIONS

10:15 a.m.–11:30 a.m. Community 1: INTERDISCIPLINARY TEAMS DELIVERING CARE IN AUSTRALIA AND THE U.S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Nir Giladi, Chair (Israel)• Robert Iansek & Beth Kirkwood (Australia) Interdisciplinary Teams Delivering Care in the United

Kingdom and Australia• Monique Giroux & Sierra Farris (USA) The US Perspective

At the conclusion of this session, participants should be able to: (1) Describe the concept ofmultidisciplinary team approach for the care of families with Parkinson’s disease; (2) Describe differentmodels of multidisciplinary team approaches in comparison to other models around the globe; (3) Discussthe advantages and difficulties of the development of a multidisciplinary team approach.

Community 2: MUSIC AND PARKINSON’S . . . . . . . . . . . . . . . . . . . . . . . Room 207 A/B

• Connie Tomaino, Chair (USA) Music Therapy to Benefit Individuals with Parkinson’s Disease• Grace Griffith (USA) Music as Tonic for Living• Heather MacTavish (USA) Rhythm, Story and Song in Group Settings Serves to Challenge Minds, Ignite

Spirits, and Create New Opportunities of Expression

At the conclusion of this session, participants should be able to: (1) Identify two applications of music tobenefit individuals with Parkinson’s; (2) Describe the benefits of music therapy for individuals with PD;(3) Identify two rehabilitation goals that can be addressed through music therapy.

12:00 p.m.–2:00 p.m. POSTER PRESENTATIONS – Even-numbered posters . . . . . . . . . . . . . . . . . . . . . . Hall D

38


SYMPOSIA SESSIONS

12:00 p.m.–1:25 p.m. Symposium 1: THE HETEROGENEITY OF PD . . . . . . . . . . . . . . . . . . . . . Room 207 A/B

• Kathleen Shannon, Chair (USA)• Roger Barker (UK) How Many Types of Parkinson’s Disease are There?• Andrew Lees (UK) What is Parkinson’s Disease?• Irene Litvan (USA) Parkinson Disease and Dementia: Two Diseases or a Continuum?

At the conclusion of this session, participants should be able to: (1) Explain the current state of knowledgeregarding etiologies of Parkinson’s disease, including recognized genetic and environmental contributors tothe phenotype; (2) Explain current state of knowledge regarding the clinical recognition of Parkinson’sdisease and its separation from other parkinsonian syndromes; (3) Explain the contribution ofclinicopathological data to our understanding of the syndrome of Parkinson’s disease; be familiar with thecurrent understanding of dementia in Parkinson’s disease and the relationship of Parkinson’s diseasedementia to Parkinson’s disease and to Diffuse Lewy Body Disease.

Symposium 2: MILD PARKINSONISM: IS IT RECOGNIZABLE? . . . . . . . . Room 202 B

• Nobuo Yanagisawa, Chair (Japan)• Eduardo Tolosa (Spain) Early Non-Motor Symptoms in Parkinson’s Disease• Wolfgang Oertel (Germany) Non-Motor and Motor Symptoms in Mild Parkinsonism – REM-Sleep

Behaviour Disorder as a Model for Early Synucleinopathy• Donald Calne (Canada) What, Exactly, is Parkinson’s Disease?

At the conclusion of this session, participants should be able to: (1) Describe predisposing factors andpremorbid characteristics of Parkinson’s disease; (2) List motor and non-motor symptoms in early Parkinson’sdisease; (3) Describe laboratory, imaging, genetic tests useful for differential diagnosis of mild Parkinsonism.

Symposium 3: OTHER TREATABLE FORMS OF PARKINSONISM . . . . . . . . Room 201

• Christopher Goetz, Chair (USA)• Stewart Factor (USA) Drug-Induced Parkinsonism• Cindy Comella (USA) Infectious and Post-Infectious Parkinsonism• Carlo Colosimo (Italy) Vascular Parkinsonism

At the conclusion of this session, participants should be able to: (1) Identify treatable causes of parkinsonismrelated to drugs, infections, post-infectious disorders, and vascular lesions of the central nervous system;(2) List commonly prescribed drugs that are associated with reversible parkinsonism; (3) Identify infectiousand post-infectious causes of parkinsonism and the role of antimicrobial, antiviral, and anti-inflammatoryagents to their treatment, and recognize the clinical and neuroimaging features that typify vascularparkinsonism and the treatment responses that occur to anti-parkinsonian therapies in these cases.

12:00 p.m.–1:25 p.m. Symposium 4: DOES HEALTH POLICY PROTECT FAMILY CAREGIVERS? . . . Room 204 C

• Lisa Shulman, Chair (USA)• Carol Levine (USA) Who Depends on Whom? The Gap Between Health Policy and Family Needs• Jeffrey Martin (USA) In Sickness and in Health: Steps to Help Prevent Parkinson’s Disease From

Consuming a Marriage and a Family• Suzanne Mintz (USA) Empowering Family Caregivers to Be a Force for Health Policy Change

At the conclusion of this session, participants should be able to: (1) Recognize the role of family membersand caregivers as a force for change in health policy; (2) Describe the impact of Parkinson’s disease onfamily members; (3) List currently unmet needs of family members of patients with Parkinson’s disease.

39

12:00 p.m.–1:25 p.m. Symposium 5: LIVING TRANSITIONS: HELPING FAMILIES WITH DIFFICULT DECISIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 206

• Patricia Archbold, Chair (USA)• Heather Young (USA) Living Environments: Helping Families Through the Process of Change• Carol Whitlatch (USA) Family Dynamics in Decision Making• Lynn Feinberg (USA) The State of the States in Family Caregiver Support: Implications for Policy

and Practice

At the conclusion of this session, participants should be able to: (1) Discuss family dynamics as they relate todecision-making about living environments; (2) Identify 3 ways to help families through the process of change inliving arrangement; (3) Recognize variability in state policies and practices regarding family caregiver support.

Symposium 6: INTIMACY AND SEXUALITY IN PD . . . . . . . . . . . . . . . . . . . Room 202 A

• Orna Moore, Chair (Israel)• Gila Bronner (Israel) Sexual Dysfunction in Parkinson’s Disease – Dynamic and Unpredictable• Susan Calne (Canada) Changes in Sexual Intimacy

At the conclusion of this session, participants should be able to: (1) Describe the variety of sexual disordersamong Parkinson’s disease and interventions; (2) Recognize the Intercourse-Outercourse approach as acoping technique; (3) Discuss that having Parkinson’s disease or living and caring for someone who has itand being intimate are not mutually exclusive.

SYMPOSIA SESSIONS

1:30 p.m.–2:55 p.m. Symposium 7: CLINICAL TRIALS: EDUCATING PARTICIPANTS . . . . . . . . Room 202 A

• Alberto Vasconcelos, Chair (Portugal)• Robin Elliott (USA) Increasing Public Awareness of Clinical Trials in Parkinson’s Disease: the North

American Experience• Cristina Sampaio (Portugal) Increasing Public Awareness of Clinical Trials in Parkinson’s Disease:

the European Experience• Ira Shoulson (USA) Communicating Evidence for Research Participant Decision Making in Parkinson’s

Disease Clinical Trials

At the conclusion of this session, participants should be able to: (1) Recognize the relevance of clinical trialsto the development of new PD therapeutic strategies; (2) Explain how clinicians can most effectively shareinformation with potential research participants about the uncertainties of risks and benefits related to thetreatment arms in clinical trials; (3) Describe the relationship between public policy and health care delivery.

Symposium 8: ADENOSINE A2A ANTAGONISTS . . . . . . . . . . . . . . . . . . . . . Room 202 B

• Peter Jenner, Chair (UK)• Michael Schwarzschild (USA) Neuroprotective and Anti-dyskinetic Potential of Adenosine A2A Blockers• Micaela Morelli (Italy) Modulatory Role of Adenosine A2A Receptors in Basal Ganglia as Basis for the

Use of A2A Antagonists in the Treatment of Parkinson’s Disease• Kjell Fuxe (Sweden) Experimental Studies and Theoretical Aspects on A2A/D2 Receptor Interactions in

Model of Parkinson’s Disease: Relevance for L-dopa Induced Dyskinesias

At the conclusion of this session, participants should be able to: (1) Identify motor complications of PD;(2) Understand the use of non-dopaminergic drugs; (3) Identify role of adenosine antagonists.


Sat

urda

y, F

ebru

ary

25

, 20

06

40


1:30 p.m.–2:55 p.m. Symposium 9: MEDIUM SPINY NEURON PLASTICITY IN PD . . . . . . . . . . . Room 201

• David Standaert, Chair (USA)• Ariel Deutch (USA) Structural Changes in the Striatum in Parkinson’s Disease• D. James Surmeier (USA) Dopamine, Calcium Channels, Dendrites and Striatal Plasticity in Parkinson’s

Disease• Paolo Calabresi (Italy) Synaptic and Molecular Mechanisms Underlying Pathological Synaptic Plasticity

in Experimental Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Describe structural changes which occurin the striatum in PD; (2) Discuss the role of dopamine and calcium channels in sinaptic plasticity disease;(3) Discuss the contribution of sinaptic plasticity to the features of Parkinson’s disease.

1:30 p.m.–2:55 p.m. Symposium 10: RACIAL AND ETHNIC DIFFERENCES IN FAMILY CAREGIVING. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 C

• Gladys Gonzalez-Ramos, Chair (USA)• Donna Benton (USA) African-American Caregivers: Strength and Hope• Alba Bonetti (Italy) The Italian Experience of Caregiving• Sandra Picot (USA) Does Ethnicity Influence the Stress and Coping Process of Parkinson Dyads?

At the conclusion of this session, participants should be able to: (1) Explain how ethnicity and the culture ofcaregivers influences their stressors, appraisals and coping over time; (2) Identify best practice models forworking with caregivers from different cultural groups; (3) Discuss caregiving stressors that are linked tocultural values of Italians.

Symposium 11: PATIENT-REPORTED OUTCOME MEASUREMENT . . . . . . Room 206

• Gun-Marie Hariz, Chair (Sweden) Activity limitations/ADL Assessments• Peter Hagell (Sweden) Health Status Measurement• Mickie Welsh (USA) Quality of Life Measurement in Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Discuss the concept of activity limitationaccording to WHO and its application in patients with Parkinson’s disease; (2) Describe various scales usedto evaluate ADL in patients with Parkinson’s disease; (3) Discuss the impact of Parkinsonism on disability andADL in women and men.

Symposium 12: COGNITIVE CHANGES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom B

• Murat Emre, Chair (Turkey)• Erik Wolters (The Netherlands) Early Cognitive Dysfunction in Parkinson’s Disease• Amos Korczyn (Israel) Cognitive Decline and Dementia in Advanced PD• S.J. Baloyannis (Greece) Ethical and Philosophical Consideration on the Emotional Changes in PD

At the conclusion of this session, participants should be able to: (1) Recognize the cognitive changes andemotional disturbances in patients with PD; (2) Describe the profile of cognitive impairments and the typicalsymptoms of dementia in PD; (3) Discuss the nature and consequences of emotional changes in PD.


1. Olfactory Dysfunction in Parkinson’s Disease: An fMRI Study, Atsushi Takeda (Japan)2. Longitudinal Progression of Odor Identification Deficits in Parkinson’s Disease, Jacqueline Rick (USA)3. Cortico-Striatal Functional Interactions in Parkinson’s Disease: A rTMS/[11C] Raclopride PET

Study, Antonio Strafella (Canada)4. Hippocampal Atrophy Predicts Occurrence of PD Dementia after STN-DBS, Selma Aybek

(Switzerland)

41



3:15 p.m.–4:15 p.m. Workshop 1: ART AS A THERAPY FOR PARKINSON’S. . . . . . . . . . . . . . . . . Room 201

• Samay Jain, Chair (USA)• Nancy Tingey (UK)

At the conclusion of this session, participants should be able to: (1) Recognize that, despite physicallimitations, patients with Parkinson’s disease are capable of producing an extraordinary range of creativeexpression in the visual arts; (2) Recognize that participation in the visual arts can contribute dramatically tothe quality of life of patients with Parkinson’s disease; (3) Identify patients with PD who might wish to beinvolved in the visual arts, encourage their participation, and educate them about the myriad artisticendeavors of their fellow PD sufferers.

Workshop 2: BALANCE PERFORMANCE, FALLS AND FEAR OF FALLING IN SEVERE PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Mia Nilsson (Sweden)

At the conclusion of this session, participants should be able to: (1) Identify the features of balanceimpairment in patients with severe Parkinson’s disease; (2) Discuss the different assessments of balanceperformance; (3) Discuss the different assessments of fear of falling.

Workshop 3: ACTIVITY LIMITATIONS/ADL ASSESSMENTS . . . . . . . . . . Room 209 A

• Gun-Marie Hariz (Sweden)

At the conclusion of this session, participants should be able to: (1) Discuss the concept of activity limitationaccording to WHO and its application in patients with Parkinson´s disease; (2) Describe various scales usedto evaluate ADL in patients with Parkinson´s disease; (3) Discuss the impact of parkinsonism on disabilityand ADL in women and men.

Workshop 4: FOR CAREGIVERS: CHANGES IN INTIMACY AND SEXUALITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 209 B

• Susan Calne (Canada)• Carmen Dyck (Canada)

At the conclusion of this session, participants should be able to: (1) Recognize that sexual medical clinics arefrequently more interested in younger clients, thus staff in Movement Disorders clinics often provide help topeople with Parkinson’s disease encountering difficulties with their sexual lives when they may not be themost appropriate people to do so; however, help can be provided in an environment that includes; listening,respect, free discussion and humor; (2) Recognize that “Normal” sexual activity and levels of intimacy areprobably impossible to define; that even the people within a relationship may be unable to articulate clearly oreven agree on what makes it good or bad; encouraging discussion carries some risks that one person will behurt; (3) Discuss that having Parkinson’s disease or living and caring for someone who has it and beingintimate are not mutually exclusive.

Workshop 5: FORUM FOR PWP: UNDERSTANDING CHANGES IN INTIMACY AND SEXUALITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 208 A

• Gila Bronner (Israel)

At the conclusion of this session, participants should be able to: (1) Identify changes in sexual and intimaterelationship of PWP and their spouses; (2) Discuss alternative approaches to cope with these changes;(3) Recognize the use of senses to enhance sensuality and sexuality.

Sat

urda

y, F

ebru

ary

25

, 20

06

42


3:15 p.m.–4:15 p.m. Workshop 6: RELIGIOUS COMPETENCE: ENHANCING THE CARE OF PARKINSON’S PATIENTS BY MEETING RELIGIOUS NEEDS . . . . . . . . . . . . Room 210

• Joyce Dubensky (USA)

At the conclusion of this session, participants should be able to: (1) Identify the range of ways in whichreligion can inform individuals’, families’ and caretakers’ healthcare decision-making, and the range of waysthat addressing religious needs enhances patient-centered care; (2) Discuss the ways that their own religion-cultural background influences their practice; (3) Define the responsibilities of each member of thehealthcare team in helping to meet patients’ religious beliefs.

Workshop 7: THE CASE FOR A SPECIALIZED ELECTRONIC HEALTH RECORD FOR PARKINSON’S CARE: DIFFERING PATIENT, PHYSICIAN AND HEALTH SYSTEM PERSPECTIVES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 209 C

• Bill Tenhoor (USA)

At the conclusion of this session, participants should be able to: (1) Describe the similarities and differencesbetween generic electronic health records and specialty health records focusing only on the care ofParkinson patients; (2) Identify the differential benefits of a specialty e-health record to patients, to clinicians,to researchers and the health care system; (3) Discuss the challenges to implementing a specialty recordsystem in the current US health care environment.

Workshop 8: POST-NEUROSURGERY SPEECH CHANGES & TREATMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 206

• Deborah Theodoros (Australia)

At the conclusion of this session, participants should be able to: (1) Describe the perceptual, acoustic, andphysiological effects of neurosurgical intervention on speech production; (2) Explain the research findings inrelation to the heterogeneous nature of PD and the inherent differences between speech and limb motorfunction; (3) Identify options for speech treatment in persons with PD with ongoing speech disturbancesfollowing neurosurgery for PD.

Workshop 9: SLEEP DISTURBANCES IN PARKINSON’S DISEASE. . Room 207 A/B

• Cynthia Comella (USA)

At the conclusion of this session, participants should be able to: (1) Describe the sleep disturbances thatcommonly affect patients with Parkinson’s disease; (2) Discuss the current theories and contributing factorsfor the various sleep disturbances in Parkinson’s disease; (3) Indicate current treatment options that havebeen suggested for the various sleep disturbances in Parkinson’s disease.

Workshop 10: PLWP AND CAREGIVERS: FINDING TRUSTWORTHY INFORMATION ON THE INTERNET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 B

• Nan Abraham (USA)• Brenda Tucker (USA)• Joy Leffler (USA)

43


3:15 p.m.–4:15 p.m. Workshop 11: FOR PROFESSIONALS: EFFECTS OF BEHAVIORAL CHANGES ON MOTOR SYMPTOMS AND FUNCTIONAL ABILITY IN PARKINSON’S DISEASE . . . . . . . . . . . . . . . Room 102 A/B

• Karen Anderson (USA)

At the conclusion of this session, participants should be able to: (1) Recognize signs and symptoms ofpsychiatric illness in Parkinson’s disease; (2) Discuss the impact of psychiatric illness on quality of life andfunction in Parkinsons’ disease; (3) Discuss the type of early memory impairment seen in PD, discuss relatedbrain activation changes, and discuss the impact of early memory impairment in PD.

Workshop 12: BRAIN HEALTH AND WELLNESS ACROSS THE LIFESPAN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 C

• Paul Nussbaum (USA)

At the conclusion of this session, participants should be able to: (1) Discuss the basics of the human brain toinclude essential structure of memory and learning; (2) Understand neural plasticity and how the humanbrain responds to environmental input; (3) Recognize lifestyle behaviors that promote brain health andreduce risk of dementia.

Workshop 13: THE MID-LEVEL PRACTIONER ON THE INTERDISCIPLINARY TEAM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 208 B

• Monique Giroux (USA)• Sierra Farris (USA)

At the conclusion of this session, participants should be able to: (1) Discuss current model for medicalmanagement of chronic disease; (2) Identify the role of the midlevel practitioner to expand chronic careservice utilizing team approach; (3) Discuss strategies to expand the team model to further enhance chronicmedical care.


Moderators: J. William Langston and David EidelbergPanelists: Eng King Tan, Francois Vingerhoets, Ole Isacson, Nir Giladi, Connie Tomaino, Kathleen Shannon, Nobuo Yanagisawa, Christopher Goetz, Lisa Shulman, Patricia Archbold, OrnaMoore, Alberto Vasconcetos, Peter Jenner, David Standaert, Gladys Gonzalez-Ramos, Gun-Marie Hariz,Murat Emre


6:00 p.m.–7:30 p.m. Guided Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D Sat

urda

y, F

ebru

ary

25

, 20

06

44

PROGRAMSunday, February 26

THEME: How can the needs of Parkinson’s disease patients and families be met in relieving symptoms, improving quality-of-life and slowingprogression of illness?


• Anthony Lang (Canada) Clinical Features and Pathogenesis of Non-Dopaminergic Motor Symptoms andSleep Disturbances in Parkinson’s Disease

• Murat Emre (Turkey) The Features of and Brain Mechanisms Underlying Cognitive and AffectiveSymptoms in PD

At the conclusion of this session, participants should be able to: (1) Describe the non-motor features ofParkinson’s disease; (2) Describe the cognitive problems that develop in Parkinson’s disease; (3) Discuss themethods to treat non-motor symptoms in Parkinson’s disease.


SCIENCE SESSIONS

10:00 a.m.–11:30 a.m. Science 1: SYMPTOMATIC THERAPY FOR THE MOTOR COMPONENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom B

• Guenther Deuschl, Chair (Germany)• Joseph Jankovic (USA) Clinical Features and Classification of Motor Symptoms of PD and Levodopa-

related Motor Complications • John Nutt (USA) Causes and Management of Levodopa-induced Dyskinesia (hyperkinetic)• Eldad Melamed (USA) Causes and Management of Levodopa-Associated Motor Fluctuations in

Parkinson’s Disease• Olivier Rascol (France) Future Symptomatic Therapies for Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Explain the phenomenology and clinicalfeatures of fluctuations and dyskinesias. Explain the causes for such fluctuations and the underlyingpharmacological mechanisms; (2) List the state-of-the-art therapies for fluctuations and dyskinesias; (3) Explainthe concepts for future therapies for fluctuations and dyskinesias in advanced Parkinson’s disease.

Science 2: SYMPTOMATIC THERAPY FOR NON-MOTOR COMPONENTS: SLEEP DISTURBANCES, DEPRESSION, DEMENTIA . . . . . . . . . . . . . . . . . . . Ballroom C

• Roger Kurlan, Chair (USA)• Yves Agid (France) Psychic Disorders in Parkinson’s Disease: Anatomic-Functional Bases and Treatment• Vladimir Kostic (Yugoslavia) Diagnosis and Treatment of Depression in Parkinson’s Disease• Justo de Yébenes (Spain) Phenotypes and Pathogenesis of Dementia in PD

At the conclusion of this session, participants should be able to: (1) Discuss the recognition and treatment ofsleep disorders that can accompany PD; (2) Discuss the recognition and treatment of mood and anxietydisorders that can accompany PD; (3) Discuss the recognition, evaluation and treatment of cognitivedisturbances that can accompany PD.

45


Sun

day,

Feb

ruar

y 2

6, 2

00

6

10:00 a.m.–11:30 a.m. Science 3: NOVEL THERAPIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom A

• Howard Federoff, Chair (USA)• Howard Gendelman (USA) Immunoregulatory Therapy for Parkinson’s Disease• Ronald McKay (USA) Will Stem Cell Biology Contribute to our Understanding of Parkinson’s Disease?• Patrik Brundin (Sweden) Restorative Therapies in Parkinson’s Disease

At the conclusion at of this session, participants should be able to: (1) Understand the critical importance ofinflammation in Parkinson’s disease pathobiology and appreciate novel vaccine approaches as therapeutictreatments; (2) Understand how proteamics techniques may be used to map glia activities in disease;(3) Appreciate that immune interventions can be used as therapies.

COMMUNITY SESSIONS

10:15 a.m.–11:30 a.m. Community 1: HOW TO DEVELOP INTERDISCIPLINARY HEALTH PROFESSIONAL TEAMS FOR PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Robert Iansek, Chair (Australia)• Monique Giroux (USA) Starting Interdisciplinary Teams• Teresa Drinka & Phillip Clark (USA) Overlooked Essentials of Interdisciplinary Teamwork: Organization,

Education, and Maintenance

At the conclusion of this session, participants should be able to: (1) Explain reasons for use ofinterdisciplinary teams in Parkinson’s; (2) Indicate roles of individual team members; (3) Identify appropriatephilosophy and approaches to enable team cohesion, communality of function and organization.

Community 2: PAIN, PALLIATIVE CARE AND PD. . . . . . . . . . . . . . . . . . . . . Room 202 B

• Barbara Habermann, Chair (USA)• Susan Heath (USA) Pain and Other Non-Motor Symptoms in Parkinson’s• Lisette Bunting-Perry (USA) Palliative Care in Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Identify primary goals in providingpalliative care to patients with chronic neurological disease; (2) Discuss ethical issues related to the care ofParkinson’s patients in need of palliative care; (3) Identify the motor and non-motor symptoms of Parkinson’sdisease to target for palliative care symptom management.


46


SYMPOSIA SESSIONS

12:00 p.m.–1:25 p.m. Symposium 1: THE FUTURE OF GENE THERAPY . . . . . . . . . . . . . . . . . . . . Room 202 A

• Martha Bohn, Chair (USA)• Jeffrey Kordower (USA) Cell and Gene Therapy for Parkinson’s Disease• Anders Björklund (Sweden) Neuroprotective Therapy Using GDNF Gene Transfer• Krystof Bankiewicz (USA) Long-term Clinical Improvement in MPTP-lesioned Primates after Gene

Therapy with AAV-hAADC

At the conclusion of this session, participants should be able to: (1) Be aware of the leading gene therapy andcell therapy approaches for Parkinson’s disease; (2) Understand the various means for delivering genes to thebrain; (3) Recognize the difficulties and pitfalls in getting gene therapies to the clinic for Parkinson’s disease.

Symposium 2: THE FUTURE OF STEM CELL THERAPY . . . . . . . . . . . . Room 207 A/B

• Lorenz Studer, Chair (USA)• Steven Goldman (USA) Selective Generation, Use and Pitfalls of Human Dopaminergic Progenitors• Clive Svendsen (USA) Combining Stem Cell and Growth Factor Therapy for Parkinson’s Disease• Evan Snyder (USA) The Developmental Role of Stem Cells May Suggest Novel Therapeutic Applications

At the conclusion of this session, participants should be able to: (1) Describe the novel developments in stemcell biology and their potential for clinical implementation in the treatment of Parkinson’s disease; (2) Discussthe importance of cell purification techniques, glial support, and environmental factors to the success of astem cell based approaches in PD; (3) Explain how neurotrophic factors can complement stem cell basedtherapies for PD.

Symposium 3: BASAL GANGLIA PHYSIOLOGY AND PATHOPHYSIOLOGY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 B

• Chris Fibiger, Chair (USA)• Ann Graybiel (USA) Ensemble Recording in Macaque Cortico-Basal Ganglia Loops• Mahlon DeLong (USA) Parkinson’s Disease: A Circuit Disorder• Jonathan Mink (USA) Basal Ganglia Function With and Without Dopamine: The Importance of Focus

At the conclusion of this session, participants should be able to: (1) Discuss the basic circuitry of theextrapyramidal system; (2) Describe functional changes in extrapyramidal circuitry in Parkinson’s disease;(3) Discuss the role of dopamine in extrapyramidal function.

12:00 p.m.–1:25 p.m. Symposium 4: ADVOCACY SYMPOSIUM: HOW TO EFFECT CHANGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 C

• Peggy Willocks, Chair (USA)• Amy Comstock (USA) Giving Voice to Parkinson’s: Effecting Change Through Public Policy• Morton Kondracke (USA) How Telling “Your” Story Makes a Difference

At the conclusion of this session, participants should be able to: (1) Discuss the impact of parkinsonism ondisability and quality-of-life; (2) Describe the relationship between public policy and health care delivery;(3) Articulate and understand the multiple stressors experienced by family caregivers and the ways toprovide care and support for this population.

47


12:00 p.m.–1:25 p.m. Symposium 5: WORKING IN THE COMMUNITY: OUTREACH AND PATHWAYS TO PWP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 B

• Gladys Gonzalez-Ramos, Chair (USA)• Margaret Holloway (UK) Pathways Through Care: a Patient Caregiver-led approach to the

Management of Parkinson’s Disease in the Community• Kenneth Bergmann (USA) African Americans and Parkinson’s Disease in South Carolina

At the conclusion of this session, participants should be able to: (1) Recognize the barriers to participation inclinical research for patients with Parkinson’s disease, in general, and for African Americans in particular asillustrated by the experience of a PD research center in South Carolina; (2) Describe the principles of userengagement in their own care and identify the features of integrated care pathways; (3) Describe thedifferences in epidemiology between African Americans with Parkinson’s disease as compared to Americansof European origin.

Symposium 6: LONG-TERM FAMILY CARE GIVING: IMPLICATIONS FOR HEALTH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 201

• Ellen Abramson, Chair (USA)• Barbara Stewart (USA) Care Giving: Implications for Health• Dag Aarsland (Norway) Which Clinical Features are Associated with Caregiver Distress?

At the conclusion of this session, participants should be able to: (1) Discuss the level of burden and impacton quality of life of caring for a person with Parkinson’s disease; (2) Which specific patient characteristicscause distress for the caregiver; (3) implications of this knowledge for the management and care of patient-caregiver couples.

SYMPOSIA SESSIONS

1:30 p.m.–2:55 p.m. Symposium 7: CO-MORBIDITIES IN PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 B

• Irene Richard, Chair (USA)• Guenther Deuschl (Germany) Common and Uncommon Tremors in Typical and Atypical PD• William Weiner (USA) The Prevalence of Other Medical Conditions in Patients with Parkinson’s Disease• Mark Stacy (USA) Pathological Gambling and Other Impulse Dyscontrol Disorders in Parkinson’s Disease

At the conclusion of this session, participants should be able to: (1) Recognize common and uncommontremors in typical and atypical PD; (2) Discuss the prevalence of other medical conditions in patients with PD;(3) Discuss repetitive behaviors occurring in patients with PD.

Symposium 8: PATHWAYS TO CELL DEATH IN DOPAMINE NEURONS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 207 A/B

• Anders Björklund, Chair (Sweden)• Robert Burke (USA) Kinase Signaling Pathways: Potential Therapeutic Targets in Parkinson’s Disease• Miquel Vila (Spain) Targeting Programmed Cell Death in Experimental Parkinsonism• Martha Bohn (USA) Gene Therapy Approaches to Protect DA Neurons Against Cell Death

At the conclusion of this session, participants should be able to: (1) Discuss alternative molecularmechanisms that induce cell death in dopamine neuron; (2) List potential molecular targets that caninterfere or block cell death in dopamine neurons; (3) Discuss possibilities to use viral vectors for genetherapy in Parkinson’s disease.

Sun

day,

Feb

ruar

y 2

6, 2

00

6

48


1:30 p.m.–2:55 p.m. Symposium 9: SIDE EFFECTS OF SYMPTOMATIC THERAPY. . . . . . . . . . Room 202 A

• Joseph Jankovic, Chair (USA)• Erwan Bezard (France) Levodopa-induced Dyskinesia: From Single Cell to Networks (re)Organization in

Animal Models• José Obeso (Spain) Pathophysiology of Levodopa-induced Dyskinesias in PD: Relevance for Newer

Therapeutic Developments• Mitsutoshi Yamamoto (Japan) Psychiatric Problems in the Treatment of PD• Fabrizio Stocchi (Italy) Systemic Side Effects of Symptomatic Therapy

At the conclusion of this session, participants should be able to: (1) Recognize the phenomenology differenttypes of levodopa-induced dyskinesia; (2) Understand the mechanisms of levodopa induced motorfluctuations; (3) Identify the best therapeutic strategies to prevent and treat levodopa related complications.

1:30 p.m.–2:55 p.m. Symposium 10: INTERVENTIONS FOR FAMILY CAREGIVING IN LATER STAGE DISEASE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 201

• Jennie Posen, Chair (Israel)• Patricia Archbold (USA) Interventions to Strengthen Family Care• Richard Schulz (USA) Health Effects of Caregiving: Transitions and Treatments• Orna Moore (Israel) Clinic for Family Caregivers of PD Patients

At the conclusion of this session, participants should be able to: (1) Identify the challenges associated withcaregiving of people in later stage disease with physical and/or cognitive care needs; (2) Know the healtheffects of this caregiving; (3) Identify effective intervention strategies for the caregivers.

Symposium 11: THE ROLE OF PATIENTS IN DEVELOPMENT OF NEW THERAPIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 206

• Ira Shoulson, Chair (USA)• Perry Cohen (USA) Patients as Partners: The Missing Ingredient in Development of New Parkinson’s

Therapies• Craig Smith (USA) Patient Advisory for Clinical Trials: An Experience from Industry• Russell Katz (USA) Regulatory Aspects

At the conclusion of this session, participants should be able to: (1) Indicate the ways in which patients andtheir families can participate appropriately and effectively in the development of new treatments forParkinson’s disease; (2) Recognize how unmet patient needs are identified and incorporated into thedevelopment of new treatments for Parkinson’s disease; (3) Identify how patient interests are addressed bythe Food & Drug Administration in the development of new treatments for Parkinson’s disease.

Symposium 12: PARKINSON DISEASE IN THE DEVELOPING WORLD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 C

• Aleksandar Janca (Australia), Chair• Mary Baker (UK) Update on World Health Organization Working Group on Parkinson’s• Alessandro Di Rocco (USA) WFN Initiative for PD in the Developing World• Jonathan Carr (South Africa) Parkinson’s Disease in the Developing World

At the conclusion of this session, participants should be able to: (1) Identify issues and problems related todiagnosis, assessment and management of people with Parkinson’s disease in the developing countries;(2) Recognize public health importance of Parkinson’s disease in both developing and developed countries;(3) List international projects and activities in the area of Parkinson’s disease carried out by the WorldHealth Organization and World Federation for Neurology.

49



1. Impact of Pramipexole on the Onset of Levodopa Related Dyskinesias, Karl Kieburtz (USA)2. Early Initiation of Entacapone Leads to Superior 5-Year Efficacy Compared to Delayed Initiation in

Parkinson’s Disease Patients Receiving Traditional Levodopa/DDCI Therapy, Helena Nissinen (Sweden)3. Sarizotan has Long-Term Efficacy in Reducing Levodopa-Induced Dyskinesia in Patients with

Parkinson’s Disease, C. Warren Olanow (USA)4. Five-Year Outcome in 50 Consecutive Advanced PD Patients Treated with STN-DBS, Christian Wider

(Switzerland)


3:15 p.m.–4:15 p.m. Workshop 1:THE CHALLENGE OF LIVING CREATIVELY WITH PARKINSON’S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 202 A

• Ruth Hagestuen (USA)• Lucy Roucis (USA)• John Ball (USA)

At the conclusion of this session, participants should be able to: (1) Describe challenges to the primarycaring and caregiving relationship which can be attributed to Parkinson disease; (2) Define a healthy, intimaterelationship; (3) List the characteristics of (a) a creative caregiver, (b) a creative person with Parkinsondisease, (c) a creative life partnership.

Workshop 2: PUBLIC HEALTH POLICY AND PD . . . . . . . . . . . . . . . . . . . . . Room 202 B

• Richard Dodel (Germany) • Margaret Holloway (UK)

Workshop 3: FROM HOME TO HOSPITAL: INTEGRATED CARE CHAIN FOR PARKINSON’S DISEASE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 101

• Bastiaan Bloem (The Netherlands)

At the conclusion of this session, participants should be able to: (1) Recognize the complexity of the healthcare system that surrounds families with Parkinson’s disease, and appreciate the vulnerability of the “chain”that links the many inter- and intra-organizational care processes in current clinical practice; (2) Identify theneed for an optimal communication and cooperation between specialized hospitals and the communityservices that can ascertain systematic follow-up actions and deliver adequate care in the immediate vicinityof the patients’ homes (“integrated chain care”); (3) Discuss recent scientific developments in this field,including the latest evidence from clinical trials, evidence-based practice guidelines and other important newprogress. Participants will also identify everyday barriers and actively debate possible solutions.

Workshop 4: FOR CAREGIVERS: END OF LIFE ISSUES and WHAT IS HOSPICE? WHEN TO USE IT? . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 208 B

• Avinoam Reches (Israel) • Marge Thurin (USA)

At the conclusion of this session, participants should be able to: (1) Identify and recognize the ethical issuesarising at the end of life; (2) Understand the role of family caregiver in “end of life issues”; (3) Recognize andunderstand the changing attitude of society towards patient rights and autonomy at end of life decisions.

Sun

day,

Feb

ruar

y 2

6, 2

00

6

50


3:15 p.m.–4:15 p.m. Workshop 5: CHOOSING A CARE FACILITY . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 210

• Heather Young (USA)

At the conclusion of this session, participants should be able to: (1) Identify a range of housing and serviceoptions available to older adults; (2) Discuss the process of making decisions about housing and services,using concepts of transitions and person-environment fit; (3) Discuss the ways families and providers canparticipate in the selection of housing and services to optimize the health and well-being of older adults withParkinson’s Disease.

Workshop 6: EXERCISE: MOTIVATING MOVES, TAI CHI AND PD . . . Room 207 A/B

• Janet Hamburg (USA) Motivating Moves, Tai Chi and PD• Sheree Loftus (USA) Energy Exercise, Qi Gong and PD

At the conclusion of this session, participants should be able to: (1) List the benefits of participating in“Motivating Moves for People with Parkinson’s” and Tai Chi; (2) Describe how these complementary movementmodalities differ from allopathic treatment; (3) Explain how to implement these interventions in clinical practice.

Workshop 7: THERAPEUTIC VALUE OF CREATIVITY IN PD . . . . . . . . . . . Room 209 C

• Adam Koss (USA)• Steve Frucht (USA)• Rose Wichman (USA)• Marjorie L. Johnson (USA)

At the conclusion of this session, participants should be able to: (1) Describe examples of how individuals withParkinson’s disease have used creative forms (e.g. artistic, musical, literary, physical, imaginative, etc.) fortherapeutic means, and the benefit (in quality and relative degree) this creativity has provided to patients;(2) Discuss the methods and values of previously, currently, and potentially useful forms of patient creativityas therapy and its role in the management of motor and non-motor features of Parkinson’s disease;(3) Indicate how providers and patients might effectively implement creativity into their Parkinson’s diseasemanagement plans.

Workshop 8: COMPLEMENTARY MEDICINE . . . . . . . . . . . . . . . . . . . . . . . . Room 209 B

• Jill Marjama-Lyons (USA)

At the conclusion of this session, participants should be able to: (1) Define the term complementaryalternative medicine (CAM) and list several different CAM therapies currently used to treat PD; (2) Brieflydescribe the 3 different nonwestern medical systems of Traditional Chinese Medicine, Ayurvedic Medicineand Homeopathy; (3) Identify the many key health professionals (Western and non-Western trained)necessary to serve as part of a holistic team to create an individualized CAM program for persons withParkinson’s disease.

Workshop 9: SPEECH AND SWALLOWING IN ADVANCED PD . . . . . . . Room 209 A

• Deborah Theodoros (Australia)• Lorraine Ramig (USA)• Ron Cole (USA)• Yael Manor (Israel)

At the conclusion of this session, participants should be able to: (1) Identify key features of speech andswallowing disorders associated with advanced Parkinson disease; (2) Describe effective treatments andcompensation (e.g., augmentation) for improving communication in advanced Parkinson disease; (3) Describeeffective interventions for improving or compensating for swallowing disorders in advanced Parkinson disease.

51


3:15 p.m.–4:15 p.m. Workshop 10: FOR CAREGIVERS: “TAKING CARE OF YOURSELF” . . . . . . Room 201

• Barbara Habermann (USA)

At the conclusion of this session, participants should be able to: (1) Describe common health problemsexperienced by PD caregivers; (2) Discuss short and long term strategies caregivers can utilize to take careof themselves; (3) Evaluate 1–2 strategies that you would be willing to implement to take care of yourself asa caregiver.

Workshop 11 : ROLE OF NURSES IN MANAGING PD. . . . . . . . . . . . . . . . Room 204 C

• Lisette Bunting-Perry (USA)• Gwen Vernon (USA)

At the conclusion of this session, participants should be able to: (1) Discuss the various roles andcontributions nursing and nursing care provides in the continuum of care of patients with Parkinson’sdisease; 2) Define the dynamic patient and family centered relationship which nurses have when caring forthose with Parkinson’s disease throughout the disease stages; 3) Explore areas of need and models of carewhich have not been utilized in the United States as potential additional avenues of expansion in the role ofnurses in managing Parkinson’s disease.

Workshop 12 : FOR PWP & CAREGIVERS: DEPRESSION AND ANXIETY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 204 B

• Laura Marsh (USA)

At the conclusion of this session, participants should be able to: (1) Recognize the clinical features ofdepression and anxiety disturbances in patients with Parkinson’s disease; (2) Describe the different causesof depression and anxiety disturbances in patients with Parkinson’s disease; (3) Discuss treatments ofdepression and anxiety disturbances in patients with Parkinson’s disease.

4:30 p.m.–5:30 p.m. CLOSING PLENARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall E

Moderators: Anthony Lang and Murat EmrePanelists: Guenther Deuschl, Roger Kurlan, Howard Federoff, Robert Iansek, Barbara Habermann,Martha Bohn, Lorenz Studer, Chris Fibiger, Peggy Willocks, Gladys Gonzalez-Ramos, Ellen Abramson,Irene Richard, Anders Björklund, Joseph Jankovic, Jennie Posen, Ira Shoulson, Aleksandar Janca

5:30 p.m.–6:00 p.m. Closing Remarks

• Stanley Fahn

Sun

day,

Feb

ruar

y 2

6, 2

00

6

52

GUIDED POSTER TOURSThursday, February 23

Thursday, February 23 Tour 1: A Closer Look at Caregiver IssuesTour Guide: Sharon Metz, R.N., M.P.H.

265 Survey of caregivers of persons with Parkinson’s disease in Alberta: Services needed, used and valued, M. Chibuk

266 Longitudinal effects of Parkinson’s disease on caregiver burden, C. Lippy

270 Mutuality and emotional health of Parkinson’s disease patients’ spouses, H. Tanji

271 Creating Parkinson’s disease awareness and skills for family caregivers, R. Wichmann

274 Stress and coping among family caregivers of Parkinson’s disease patients, W. Witt

275 Bearing Parkinson’s disease: Spouse caregivers’ challenges: Results from northern and central Alberta, Canada, T. Yang

Tour 2: Animal and Cellular Models I Tour Guide: Serge Przedborski, M.D., Ph.D.

68 The G309D-Pink1 knock-in mouse model of PARK6, S. Gispert

69 Effects of proteasome inhibition on catecholaminergic neurons of rats in CNS and PNS, S. Haas

70 Synergistic interaction between alpha-synuclein and oxidized catechol metabolites produced by tyrosinase: Implications for selectiveneurodegeneration in Parkinson’s disease, T. Hasegawa

72 A chemically defined, cellular model for intraneuronal assembly of a-synuclein aggregates, L. Ko

74 Nigrostriatal dopamine loss and motoneuron disease in parkin null mice overexpressing human tau protein, M. Mena

76 Alpha synuclein activation of PP2A regulates multiple phosphorylation sites on tyrosine hydroxylase, S. Montoya

77 Functional dopamine neurons from primate embryonic stem (ES) cells, R. Sanchez Pernaute

79 Transplantation of CSM14.1-cells into a neonatal 6-OHDA-lesion model exhibit significant behavioral recovery, O. Schmitt

80 PSI induce proteasome inhibition and motor disturbances in rats, A. Thomas

81 Neuroprotective effects of 20(S)-ginsenoside Rg3 on dopamine levels in the 6-hydroxydopamine lesioned mouse brain, J. Tian

Poster tours will run from 6:00 p.m. to 7:30 p.m. and will start at the first poster listed in the tour.

53

Tour 3: Association of Etiology, Genetics, Epidemiology, and ToxicantsTour Guide: Peter Heutink, Ph.D.

3 Prospective study of plasma uric acid and risk of Parkinson’s disease, A. Ascherio

8 Risk susceptibility of Parkinson’s disease associated with genotype polymorphisms of oxidative stress-metabolizing genes andpesticides exposures in southwestern Taiwanese, CS. Fong

10 Genetic epidemiology of 120 Tunisian families with Parkinson’s disease: How valid are the information given by the index cases?,N. Gouider-Khouja

11 Association of iNOS in Parkinson disease and the modulating effect of smoking, D. Hancock

12 Association of MAOB polymorphism and Parkinson’s disease, E. Martin

16 Polymorphism in NOD2/CARD15 gene may be a risk factor for sporadic Parkinson’s disease, G. Klodowska-Duda

18 Familial risks of Parkinson’s disease in first-degree relatives: A nationwide follow-up study from Sweden, X. Li

23 Candidate gene association study of BAG5 with idiopathic Parkinson’s disease, S. Scholz

24 The sepiapterin reductase gene region reveals association in the PARK3 locus: Analysis of familial and sporadic Parkinson disease inEuropean populations, M. Sharma

25 Hypertension, hypercholesterolemia, diabetes and risk of Parkinson’s disease, K. Simon

Tour 4: Biomarkers and Neuroimaging: Pathophysiology & Genetics Tour Guide: Joel Perlmutter, Ph.D.

172 Hippocampal atrophy predicts occurrence of PD dementia after STN-DBS, S. Aybek

174 Metabolic patterns associated with cognitive function in Parkinson’s disease, C. Huang

175 Relationship between non-motor signs and asymmetry of striatal dopamine transporter (DAT) loss in patients with early Parkinson’sdisease measured with ([sup]123[/sup]I)Ioflupane-SPECT, I. Isaias

176 Striatal dopamine transporter binding in Parkinson’s disease associated with LRRK2 Gly2019Ser mutation, I. Isaias

179 Cardiac MIBG SPECT in vascular parkinsonism, J. S. Kim

185 Cortico-striatal functional interactions in Parkinson’s disease: A rTMS/[11C] raclopride PET study, A. Strafella

186 Assessment of abnormal metabolic brain networks by cerebral blood flow measurement in patients with Parkinson’s disease: A H2Oand FDG PET study, C. Tang

Tour 5: Clinical Features: Other Forms of Parkinsonism Besides PDTour Guide: Nir Giladi, M.D.

97 Ten steps to identify atypical parkinsonism, W. Abdo

99 Spontaneous arm levitation in a patient with Creutzfeld-Jakob disease presenting as corticobasal syndrome, T. Ahn

110 Essential tremor prevalence is unusally low in Arabic villages in Israel – A population based study, R. Inzelberg

112 Clinical and genetic risk factors for drug-induced parkinsonism, Y. Kim

113 A case report: Left ventricular systolic dysfunction in a man possibly caused by cardiac sympathetic nerve disturbance accompaniedwith Parkinson’s disease, K. Kimura

116 A case of sporadic rapid-onset dystonia-parkinsonism associated with mutations in the ATP1A3 gene, J. Leegwater-Kim

124 Apraxia of lid opening after traumatic brain injury: A delayed complication, M. Park

136 Progressive parkinsonism following bilateral pallidal lesions, A. Thomas

Tour 6: Clinical Features: Quantifying Parkinsonian FeaturesTour Guide: Joseph H. Friedman, M.D.

109 Familial Parkinson’s disease with LRRK2 gene mutations in Israel – A possible founder effect, R. Inzelberg

118 Abnormal N30 component of the somatosensory evoked potentials in patients with asymmetric Parkinsonian symptoms, H. Ma

119 Normal control of hand trajectory in Parkinson’s disease patients performing a speed-accuracy reaching task, P. Mazzoni

121 Disorders of movement scaling during gait in Parkinson’s disease and Huntington’s disease, M. Morris

127 Potential early diagnostic markers of Parkinson’s disease in idiopathic REM sleep behaviour disorder, R. Postuma

129 Quality of life in young onset Parkinson’s disease patients, M. Relja

139 Movement-evoked potential and hemiparkinsonism, M. Vendrova

142 Stability of visual fixation in Parkinson’s disease, P. Wetzel

GUIDED POSTER TOURSThursday, February 23Poster tours will run from 6:00 p.m. to 7:30 p.m. and will start at the first poster listed in the tour.

Thur

sday

, Feb

ruar

y 2

3, 2

00

6

54


Tour 7: Clinical Trials ITour Guide: TBA

223 Malignant melanoma in early Parkinson’s disease – DATATOP trial, R. Constantinescu

224 Treatment of levodopa-induced dyskinesias with donepezil, J. Duda

225 Clinical research coordinator workload in clinical trials in Parkinson’s disease, K. Dustin

226 Baseline comparison of the PRECEPT and DATATOP clinical trial cohorts, Parkinson Study Group

227 At-home testing battery for collecting objective motor data: Technology to capture longitudinal changes in Parkinson’s disease,C. Goetz

228 The role of balance tests as predictors of the fall risk in patients with Parkinson’s disease, E. Kerckhofs

231 Sarizotan does not influence the pharmacokinetics or safety of digoxin in healthy male volunteers, S. Krosser

Tour 8: Disability and Quality of Life ITour Guide: Laura Marsh, M.D.

301 Impact of levodopa-induced dyskinesia on Parkinson’s disease patients’ health-related quality of life: Results from in-depth patientinterviews, L. Abetz

304 Coping strategies used by individuals with young onset Parkinson’s disease, M. Gerstenhaber

305 Impact of optimism and locus of control on disability and quality of life in Parkinson’s disease patients, A. Gruber-Baldini

306 New diary developed to assess duration and severity of dyskinesia in Parkinson’s disease (PD) patients, R. Hauser

312 Further development and validation of the parental illness impact scale (PIIS), D. Morley

313 Does the trunk impairment scale discriminate between trunk motor performance in patients with Parkinson’s disease and age-matched controls?, A. Nieuwboer

317 Quality of life in persons with Parkinson’s disease appropriate for treatment with deep brain stimulation, F. Weaver


55

Tour 9: Dopamine Receptors and Other NeurotransmittersTour Guide: Cindy Lawler, Ph.D.

89 Lemon-induced modulation of mGluR5 function in the olfactory bulb in a rodent PD model, A. Brownell

90 Neuroadaptive changes in striatum and substantia nigra reticulata associated with a dyskinetic L-DOPA treatment are not induced bythe low dyskinetic drug ropinirole, A. Carta

91 Intermittent stimulation of the D2 dopaminergic receptors abolishes adenylyl cyclase superactivation, L. Mann

92 The in vivo characterization of SLV308: A novel dopamine D2/D3 partial agonist and 5-HT1A full agonist for the treatment ofParkinson’s disease, A. McCreary

93 The in vitro characterization of SLV308: A novel dopamine D2/D3 partial agonist and 5-HT1A full agonist for the treatment ofParkinson’s disease, A. McCreary

94 Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist for the treatment of Parkinson’s disease, D. Scheller

95 Potential antiparkinsonian action of trace amine 1 receptor (TA1R) ligands in a novel acute mouse model of severe dopaminedeficiency, T. Sotnikova

96 Adenosine A2A receptors in mouse models of L-dopa-induced dyskinesia, D. Xiao

Tour 10: Education: Lay and Professional/Health literacyTour Guide: Gale Kittle, R.N., M.P.H.

292 Evaluation of a national model interdisciplinary training program in Parkinson disease for allied health professionals, R. Hagestuen

293 Nurses’ knowledge on genetics, J. Lee

294 Evaluation of an education, exercise and relaxation group for patients with Parkinson’s disease, F. Lindop

295 Survey of knowledge and attitudes towards genetic testing in Parkinson’s disease (PD), M. Nance

296 Advance care planning in Parkinson’s disease, H. Watson

297 The TULIPS program: A pilot program of Parkinson’s disease education and awareness for long-term care facilities, R. Wichmann

298 Concerns and stress levels among care partners of people with Parkinson’s disease in the Upper Midwest, R. Wichmann

299 Concerns and confidence levels among patients with Parkinson’s disease in the Upper Midwest, R. Wichmann

300 Concerns and confidence levels among health care professionals working with patients with Parkinson’s in the Upper Midwest,R. Wichmann

Tour 11: Medical Therapy ITour Guide: Stephen Reich, M.D.

187 The human experience with intravenous levodopa, N. Abraham

189 Acute vascular parkinsonism after unilateral caudate infarct and spontaneous improvement, S. M. Choi

191 Survey of levodopa treatment patterns by clinical practitioners, S. Fahn

193 Intravenous levodopa administration in humans based on a tracer kinetic model, M. Gordon

195 Effects of apomorphine subcutaneous injections in 50 consecutive patients with parkinsonism, S. Isaacson

197 Early initiation of entacapone leads to superior 5-year efficacy compared to delayed initiation in Parkinson’s disease patients receivingtraditional levodopa/DDCI therapy, M. Leinonen

199 Genetic polymorphism angiotensin converting enzyme gene and L-dopa-induced adverse effects in Parkinson’s disease, J. Lin

201 An anti-parkinson botanical with symptomatic and neuroprotective effect, B. Manyam

203 Subcutaneous apomorphine infusion: Clinical and neuropsychological follow-up at 12 months in patients with complicated PD, C. Siri

205 L-dopa improves flexible control of movement in Parkinson’s disease patients when moving in altered contexts, E. Tunik

207 StalevoTM is efficient and well-tolerated in patients with Parkinson’s disease experiencing wearing-off symptoms, B. Zeiler

GUIDED POSTER TOURSThursday, February 23Poster tours will run from 6:00 p.m. to 7:30 p.m. and will start at the first poster listed in the tour.

Thur

sday

, Feb

ruar

y 2

3, 2

00

6

56

Tour 11: Non-motor Features: Cognition Tour Guide: Zvezdan Pirtosek, M.D., Ph.D.

146 Duration of parkinsonism prior to dementia is associated with a different pattern of neuropathological and neurochemical substratesin DLB and PDD, D. Aarsland

147 The neuropathology of dementia in Parkinson disease: A prospective, community-based study, D. Aarsland

151 Expressive language after PD: Deficits in use but not form, C. Ellis

156 Computerized measures of working memory in Parkinson’s disease, A. Hancock

161 Have patients with Parkinson’s disease in HY-stage III the ability to implicit sequential learning?, E. Kerckhofs

162 Cognitive impairment and cerebral blood flow in non-demented patients with Parkinson’s disease, J. Kim

164 “Pure” Lewy body fementia in a community-based autopsy study, J. Leverenz

166 Functional deficits and underlying cognitive dysfunction in Parkinson’s disease, J. Sinni

169 Prospective study of smoking and decline in cognitive function in Parkinson’s disease, M. Weisskopf

170 Selective cognitive impairments associated with executive dysfunction in Parkinson’s disease, J. Williams

Tour 12: Non-pharmacologic Therapies ITour Guide: Becky Farley, Ph.D., PT

245 The use of low-protein food in Parkinson’s disease patients on levodopa therapy, M. Barichella

247 High intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson disease, L. Dibble

249 Self-perception of active and passive turning in Parkinson disease, G. Earhart

251 The rotating treadmill: A new tool for gait rehabilitation, M. Hong

253 Resistance training and creatine supplementation inParkinson’s disease, J. Juncos

255 Quality of allied health care in Parkinson’s disease,M. Nijkrake

257 Improvement of gait using step-synchronized vibrationstimulation of soles in Parkinson’s disease, P. Novak

259 Treating speech and voice in Parkinson’s diseasefollowing deep brain stimulation of the subthalamicnucleus: Preliminary findings, J. Spielman

261 Long-term locomotor training for gait and balance in apatient with mixed progressive supranuclearpalsy/corticobasal degeneration features, T. Steffen

263 Combination of mental practice and physiotherapy ingroup treatment of patients with Parkinson’s disease,R. Tamir

Tour 13: Protein Misfolding and HandlingTour Guide: Ted Dawson, Ph.D.

45 Alpha-synuclein associates with lipid rafts in vitro,S. Kubo

46 Synuclein, dopamine and oxidative stress in Parkinson’sdisease, K. Maguire-Zeiss

47 Diverse effects of the pathogenic mutations of parkinthat catalyzes multiple mono-ubiquitylation, N. Matsuda

48 Effect of membranes and oxidative stress on alpha-synuclein aggregation in dopaminergic neurons,J. Rochet

49 14-3-3eta is a novel regulator of parkin ubiquitin-ligase,S. Sato

50 Identification of conformation-specific alpha-synucleinsingle-chain antibodies, C. Wang



57

Friday, February 24Tour 1: Brain Physiology, Circuitry and Pathology Tour Guide: Jonathan Mink, M.D., Ph.D.

62 Does striatal pathology distinquish DLB from PDD?, J. Duda

63 Parkinsonism and Nocardia: A clinco-pathological case, S. Jain

64 Increased slow oscillatory activity in the basal ganglia during apomorphine-induced dyskinesia in the MPTP-macaque model: A multi-single unit recording study, A. Nadjar

84 The automatic and voluntary orienting of visual attention in Parkinson disease patients, A. Mota

85 Passage of oscillatory activity in basal ganglia-thalamocortical pathways in parkinsonism, L. Parr-Brownlie

86 Determination of regional differences in content and in T2 relaxation times of the main cerebral metabolites in patients withParkinson’s disease (PD): In vivo[sup] 1[/sup]H MRS study, Z. Rozhkova

87 Time perception in Parkinson’s disease, K. Silva

88 Disturbed surround inhibition in idiopathic Parkinson’s disease, Y. Sohn

Tour 2: Care Delivery: Fitness, Wellness, Working and DrivingTour Guide: Beth Kirkwood, O.T.

276 The prevalence and burden of constipation amongst people with Parkinson’s disease: A pilot study, H. Gage

277 Driving health in Parkinson’s disease: Comparing patient perceptions with computer adaptive testing results, M. Gomez

278 Theoretical model and evaluation of self-management programs for people with early Parkinson’s: Findings from the Parkinson’s EarlyIntervention Program (PEIP) and the Early Management/Self- Management Program (EMP/SMP), R. Gruber

279 The influence of the art of moving exercise program on quality of life for people with PD, D. O’Donnell

280 Preliminary evaluation of self-directed, community-based exercise designed to minimize secondary physical complications in peoplewith Parkinsons, G. Turnbull

281 Effect of road type on driving safety in Parkinson’s disease, E. Uc

282 Integrative yoga program for the person with Parkinson’s disease, M. Walde-Douglas

Tour 3 Cell Death Mechanisms, Neuroprotection and Trophic Factors: Pathogenic MechanismsTour Guide: Miquel Vila, M.D., Ph.D.

27 Dopaminergic axonal degeneration in striatum induced by 6-hydroxydopamine (6OHDA) in adult mice is associated withmacroautophagy, H. Cheng

31 Study of gene expression and modulation of group III metabotropic glutamate receptors (mGluRs) in the basal ganglia of normal andParkinsonian rodents: Investigation of potential drug targets to treat Parkinson’s disease, M. Marvanova

32 The effects of PDGF on the differentiation and survival of adult human multipotential progenitor/stem cells, J. McClain

33 Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity, M. Mena

34 Neurogenesis of Parkinson’s diseased model and Parkinson’s disease, H. Mochizuki

36 A constitutively active form of the oncoprotein AKT protects dopamine neurons of the substantia nigra in a neurotoxin model ofParkinson’s disease, V. Ries

39 Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi, M. Sapru

44 The ER stress-induced transcription factor CHOP alters susceptibility of dopaminergic (DA) MN9D cells to toxic insult, J. Yates

Tour 4: Clinical Features: Natural History and Progression of PDTour Guide: Yoshikuni Mizuno, M.D.

104 Longitudinal changes in brain network activation during sequential reaching in Parkinson’s disease, M. Carbon

105 Clinical features in twins concordant for Parkinson’s disease (PD), A. Chade

107 Gender differences in Parkinson’s disease, C. Haaxma

117 The changing face of deglutition in idiopathic Parkinson’s disease (IPD), J. Logemann

125 Heterogeneity in newly diagnosed Parkinson’s disease, J. Post

126 –CANCELLED– Prognostic factors for the progression of Parkinson’s disease; a systematic review of literature –CANCELLED–

130 Longitudinal progression of odor identification deficits in Parkinson’s disease, J. Rick

132 Apomorphine as a diagnostic tool for Parkinson’s disease, M. Stacy

145 The G2019S mutation in LRRK2 causes typical PD: Clinical analysis of a large Italian PD sample, M. Zini

GUIDED POSTER TOURSFriday, February 24Poster tours will run from 6:00 p.m. to 7:30 p.m. and will start at the first poster listed in the tour.

Frid

ay, F

ebru

ary

24

, 20

06

58

Tour 5: Clinical Features: Other Signs and Symptoms Besides Cardinal SignsTour Guide: Robert Iansek, Ph.D., FRACP

100 Frequency of restless legs syndrome symptoms in a population ofParkinson’s disease patients attending a movement disorders clinic,K. Amar

111 Drooling in Parkinson’s disease, J. Kalf

115 Lower back pain in Parkinson’s disease, M. Lee

120 Phenylthiocarbamide (PTC) perception in Parkinson’s disease,P. Moberg

131 Fatigue in levodopa-naive subjects with early PD, G. Schifitto

135 A pilot study: Physical function in individuals with Parkinson’s disease(PD) as compared to national norms, M. Suteerawattananon

141 A pilot study of procedural learning in Chinese patients with non-demented Parkinson’s disease, X. Wang

144 –CANCELLED– Affects of dopamine-replacing drugs on motor imageryin Parkinson’s disease –CANCELLED–

Tour 6: Clinical Trials IITour Guide: TBA

229 The ParkNet trial: Implementation of an evidence-based guideline forphysical therapy in Parkinson’s disease, S. Keus

230 Impact of pramipexole on the onset of levodopa related dyskinesias,K. Kieburtz

232 Effect of sarizotan on the pharmacokinetics of probe drugs for majorcytochrome P450 isoenzymes: A combined cocktail study, S. Krosser

233 Sarizotan does not change levodopa pharmacokinetics, S. Krosser

236 Comparison of pharmacokinetics of levodopa and carbidopa betweenIPX054 and Sinemet and Sinemet CR tablets under fasting conditions,E. Liang

237 Sarizotan is well tolerated during long-term treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease, W. Olanow

239 Pooled analysis of two identical phase-3 studies of a novel selegilinepreparation as adjunctive therapy for Parkinson’s disease, W. Ondo

Tour 7: Complications of TherapyTour Guide: Oscar Gershanik, M.D.

217 Valvular heart disease in treatment of Parkinson’s disease with ergotderivative dopamine agonists, J. Kim

218 Chronic pain in Parkinson’s disease: Interim analysis of the DoPaMiPstudy, a cross-sectional survey in south-west of France, L. Negre-Pages

219 Pergolide-induced fibrotic complications in Parkinson disease,M. Panisset

220 Neuropsychological function and age impact extended hospital stayfollowing DBS, J. Pavon

221 Effects of CHF 1512, a new combination of levodopa methylester andcarbidopa, on motor fluctuations in Parkinson’s disease: Results from aEuropean study, F. Stocchi

222 A prospective study of pathological gambling and hypersexuality inParkinson’s disease: Prevalence rates and association withdopaminergic medications, V. Voon

GUIDED POSTER TOURSFriday, February 24


59

Tour 8: Disability and Quality of Life IITour Guide: Kevin Biglan, M.D.

302 The influence of sleep disturbances in Parkinson’s disease on health-related quality of life, M. Boczarska-Jedynak

307 The impact of fatigue, motor impairment and depression on performance of activities of daily living in Parkinson’s disease, J. Jansa

308 An exploration of functional activity in Parkinson’s disease using activity monitoring and activity diaries, D. Jones

309 Role changes and role performance satisfaction among individuals with young onset Parkinson’s disease, L. Larson

311 The quality of life of people with Parkinson’s disease: A study in a sample of 101 subjects, S. Montel

314 Description of participant population in Parkinson’s Disease Registry, S. Oswald

315 Test-retest reliability of the activities-specific balance confidence scale for people with Parkinson’s disease, M. Venglar

319 Implications of motor fluctuations in Parkinson’s patients on chronic therapy (IMPACT) registry: Quality of life (QOL) data, R. Wilson

Tour 9: Health Care Accessibility ITour Guide: Patricia Kavanagh, M.D.

324 Multidisciplinary approach to Parkinson’s disease, J. Vanderheyden

331 The Parkinson Speech Group, B. Bereskin

332 Community Partners in Parkinson Care (CPP): Outreach to underserved diverse communities, G. Gonzalez-Ramos

333 The impact of fractured finance on care for American VA patients with Parkinson’s disease, A. Hendricks

335 Surveys with persons living with Parkinson’s disease in Alberta, Canada: The information and services they value and need, K. Kovacs Burns

339 Specialty clinic for veterans with Parkinson’s disease achieves high satisfaction, N. Nelson

340 Social work at the crossroads of Parkinson’s disease, J. Posen

Tour 10: Medical Therapy IITour Guide: Fabrizio Stocchi, M.D., Ph.D.

188 Therapeutic efficiency of venlafaxine in depressive patients with Parkinson’s disease, K. Bayulkem

190 Efficacy of entacapone in patients with Parkinson’s disease and motor fluttuations: A 6-year clinical follow-up study, R. Cilia

192 Intermittent subcutaneous apomorphine: Evidence for efficacy at early timepoints in Parkinson’s disease, H. Fernandez

194 Intraduodenal application of levodopa in advanced Parkinson’s disease, M. Hahn

196 Efficacy and tolerability of entacapone in elderly patients with Parkinson’s disease, S. Isaacson

198 Memantine may alleviate psychosis and cognitive dysfunction in dementia with Lewy bodies, D. Lichter

200 Assessment and treatment of speech and swallowing at the Parkinson center facility, the Tel-Aviv experience, Y. Manor

202 Depression and anxiety symptoms in Parkinson’s disease: Interim analysis of the DoPaMiP study, a cross-sectional survey in south-west of France, L. Negre-Pages

204 Can we predict the responsiveness of Parkinsonian rest tremor to dopaminergic treatment?, Y. Sung

206 Tolkapone in treatment of Parkinson’s disease, M. Vendrova

Tour 11: Mitochondria, Oxidative Stress, Inflammation and other PathogenesesTour Guide: TBA

51 Microglial activation and perpetuation of neurodegeneration in Parkinsonian monkeys, D. Anderson

52 Parkinson’s disease and gluten sensitivity, B. Aranda

53 Microglia mediates dopaminergic neurotoxicity induced by femtomolar fMLP in midbrain primary neuron-glia culture, X. Gao

54 Knockdown of uncoupling protein-5 expression reduces mitochondrial membrane depolarization and increases oxidative stressinduced by MPP[sup]+[/sup], S. Ho

55 Mitochondrial targeting signal and 5’untranslated region sequences are required for uncoupling protein 5 (UCP5) expression inmitochondria, S. Ho

56 Effect of MPTP on the brain amino acid concentrations, P. Klivenyi

57 Rotenone induces dopamine cell death and microglial activation in parkin knock-out mice. Protection with minocycline, M. Mena

58 Oxidative stress induced by human alpha-synuclein overexpression, D. Short

59 Microglial activation in the SYN+/+ model of Parkinson’s disease, X. Su

60 Iron-catalyzed oxidative stress causes the aggregate assembly in human neuronal cells overexpressing wild-type alpha-synuclein, M. Takahashi

61 On the mechanism of mutant a-synuclein-, A30P and A53T, elicited dopaminergic neurodegeneration: Role of microglial Mac-1 andPHOX, W. Zhang

GUIDED POSTER TOURSFriday, February 24Poster tours will run from 6:00 p.m. to 7:30 p.m. and will start at the first poster listed in the tour.

Frid

ay, F

ebru

ary

24

, 20

06

60

Tour 12: Mutations in Etiology, Genetics, Epidemiology, and ToxicantsTour Guide: David Sulzer, M.D.

2 Heterozygous PINK1 mutations are a significant risk factor in sporadic PD, P. Abou-Sleiman

4 Genes and Parkinson’s disease – A clinic-based study in a Portuguese cohort, J. Bras

6 The LRRK2 mutation, Gly2019Ser, in a US Jewish PD population, L. Clark

7 Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease, A. Di Fonzo

13 Analysis of the G2019S dardarin mutation in an open access DNA repository of Parkinson’s disease and control samples, J. Keen

14 Screening of SCA2 and SCA3 in the patients with Parkinson disease in Korea, H. Kim

15 G2019S and I2020T mutations of LRRK2 gene are rare causes of Parkinson’s disease (PD) in the Polish population, G. Klodowska-Duda

19 Mutations in LRRK2 – A clinical and genetic study in a Portuguese population, A. Morgadinho

20 Screening for known LRRK2 mutations in familial Parkinson disease, W. Nichols

Tour 13: Non-motor Features: Depression and PsychosisTour Guide: Cynthia A. Holmes, Ph.D.

150 Minor depression in patients with Parkinson’s disease and dementia – Clinical and demographic correlates, U. Ehrt

152 Depressive symptom pattern among Parkinson’s disease patients with major depressive disorder, A. Farabaugh

158 Non motor manifestations in Parkinson’s disease: Description and risk factors, C. Juri

159 Depression and motor manifestations in Parkinson’s disease, C. Juri

163 Delusion and dopaminergic systems in Parkinson’s disease: A comparison study with hallucination in Parkinson’s disease, E. Lee

165 Clinical features associated with impulsecontrol disorders in Parkinson’s disease,G. Pontone

168 Hedonistict homeostatic dysregulation inParkinson’s disease: Prevalence andincidence, A. Thomas

171 Young age, disease severity diseaseduration predict depressive disorder duringthe course of Parkinson disease, L. Yap

Tour 14: Public Policy and Advocacy Tour Guide: Lisa Shulman, M.D.

325 “You say ‘advocate,’ I say ‘activist.’” Dosome leaders of health-impacted groupshave a different approach to social changefrom their “healthy” colleagues inenvironmental health groups?,J. Christensen

326 Advocacy for PD and environmental health:The Collaborative on Health and theEnvironment Working Group on Parkinson’sDisease and the Environment,J. Christensen

327 Multi-method evaluation of VA’s efforts toimprove care for Parkinson’s disease,I. Cramer

328 International comparison of Parkinson’spatients’ experiences: A pilot study,H. Gage

329 Parkinson nurse specialist as thecoordinator of a multidisciplinary team –The Tel-Aviv model, O. Moore

330 Funding surgical device research:Perspectives of Parkinson’s diseaseresearchers, D. Vawter

GUIDED POSTER TOURSFriday, February 24


61

Saturday, February 25 Tour 1: A Look at the Lived Experience of People Living with Parkinson’s Tour Guide: Alba Bonetti, R.N.

267 Short term crisis intervention with Parkinson patients and families, J. Posen

268 Optimizing function in Parkinson’s patients – The lived experience of caregivers and patients, I. Pretzer-Aboff

269 The experience of stigma among people living with Parkinson’s disease, L. Rintamaki

272 Sexuality and intimacy in young onset Parkinson’s disease, C. Wielinski

273 Sexuality and intimacy in couples with young onset Parkinson’s disease, C. Wielinski

Tour 2: Alternative and Complementary Therapies & Creativity Tour Guide: Allan Kroland, D.C.

283 “Circle of Support” – Intensive and ongoing speech therapy with Parkinson Plus disorders, B. Bereskin

284 The Tel-Aviv experience of a multidisciplinary team approach in an out-patient Parkinson center, located in a large, academic, tertiarymedical center, N. Giladi

285 The effects of the [quot]Motivating Moves for People with Parkinson’s[quot] exercise program on the participants’ physical functionand quality of life, J. Hamburg

286 Neurologic music therapy interventions to improve sensorimotor functioning in people with Parkinson’s disease, S. Holten

287 The club CREATE players: A model for creative expression, M. Johnson

288 Taiji buddies: An instructional video for individuals with Parkinson’s and their support partners, P. Klein

289 Videotapes of the drum story song activity model (an interactive, facilitated activity blending rhythm, stories, and songs with cluing andpositive triggering techniques) enhances the movement, attention, and communication, H. MacTavish

290 Validating spirituality in Parkinson’s disease, B. McHale

291 Horticulture therapy in treatment of Parkinson’s disease, R. VandenDolder

Tour 3: Animal and Cellular Models IITour Guide: Etienne Hirsch, Ph.D.

65 Mechanism of antidyskinetic action of sarizotan, G. Bartoszyk

66 Receptor pharmacology of the antidyskinetic drug sarizotan, G. Bartoszyk

67 Antidyskinetic efficacy of sarizotan, M. Gerlach

71 Co-administration of LDOPA/carbidopa with entacapone avoids dyskinesia induction in MPTP-treated primates with full or partial nigrallesions, P. Jenner

73 The evolution of L-dopa-induced dyskinesia in relation to L-dopa dose magnitude and frequency of administration, S. Konitsiotis

75 L-dopa induced increase in striatal glutamate following a 6-OHDA lesion of the nigrostriatal pathway, C. Meshul

78 Comparison of continuous vs pulsatile administration of rotigotine in the MPTP-treated marmoset model of Parkinson’s disease,D. Scheller

82 Developing a preclinical model of Parkinson’s disease: A study in rats with graded 6-OHDA lesions, L. Truong

83 Transplantation of fetal ventral mesencephalic cell suspensions lacking the dopamine transporter as a model of graft induceddyskinesias, A. Vinuela

Tour 4: Biomarkers and Neuroimaging: Diagnostic Imaging and Treatment Effects Tour Guide: TBA

173 Cardiac 123I-MIBG scintigraphy and autonomic function test in Parkinson’s disease and subtypes of multiple system atrophy, E. Chung

177 InSPECT: An investigation of the effects of short-term treatment with pramipexole or levodopa on [123I] B-CIT and SPECT imaging inearly Parkinson disease, D. Jennings

178 Dopamine transporter imaging as a tool for early diagnosis in Parkinsonian syndrome, D. Jennings

180 Myocardial MIBG scintigraphy in patients with atypical tremor disorders, H. Kim

181 Evidence for increased activation of subcortical motor structures following acupuncture in a case of ideopathic Parkinson’s disease,J. Lazarus

182 Differentiation of Parkinson disease and the Parkinsonian variant of multiple system atrophy by measuring cardiac MIBG uptake,K. Lee

183 Proteomic analysis of peripheral leukocytes in neurodegenerative diseases, T. Mhyre

184 Role of DAT scan in movement disorder clinic, S. Raha

GUIDED POSTER TOURSSaturday, February 25Poster tours will run from 6:00 p.m. to 7:30 p.m. and will start at the first poster listed in the tour.

Sat

urda

y, F

ebru

ary

25

, 20

06

62

Tour 5: Cell Death Mechanisms, Neuroprotection and Trophic Factors: Experimental TherapiesTour Guide: TBA

26 GDNF induced restoration of dopamine release and content in the nigrostriatal system of young and aged rats lesioned withintrastriatal 6-OHDA, W. Cass

28 Striatal administration of an AAV-2 vector encoding human neurturin (CERE-120) reverses the age related decline in markers ofnigrostriatal function in rhesus monkeys, B. Dass

29 Estrogen protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection,O. Korzh

30 Assessment of the neuroprotective function of DJ-1 in cell-culture models of Parkinson’s disease, F. Liu

35 Green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) regulates the expression of the iron-responsive proteins amyloid precursorprotein (APP) and transferrin receptor and reduces the Alzheimer’s disease-related [beta]-amyloid peptide, L. Reznichenko

37 EGb761 restores of damage produced by 1-methyl-4-pheyl-1,2,3,6-tetrahydropyridine, P. Rojas

38 Neurorescue activity of rasagiline in post MPTP treatment is associated with activation of tyrosine kinase receptor (Trk) down streamRas-PI3K-Akt survival pathway, Y. Sagi

40 Neuroprotection in animal models of parkinsonism: Influence of toxin administration protocols, J. Schneider

41 Neuroprotective effects of 20(S)-ginsenoside Rg3 on levodopa induced cytotoxicity of neural stem cells, J. Tian

42 Neuroprotective effects of modafinil in a non-human primate Parkinson model, S. van Vliet

43 AAV delivery of human GDNF for treatment of Parkinson’s disease (PD), N. West

GUIDED POSTER TOURSSaturday, February 25


63

Tour 6: Clinical Features: Cardinal Signs and Symptoms of PDTour Guide: Mark Stacy, M.D.

98 The feature of perceived stability limits in the patients with Parkinson’s disease, K. Abe

101 Quantitative analysis of Parkinsonian rigidity as a function of speed and correlation to clinical scales, M. Baron

106 Disappearance of resting tremor after contralateral thalamic infarction, S. Choi

114 Reliability and validity of the Tinetti mobility test for individuals with Parkinson’s disease, A. Kloos

122 Postural control in Parkinson’s disease: A comparison between freezers, non-freezers and controls, A. Nieuwboer

128 Posture, matted romberg, tandem gait, push test and turns in elderly Parkinsonian and elderly neurologic patients, A. Rapoport

134 The effects of cognitive/linguistic load on gait in individuals with Parkinson’s disease, J. Stierwalt

137 Camptocormia in Lewy body dementia in comparison with Parkinson’s disease, A. Thomas

Tour 7: Clinical Features: Effects of Anti-PD MedicationsTour Guide: Kathleen Shannon, M.D.

102 Hyperhomocysteinemia in Parkinson patients treated with L-DOPA, K. Bayulkem

103 L-DOPA addiction in a young-adult woman patient with Parkinson’s disease, K. Bayulkem

108 Does levodopa help or hinder speech in Parkinson’s disease?, A. Ho

123 End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson’s disease, M. Onofrj

133 Implications of motor fluctuations in Parkinson’s patients on chronic therapy (IMPACT) registry: Comparison of patient- and physician-reported data, M. Stacy

138 Catamenial end-off dose in Parkinson’s disease, A. Thomas

140 Oldest risks for Parkinson’ disease: Some plants from traditional Chinese medicinal herbs?, X. Wang

143 Implications of motor fluctuations in Parkinson’s patients on chronic therapy (IMPACT) registry: Relationship between Hoehn & Yahrstage and patient- and disease-related characteristics, R. Wilson

Tour 8: Clinical Trials IIITour Guide: Christopher Hyson, M.D., FRCPC

234 Sarizotan: A review of its clinical pharmacokinetics, S. Krosser

235 Assessment of the effect of entacapone on the pharmacokinetics of IPX054, E. Liang

238 Sarizotan has long-term efficacy in reducing levodopa-induced dyskinesia in patients with Parkinson’s disease, W. Olanow

240 The effects of cueing therapy on gait and gait related mobility in people with Parkinson’s disease: The RESCUE project, L. Rochester

241 Does a two-rater system improve reliability of UPDRS motor scoring of mild Parkinson’s patients?, J. Schneider

242 Rotigotine patch improves quality of life when used in the treatment of moderate to severe idiopathic restless legs syndrome – Adouble-blind placebo-controlled multi-center dose-finding study, K. Stiasny-Kolster

243 Follow-up of persons with neurologic diseases (FOUND): Up to 46 months followup, C. Tanner

244 Ethical issues in deep brain stimulation (DBS) research: Perspectives of surgical researchers studying Parkinson’s disease (PD),D. Vawter

Tour 9: Disability and Quality of Life III Tour Guide: Mary Baker, M.B.E.

303 Evaluation of voice-related quality of life (V-RQOL) secondary to Parkinson’s disease, P. Doyle

310 Multidisciplinary intervention in Parkinson’s disease; a comparison of fatigue and conventional disease measures, M. Makoutonina

316 Continuum of care upon PT discharge: A collaborative approach-case study, M. Walde-Douglas

318 Developing Parkinson’s specialty care in assisted living: A collaborative model, R. Wichmann

320 Caregiver burden in Parkinson’s disease and caregiver assessment of the value of professional assistance, B. Winkler

321 Personality’s influence on quality of life in Parkinson’s disease patients, S. Yeager

322 Observation day: A nursing clinic to help define patterns of symptoms, J. Gardner

323 Technology supported speech treatment for Parkinson’s disease, A. Halpern


Sat

urda

y, F

ebru

ary

25

, 20

06

64

Tour 10: Health Care Accessibility IITour Guide: Patricia Kavanagh, M.D.

334 Videoconferencing can provide people in country Australia with regular access to city-based movement disorders specialists,B. Kirkwood

336 Treatment initiatives for the management of dyskinesia in Parkinson’s disease patients: Findings of an international survey, T. Muller

337 The first incidence of dyskinesia can be at any stage of Parkinson’s disease and at any point during levodopa treatment, T. Muller

338 Dyskinesia is treated more aggressively by physicians in the United States and Europe than in Japan, T. Muller

341 Results of a psychosocial needs assessment of people with PD, M. Welsh

342 Only half of specialist physicians find the current options for the management of dyskinesia acceptable, D. Woitalla

Tour 11: Non-pharmacologic Therapies IITour Guide: Roger Rossi, D.O.

246 Delayed auditory feedback in Parkinson’s disease (PD) patients with festinating speech, K. Chou

248 Treating depression in Parkinson’s disease: A cognitive-behavioral approach, R. Dobkin

250 Efficacy of comprehensive multi-disciplinary long-term group therapy for persons with Parkinson’s disease, R. Frohner

252 Implementing cueing therapy evidence in Parkinson’s disease: The Rescue project CD rom, D. Jones

254 Evidence-based clinical practice guideline for physical therapy in Parkinson’s disease, S. Keus

256 A multifaceted implementation strategy for an evidence-based physical therapy guideline, M. Nijkrake

258 A description of balance characteristics in Parkinson’s disease using computerized dynamic posturography, A. Qutubuddin

260 The use of cues in improving gait in persons with Parkinson’s disease: A systematic literature review, T. Steffen

262 Pilot evaluation of the WalkAbout in a sample of persons with Parkinson’s disease, M. Suteera-wattananon

264 Biomechanical vs neurological influences on hypokinetic gait in Parkinson’s disease, A. Threlkeld

GUIDED POSTER TOURSSaturday, February 25


65

Tour 12: Surgical TherapyTour Guide: TBA

208 Subthalamic deep brain stimulation under general anesthesia in Parkinson’s disease, S. Chen

209 Deep brain stimulation effects on posture control in Parkinson’s disease, N. Krishnamurthi

210 Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease may decelerate the degeneration of nigrostriatal pathway –A prospective [sup]18[/sup]F-DOPA PET study, S. Lin

211 Continuous high frequency electrical stimulation affects the impedance of monopolar deep brain electrodes, H. Moore

212 Detection of the subthalamic nucleus in microelectrographic recordings in Parkinson’s disease using the high frequency ([gt]500 Hz)neuronal background, P. Novak

213 Comparing pre- and postoperative assessments of depression and suicide following DBS, C. Rosado

214 Unilateral deep brain stimulation of subthalamic nucleus for Parkinson’s disease, J. Slowinski

215 Effect of subthalamic stimulation on tremor dominant Parkinson’s disease, S. Tsai

216 Five-year outcome in 50 consecutive advanced PD patients treated with STN-DBS, C. Wider

Tour 13: Various Etiology, Genetics, Epidemiology, and ToxicantsTour Guide: TBA

1 CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease, W. Abdo

5 Dopamine neurotoxins lead to leakage of the blood brain barrier (BBB) in several animal models, P. Carvey

9 Clinical characterization of incidental Lewy body disease: Age, gender and smoking, G. Glass

17 Parkinson’s disease: Demographic and geographic distribution of affected veterans (1998-2002), E. Lai

21 FosB splicing regulation is disrupted in an MPTP model, J. Potashkin

22 Evaluation of Parkinson’s disease (PD) prevalence in patients with malignant melanoma (MM), D. Rigel

Tour 14: Various Non-motor FeaturesTour Guide Ron Pfeiffer, M.D.

148 Short-term monitoring of respiratory parameters in severe fluctuating Parkinson’s disease: Relevance for dopaminergic treatment,S. Bohlhalter

149 The phenomenology of dreams in Parkinson’s disease, L. Borek

153 REM sleep behavior disorder and testosterone levels in men with Parkinson’s disease, J. Friedman

154 A comparison of fatigue measures in Parkinson’s disease, J. Friedman

155 Motor skill consolidation in Parkinson’s disease (PD), M. Ghilardi

157 Longitudinal effect of Parkinson’s disease on managing distraction during cognitive tasks, A. Hancock

160 Impact of fatigue in a community-based sample of Parkinson’s disease patients, M. Kasten

167 Olfactory dysfunction in Parkinson’s disease: An fMRI study, A. Takeda


Sat

urda

y, F

ebru

ary

25

, 20

06

68

FACULTY

Dag Aarsland (Norway). . . . . . . . . . . . . . . . . . . . . 47Nan Abraham (USA) . . . . . . . . . . . . . . . . . . . . . . . 42Ellen Abramson (USA) . . . . . . . . . . . . . . . . . . . . . . 47, 51Patrick Aebischer (Switzerland) . . . . . . . . . . . . 37Yves Agid (France) . . . . . . . . . . . . . . . . . . . . . . . . . 44Eric Ahlskog (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 23, 27Karen Anderson (USA) . . . . . . . . . . . . . . . . . . . . . 43Patricia Archbold (USA) . . . . . . . . . . . . . . . . . . . . 39, 43, 48John Argue (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 32Mary Baker (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . 18, 21, 48John Ball (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49Stavros Baloyannis (Greece) . . . . . . . . . . . . . . . . 40Krystof Bankiewicz (USA) . . . . . . . . . . . . . . . . . . . 46Roger Barker (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 38Flint Beal (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28Mara Behlau (Brazil) . . . . . . . . . . . . . . . . . . . . . . . 24Alim Benabid (France) . . . . . . . . . . . . . . . . . . . . . . 30Donna Benton (USA) . . . . . . . . . . . . . . . . . . . . . . . 40Kenneth Bergmann (USA) . . . . . . . . . . . . . . . . . . 47Erwan Bezard (France) . . . . . . . . . . . . . . . . . . . . . 48Kevin Biglan (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 34Anders Björklund (Sweden) . . . . . . . . . . . . . . . . . 46, 47, 51Judith Blazer (USA) . . . . . . . . . . . . . . . . . . . . . . . . 24, 27Bastian Bloem (The Netherlands) . . . . . . . . . . . 49Martha Bohn (USA) . . . . . . . . . . . . . . . . . . . . . . . . 47, 51Alba Bonetti (Italy). . . . . . . . . . . . . . . . . . . . . . . . . . 40Vincenzo Bonifati (Italy) . . . . . . . . . . . . . . . . . . . . . 21Melanie Brandabur (USA) . . . . . . . . . . . . . . . . . . 24Richard Bringewatt (USA) . . . . . . . . . . . . . . . . . . 30Gila Bronner (Israel) . . . . . . . . . . . . . . . . . . . . . . . . 39, 41David Brooks (UK). . . . . . . . . . . . . . . . . . . . . . . . . . 28, 35Patrik Brundin (Sweden) . . . . . . . . . . . . . . . . . . . . 45Lisette Bunting-Perry (USA). . . . . . . . . . . . . . . . . 31, 35, 44, 51J. Peter Burbach (The Netherlands) . . . . . . . . 22Robert Burke (USA) . . . . . . . . . . . . . . . . . . . . . . . . 47Paolo Calabresi (Italy). . . . . . . . . . . . . . . . . . . . . . . 40Donald Calne (Canada) . . . . . . . . . . . . . . . . . . . . . 23, 27, 38Susan Calne (Canada) . . . . . . . . . . . . . . . . . . . . . . 39, 41Marc Caron (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 23Jonathan Carr (South Africa) . . . . . . . . . . . . . . . 48Julie Carter (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 23, 30, 35Harvey Checkoway (USA) . . . . . . . . . . . . . . . . . . . 20Phillip Clark (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 45Perry Cohen (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 32, 48Ron Cole (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50Carlo Colosimo (Italy) . . . . . . . . . . . . . . . . . . . . . . . 38, 42Cynthia Comella (USA). . . . . . . . . . . . . . . . . . . . . . 22, 27, 46Amy Comstock (USA) . . . . . . . . . . . . . . . . . . . . . . 42Michael Conneally (USA). . . . . . . . . . . . . . . . . . . . 36Mark Cookson (USA) . . . . . . . . . . . . . . . . . . . . . . . 28Anna Czlonkowska (Poland) . . . . . . . . . . . . . . . . . 31Ted Dawson (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 23, 28, 35Valina Dawson (USA) . . . . . . . . . . . . . . . . . . . . . . . 21Mahlon DeLong (USA). . . . . . . . . . . . . . . . . . . . . . 46

Susan Dentzer (USA). . . . . . . . . . . . . . . . . . . . . . . 30Gunther Deuschl (Germany) . . . . . . . . . . . . . . . . 44, 47, 51Ariel Deutch (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 40Dennis Dickson (USA) . . . . . . . . . . . . . . . . . . . . . . 22Mariann Di Minno (USA). . . . . . . . . . . . . . . . . . . . 26, 31Alessandro DiRocco (USA) . . . . . . . . . . . . . . . . . 29, 35, 48Richard Dodel (Germany) . . . . . . . . . . . . . . . . . . . 49Teresa Drinka (USA). . . . . . . . . . . . . . . . . . . . . . . . 45Joyce Dubensky (USA). . . . . . . . . . . . . . . . . . . . . . 42Carmen Dyck (Canada) . . . . . . . . . . . . . . . . . . . . 41Jim Eberwine (USA) . . . . . . . . . . . . . . . . . . . . . . . . 37David Eidelberg (USA) . . . . . . . . . . . . . . . . . . . . . . 36, 43Robin Elliott (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 39Murat Emre (Turkey) . . . . . . . . . . . . . . . . . . . . . . . 40, 43, 44, 51Stewart Factor (USA) . . . . . . . . . . . . . . . . . . . . . . 38Stanley Fahn (USA). . . . . . . . . . . . . . . . . . . . . . . . . 18, 20, 27, 51Becky Farley (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 32, 34, 35Sierra Farris (USA). . . . . . . . . . . . . . . . . . . . . . . . . 37, 43Mel Feany (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 29Howard Federoff (USA). . . . . . . . . . . . . . . . . . . . . 37, 45, 51Lynn Feinberg (USA). . . . . . . . . . . . . . . . . . . . . . . . 39Chris Fibiger (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 46, 51Beth Fisher (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 32Tatiana Foroud (USA). . . . . . . . . . . . . . . . . . . . . . . 25Cynthia Fox (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 27, 34Kirk A. Frey (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 36Karl Friedl (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 22Joseph Friedman (USA) . . . . . . . . . . . . . . . . . . . . 29Steve Frucht (USA). . . . . . . . . . . . . . . . . . . . . . . . . 50Hidenao Fukuyama (Japan) . . . . . . . . . . . . . . . . . 36Kjell Fuxe (Sweden) . . . . . . . . . . . . . . . . . . . . . . . . . 39Thomas Gasser (Germany) . . . . . . . . . . . . . . . . . 21Howard Gendelman (USA). . . . . . . . . . . . . . . . . . 45Oscar Gershanik (Argentina). . . . . . . . . . . . . . . . 26, 30Nir Giladi (Israel) . . . . . . . . . . . . . . . . . . . . . . . . . . . 18, 29, 37, 43Monique Giroux (USA) . . . . . . . . . . . . . . . . . . . . . . 37, 43, 45Christopher Goetz (USA) . . . . . . . . . . . . . . . . . . . 18, 33, 38, 43Steven Goldman (USA) . . . . . . . . . . . . . . . . . . . . . 46Gladys Gonzalez-Ramos (USA) . . . . . . . . . . . . . . 26, 40, 43, 47, 51Ann Graybiel (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 46Tim Greenamyre (USA). . . . . . . . . . . . . . . . . . . . . 31Grace Griffith (USA) . . . . . . . . . . . . . . . . . . . . . . . . 37Katrina Gwinn-Hardy (USA) . . . . . . . . . . . . . . . . . 22, 27Barbara Habermann (USA). . . . . . . . . . . . . . . . . 51, 45Peter Hagell (Sweden). . . . . . . . . . . . . . . . . . . . . . 21, 27, 40Ruth Hagestuen (USA) . . . . . . . . . . . . . . . . . . . . . 21, 29, 35, 49Janet Hamburg (USA). . . . . . . . . . . . . . . . . . . . . . 50John Hardy (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 36Gun-Marie Hariz (Sweden) . . . . . . . . . . . . . . . . . . 40, 41, 43Nobutaka Hattori (Japan) . . . . . . . . . . . . . . . . . . 23Susan Heath (USA) . . . . . . . . . . . . . . . . . . . . . . . . 31, 45Peter Heutink (The Netherlands). . . . . . . . . . . . 21, 27, 36David Heydrick (USA) . . . . . . . . . . . . . . . . . . . . . . . 32Etienne Hirsch (France) . . . . . . . . . . . . . . . . . . . . 20, 31, 35

69

FACULTY

Shu-Leong Ho (Hong Kong) . . . . . . . . . . . . . . . . . 23, 27Magaret Holloway (UK). . . . . . . . . . . . . . . . . . . . . 26, 47, 49Jau Shyong Hong (USA) . . . . . . . . . . . . . . . . . . . . 31Oleh Hornykiewicz (Austria) . . . . . . . . . . . . . . . . . 20, 27Robert Iansek (Australia) . . . . . . . . . . . . . . . . . . . 34, 37, 45, 51Tom Issacs (UK). . . . . . . . . . . . . . . . . . . . . . . . . . . . 34Ole Isacson (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 37, 43Pnina Isseroff (Israel). . . . . . . . . . . . . . . . . . . . . . . 34Samay Jain (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 41Aleksandar Janca (Australia) . . . . . . . . . . . . . . . 48, 51Joseph Jankovic (USA) . . . . . . . . . . . . . . . . . . . . . 17, 44, 48, 51Kurt Jellinger (Austria) . . . . . . . . . . . . . . . . . . . . . 20Peter Jenner (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 17, 39, 43James Joseph (USA) . . . . . . . . . . . . . . . . . . . . . . . 28Russell Katz (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 48Karl Kieburtz (USA) . . . . . . . . . . . . . . . . . . . . . . . . 17, 29Beth Kirkwood (Australia) . . . . . . . . . . . . . . . . . . 26, 34, 37Gale Kittle (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 33Morton Kondracke (USA). . . . . . . . . . . . . . . . . . . 46Ron Kopito (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 31Amos Korczyn (Israel) . . . . . . . . . . . . . . . . . . . . . . 40Jeffrey Kordower (USA) . . . . . . . . . . . . . . . . . . . . 46Adam Koss (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 50Vladimir Kostic (Yugoslavia) . . . . . . . . . . . . . . . . . 44Allan Kroland (USA) . . . . . . . . . . . . . . . . . . . . . . . . 24, 26, 27, 32, 35Holly Kroland (USA) . . . . . . . . . . . . . . . . . . . . . . . . 26Roger Kurlan (USA) . . . . . . . . . . . . . . . . . . . . . . . . 44, 51Story Landis (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 22Anthony Lang (Canada). . . . . . . . . . . . . . . . . . . . . 44, 51J. William Langston (USA) . . . . . . . . . . . . . . . . . . 21, 36, 43Peter Lansbury (USA) . . . . . . . . . . . . . . . . . . . . . . 23, 27, 28Michael Lee (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 29Virginia Lee (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 23Andrew Lees (UK). . . . . . . . . . . . . . . . . . . . . . . . . . 18, 38Joy Leffler (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 42Michael Lerner (USA) . . . . . . . . . . . . . . . . . . . . . . 24Carol Levine (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 38Irene Litvan (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 38Sheree Loftus (USA) . . . . . . . . . . . . . . . . . . . . . . . 34, 50Andres Lozano (Canada) . . . . . . . . . . . . . . . . . . . 30Melanie Maar (Austria). . . . . . . . . . . . . . . . . . . . . 18Heather MacTavish (USA) . . . . . . . . . . . . . . . . . . 37Kathleen Maguire-Zeiss (USA) . . . . . . . . . . . . . . 29Silvia Mandel (Israel) . . . . . . . . . . . . . . . . . . . . . . . 22Yael Manor (Israel) . . . . . . . . . . . . . . . . . . . . . . . . . 50, 29Bala Manyam (USA). . . . . . . . . . . . . . . . . . . . . . . . 32Demetrius Maraganore (USA) . . . . . . . . . . . . . . 22Karen Marder (USA) . . . . . . . . . . . . . . . . . . . . . . . 20, 22, 27Kenneth Marek (USA) . . . . . . . . . . . . . . . . . . . . . . 25, 29Jill Marjama-Lyons (USA) . . . . . . . . . . . . . . . . . . . 50Laura Marsh (USA) . . . . . . . . . . . . . . . . . . . . . . . . 29, 51Jeffrey Martin (USA) . . . . . . . . . . . . . . . . . . . . . . . 38Marta Martinez-Vicente (USA) . . . . . . . . . . . . . . 31Eliezer Masliah (USA). . . . . . . . . . . . . . . . . . . . . . . 22, 29, 35

David McFarland (USA). . . . . . . . . . . . . . . . . . . . . 34Patrick McGeer (Canada). . . . . . . . . . . . . . . . . . . 31Ronald McKay (USA) . . . . . . . . . . . . . . . . . . . . . . . 22, 27, 45Kevin McNaught (USA) . . . . . . . . . . . . . . . . . . . . . 28Eldad Melamed (Israel) . . . . . . . . . . . . . . . . . . . . . 44Jonathan Mink (USA). . . . . . . . . . . . . . . . . . . . . . . 46Suzanne Mintz (USA) . . . . . . . . . . . . . . . . . . . . . . . 38Yoshikuni Mizuno (Japan) . . . . . . . . . . . . . . . . . . . 20, 27Erwin Montgomery (USA) . . . . . . . . . . . . . . . . . . 28Orna Moore (Israel) . . . . . . . . . . . . . . . . . . . . . . . . 29, 39, 43, 48, 51Micaela Morelli (Italy) . . . . . . . . . . . . . . . . . . . . . . . 39David Morley (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . 33Meg Morris (Australia) . . . . . . . . . . . . . . . . . . . . . 25, 28Miguel Nicolesis (Brazil) . . . . . . . . . . . . . . . . . . . . 30Mia Nilsson (Sweden) . . . . . . . . . . . . . . . . . . . . . . 41Paul Nussbaum (USA). . . . . . . . . . . . . . . . . . . . . . 43Robert Nussbaum (USA) . . . . . . . . . . . . . . . . . . . 23John Nutt (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 23, 44José Obeso (Spain). . . . . . . . . . . . . . . . . . . . . . . . . 17, 48Wolfgang Oertel (Germany). . . . . . . . . . . . . . . . . 17, 29, 35, 38C. Warren Olanow (USA) . . . . . . . . . . . . . . . . . . . 17, 18, 28Nancy Pearson (USA) . . . . . . . . . . . . . . . . . . . . . . 24Joel Perlmutter (USA) . . . . . . . . . . . . . . . . . . . . . . 36Dan Perry (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 33Leonard Petrucelli (USA) . . . . . . . . . . . . . . . . . . . 28Ron Pfeiffer (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 29Sandra Picot (USA) . . . . . . . . . . . . . . . . . . . . . . . . 40Zvezdan Pirtosek (Slovenia) . . . . . . . . . . . . . . . . . 26Werner Poewe (Austria) . . . . . . . . . . . . . . . . . . . 17, 29Jennie Posen (Israel) . . . . . . . . . . . . . . . . . . . . . . . 29, 48, 51Serge Przedborski (USA) . . . . . . . . . . . . . . . . . . . 28, 31, 35Kimberly Quaid (USA) . . . . . . . . . . . . . . . . . . . . . . 36Maryka Quik (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 27Remi Quirion (Canada) . . . . . . . . . . . . . . . . . . . . . 22Lorraine Ramig (USA) . . . . . . . . . . . . . . . . . . . . . . 24, 34, 50Olivier Rascol (France). . . . . . . . . . . . . . . . . . . . . . 17, 44Bernard Ravina (USA) . . . . . . . . . . . . . . . . . . . . . . 27Kathleen Reardon (USA). . . . . . . . . . . . . . . . . . . . 35Avinoam Reches (Israel) . . . . . . . . . . . . . . . . . . . . 49Stephen Reich (USA) . . . . . . . . . . . . . . . . . . . . . . . 27Irene Richard (USA) . . . . . . . . . . . . . . . . . . . . . . . . 47, 51Peter Riederer (Germany) . . . . . . . . . . . . . . . . . . 28, 35Beate Ritz (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Webster Ross (USA) . . . . . . . . . . . . . . . . . . . . . . . 20Lucy Roucis (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 49Oliver Sacks (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 23, 24Cristina Sampaio (Portugal). . . . . . . . . . . . . . . . . 39Joan Samuelson (USA) . . . . . . . . . . . . . . . . . . . . . 21Anthony Schapira (UK) . . . . . . . . . . . . . . . . . . . . . 28Michael Schlossmacher (USA) . . . . . . . . . . . . . . 23Richard Schulz (USA). . . . . . . . . . . . . . . . . . . . . . . 48Michael Schwarzschild (USA) . . . . . . . . . . . . . . . 39Kapil D. Sethi (USA) . . . . . . . . . . . . . . . . . . . . . . . . 18, 28, 35Kathleen Shannon (USA) . . . . . . . . . . . . . . . . . . . 38, 43

70

FACULTY

Jie Shen (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31Ira Shoulson (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 25, 39, 48, 51Lisa Shulman (USA) . . . . . . . . . . . . . . . . . . . . . . . . 30, 33, 38, 43Andrew Siderowf (USA) . . . . . . . . . . . . . . . . . . . . 17Bernard Siegel (USA). . . . . . . . . . . . . . . . . . . . . . . 33Eric Siemers (USA). . . . . . . . . . . . . . . . . . . . . . . . . 25Horst Simon (Germany) . . . . . . . . . . . . . . . . . . . . 22Andrew Singleton (USA) . . . . . . . . . . . . . . . . . . . . 21Craig Smith (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 48Evan Y. Snyder (USA) . . . . . . . . . . . . . . . . . . . . . . . 46Maria Spillantini (UK) . . . . . . . . . . . . . . . . . . . . . . . 20Mark Stacy (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 47David Standaert (USA) . . . . . . . . . . . . . . . . . . . . . 40, 43Leonidas Stefanis (Greece) . . . . . . . . . . . . . . . . . 23Matthew Stern (USA) . . . . . . . . . . . . . . . . . . . . . . 18, 36Barbara Stewart (USA) . . . . . . . . . . . . . . . . . . . . 30, 47Fabrizio Stocchi (Italy) . . . . . . . . . . . . . . . . . . . . . . 18, 48Jon Stoessl (Canada). . . . . . . . . . . . . . . . . . . . . . . 25Lorenz Studer (USA) . . . . . . . . . . . . . . . . . . . . . . . 46, 51David Sulzer (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 23, 31D. James Surmeier (USA) . . . . . . . . . . . . . . . . . . 40Clive Svendsen (USA). . . . . . . . . . . . . . . . . . . . . . . 46Ryosuke Takahashi (Japan) . . . . . . . . . . . . . . . . . 31Eng King Tan (Singapore) . . . . . . . . . . . . . . . . . . . 36, 43Haruko Tanji (Japan) . . . . . . . . . . . . . . . . . . . . . . . 30Caroline Tanner (USA) . . . . . . . . . . . . . . . . . . . . . . 20, 27Bill Tenhoor (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . 42Deborah Theodoros (Australia) . . . . . . . . . . . . . 24, 42, 50Cathi Thomas (USA). . . . . . . . . . . . . . . . . . . . . . . . 31Marge Thurin (USA). . . . . . . . . . . . . . . . . . . . . . . . 49Nancy Tingey (UK). . . . . . . . . . . . . . . . . . . . . . . . . . 41Eduardo Tolosa (Spain) . . . . . . . . . . . . . . . . . . . . . 18, 38Concetta Tomaino (USA) . . . . . . . . . . . . . . . . . . . 37, 43

Anna Lena Törnqvist (Sweden). . . . . . . . . . . . . . 30, 35Karol Traviss (Canada) . . . . . . . . . . . . . . . . . . . . . 32John Trojanowski (USA) . . . . . . . . . . . . . . . . . . . . 22Brenda Tucker (USA) . . . . . . . . . . . . . . . . . . . . . . . 42Enza Maria Valente (Italy) . . . . . . . . . . . . . . . . . . . 21Alberto Vasconcelos (Portugal) . . . . . . . . . . . . . 39, 43Gwen Vernon (USA) . . . . . . . . . . . . . . . . . . . . . . . . 51Miquel Vila (Spain). . . . . . . . . . . . . . . . . . . . . . . . . . 47Francois Vingerhoets (Switzerland). . . . . . . . . . 36, 43Jerrold Vitek (USA). . . . . . . . . . . . . . . . . . . . . . . . . 30Jean-Paul Vonsattel (USA) . . . . . . . . . . . . . . . . . . 20, 22, 27Cheryl Waters (USA). . . . . . . . . . . . . . . . . . . . . . . 17, 25Ray Watts (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 17William Weiner (USA) . . . . . . . . . . . . . . . . . . . . . . 26, 47Mickie Welsh (USA) . . . . . . . . . . . . . . . . . . . . . . . . 40Olie Westheimer (USA). . . . . . . . . . . . . . . . . . . . . 25Carol Whitlatch (USA) . . . . . . . . . . . . . . . . . . . . . . 39Peggy Willocks (USA). . . . . . . . . . . . . . . . . . . . . . . 32, 46, 51Benjamin Wolozin (USA) . . . . . . . . . . . . . . . . . . . . 31Erik Wolters (The Netherlands) . . . . . . . . . . . . . 40Nicholas Wood (UK). . . . . . . . . . . . . . . . . . . . . . . . 22Zbigniew Wszolek (USA). . . . . . . . . . . . . . . . . . . . 21, 27Wolfgang Wurst ( Germany). . . . . . . . . . . . . . . . 22Mitsutoshi Yamamoto (Japan) . . . . . . . . . . . . . . 48Nobuo Yanagisawa (Japan) . . . . . . . . . . . . . . . . . 38, 43Justo Garcia de Yébenes (Spain). . . . . . . . . . . . 44Moussa Youdim (Israel). . . . . . . . . . . . . . . . . . . . . 28Anne Young (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 23, 27Heather Young (USA) . . . . . . . . . . . . . . . . . . . . . . 39, 50Luigi Zecca (Italy). . . . . . . . . . . . . . . . . . . . . . . . . . . 23Kathryn Zerbe (USA) . . . . . . . . . . . . . . . . . . . . . . . 30Michael Zigmond (USA) . . . . . . . . . . . . . . . . . . . . 28, 32

Novartis and Orion are proud to be the soleplatinum-level sponsor of the World Parkinson Congress

Please visit us at booth 401

Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 © 2006 Novartis Printed in USA 1/06 SLV-AD-0430-A

Keep moving forward!

72

EXHIBITOR DIRECTORY

American Academy of Neurology1080 Montreal AvenueSaint Paul, MN 55116Phone: (800) 879-1960 or (651) 695-2717Fax: (651) 695-2791Email: [email protected]: www.aan.com/www.thebrainmatters.orgBooth Number: 217

The American Academy of Neurology (AAN) is an internationalprofessional association of nearly 19,000 neurologists andneuroscience professionals dedicated to providing the best possiblecare for patients with neurological disorders.

The American Occupational Therapy Association4710 Montgomery LaneBethesda, MD 20814Phone: (301) 652-6611Fax: (301) 656-3218Email: [email protected] Number: 425A

The American Occupational Therapy Association (AOTA) is thenationally recognized professional association of approximately35,000 occupational therapists, occupational therapy assistants,and students of occupational therapy.

American Parkinson Disease Association, Inc.1250 Hylan Boulevard, Suite 4-BStaten Island, NY 10305Phone: (800) 223-2732Fax: (718) 981-4399Website: www.apdaparkinson.orgBooth Number: 327

The American Parkinson Disease Association is a non-profitorganization founded in 1901, dedicated “to ease the burden andfind the cure” for PD patients and caregivers through research,patient services, education, public awareness and patient advocacy.

American Physical Therapy Association1111 N. Fairfax StreetAlexandria, VA 22314Phone: (703) 706-3215Fax: (703) 706-8578Website: www.apta.orgBooth Number: 221

The American Physical Therapy Association is a nationalprofessional organization representing 68,000 members. Its goal isto foster advancements in physical therapy practice, research andeducation.

American Speech-Language-Hearing Association10801 Rockville PikeRockville, MD 20852Phone: (800) 638-5255Website: www.asha.comBooth Number: 518

The American Speech-Language-Hearing Association (ASHA) is theprofessional, scientific and credentialing association for over120,000 speech-language pathologists, audiologists and speech,language and hearing scientists.

Applied Neurology Magazine600 Harrison Street, Floor 6San Francisco, CA 94107Phone: (800) 947-6488Fax: (415) 947-6099Email: [email protected]: www.appneurology.comBooth Number: 510

Applied Neurology magazine provides clinical information presentedin the context of day-to-day practice. Staff and clinician writtencontent focuses on clinical medicine, including reviews of scientificresearch and its clinical applications, professional development andpractice recommendations, news and meeting coverage, disciplineperspectives, case studies and pharmacology overviews, all from apractical perspective.

Aquatics by SprintP.O. Box 3840San Luis Obispo, CA 93403-3840Phone: (800) 235-2166Email: [email protected]: www.sprintaquatics.comTable Number: 421

Sprint has a DVD on water exercises for Parkinson’s patients. Sprinthas also developed a swim suit for women with PD to get in and outof more easily.

Athena Diagnostics, Inc.Four Biotech Park377 Plantation StreetWorcester, MA 01605Phone: (508) 756-2886 x3028Fax: (508) 752-7421Email: [email protected] Number: 413

Founded in 1989, Athena Diagnostics offered the first diagnosticservice for muscular dystrophy. Since then, Athena has focused onneurological, renal and endocrine disorders by offering an extensivemenu of tests. Athena focuses exclusively on assisting physicians intheir efforts to provide the best possible diagnoses of these disorders.

73

EXHIBITOR DIRECTORY

Boehringer Ingelheim Pharmaceuticals, Inc.900 Ridgebury RoadRidgefield, CT 06877Phone: (203) 798-9988Website: us.boehringer-ingelheim.comBooth Number: 201

Boehringer Ingelheim Pharmaceuticals, Inc. is an internationalresearch-based pharmaceutical company focusing onrheumatology, neurology, pulmonology, urology and cardiology.Please visit the Boehringer Ingelheim exhibit to discuss the latestclinical information on Mirapex® (pramipexole dihydrochloride).

Boston Life Sciences85 Main StreetHopkinton, MA 01748Phone: (508) 497-2360Fax: (508) 497-9964Email: [email protected]: www.BostonLifeSciences.comBooth Number: 226

Boston Life Sciences develops diagnostics and therapeutics forcentral nervous system disorders including PD and stroke. BLSI isenrolling a Phase ll trial (POET – Parkinson’s or Essential Tremor)for the diagnosis of Parkinsonian Syndrome in persons with tremor.Current research collaborations include Harvard Medical, Children’sHospital of Boston, University of Massachusetts-Worcester.

ChatterVox.com39 Crestland RoadIndian Creek, IL 60061Phone: (888) 888-9060Fax: (847) 816-8581Email: [email protected]: www.chattervox.comBooth Number: 224

Light weight, portable voice amplifier so that people with Parkinson’scan be heard in their own voice.

CIR Systems – Gaitrite60 Garior DriveHavertown, PA 19083Phone: (610) 449-4879Fax: (610) 853-2925Email: [email protected]: www.gaitrite.comBooth Number: 112

GAITRite is an easy to use, commercially available gait analysissystem that instantaneously measures cadence step length, baseof support, velocity and many other important gait parameters. Theelectronic walkway is 1/8" thick, 2-feet wide by 14-feet long andcontains 16,128 sensors. Finally, you can accurately evaluatetemporospatial gait performance outside the laboratory by takingGAITRite into community centers, nursing homes and independentliving facilities.

CleveMed4415 Euclid AvenueCleveland, OH 44105Phone: (216) 791-6720Fax: (216) 791-6739Email: [email protected]: www.clevemed.comBooth Number: 418

ParkinSenseTM is a small, lightweight, wireless system worn on thehand and wrist for monitoring Parkinson’s motor symptoms. Thesystem hardware monitors three-dimensional motion andelectromyography. The software displays movies that instructsubjects through upper extremity Unified Parkinson’s DiseaseRating Scale motor tasks and automatically quantifies results.

CNP Professionals2800 Ayers AvenueLos Angeles, CA 92352Phone: (323) 415-8544Fax: (323) 268-4068Email: [email protected]: www.dyapproved.comBooth Number: 219

We will be exhibiting the Hora System of treatment for Parkinson’spatients. It was developed in Germany and has been formallyendorsed by the German Parkinson’s Association.

74

Coakley Cane Company7520 Connelly DriveHanover, MD 21076Phone: (410) 766-4053Email: [email protected]: www.coakleycane.comTable Number: 419

You will almost want to sleep with The Coakley Cane—you’ll love it somuch! Designed for your hand; engineered for your body. New foundfreedom, security and ease of use combined with ability to enjoyyour life with rediscovered abilities like beach walking. It will changeyour life again.

Elsevier, Inc.8701 Ivyberry WayGaithersburg, MD 20886Phone: (301) 527-9248Fax: (301) 527-9038Booth Number: 115

Elsevier Inc. is the world’s leading publisher of medical books andperiodicals. Please stop by our booth to view the latest titles inneurology and Parkinson disease.

EMD Pharmaceuticals (affiliate of Merck KG&A)3211 Shannon Road, Suite 500Durham, NC 27707Phone: (919) 401-7100Website: www.emdpharmaceuticals.comBooth Number: 211

EMD Pharmaceuticals is focused on developing novel products forpeople suffering from serious illnesses. Headquartered in Durham,N.C., EMD is the U.S. affiliate of Merck KGaA, Darmstadt Germany.

European Parkinson’s Disease Association4 Golding RoadSevenoaks, Kent TN13 3NJUnited KingdomPhone: +44 (0) 1732 457 683Fax: +44 (0) 7787 554 856Email: [email protected]: www.epda.eu.comTable Number: 520 A

The EPDA is a non-political, non-religious and non-profit organizationwith the aim of developing a dialogue between science and society.Close collaboration with international patient and neurologicalorganizations, the European Commission, World Health Organization,World Federation of Neurology and the pharmaceutical industry hasresulted in the development of Qol Research projects, educationmaterials and multidisciplinary conferences.

FHC, Inc.9 Maine Street Bowdingham, ME 04287-7302Phone: (207) 666-5651Fax: (207) 666-8292Email: [email protected]: www.fh-co.comBooth Number: 415

FHC’s microTargeting® products are used in the placement of DBSelectrodes to treat symptoms of PD and other movementdisorders. FHC’s microTargeting® Platform (2004 MDEA goldaward winner) streamlines functional neurosurgery; it attaches toanchors just before surgery, allowing frame-free patient comfortand can be configured for simultaneous bilateral procedures.

Georgetown University Hospital3800 Reservoir RoadWashington, DC 20007Phone: (202) 444-3942Fax: (202) 444-4395Email: [email protected]: www.georgetownuniversityhospital.orgBooth Number: 117

Georgetown offers the most thorough evaluations, accuratediagnosis and treatments to manage Parkinson’s disease, essentialtremor and other movement disorders with optimum results.Georgetown has the full complement of leading technologies likeDeep Brain Stimulation (DBS) and research to improve the quality oflife for patients suffering from movement disorders.

GlaxoSmithKlineFive Moore DriveResearch Triangle Park, NC 27709Phone: (888) 825-5249Fax: (919) 315-6049Website: www.gsk.comBooth Number: 109

GlaxoSmithKline offers a number of programs to support effectivehealth management strategies and improve patient care. Visit ourexhibit for information about our products and programs.

EXHIBITOR DIRECTORY

75

EXHIBITOR DIRECTORY

Hilton Grand Vacations Club1301 Pennsylvania Avenue NW Suite 1020Washington, DC 20004Phone: (202) 393-0582Fax: (202) 638-2945Email: [email protected]: www.hiltongrandvacations.comBooth Number: 420

Hilton Grand Vacations Club (HGVClub) is the vacation ownershipdivision of Hilton Hotels Corporation. With 27 beautifully appointedresorts in some of the world’s top vacation destinations, HGVClubprovides luxury accommodations with an array of superioramenities and services. Show attendees will be offered specialvacation packages to Orlando, Las Vegas, Hawaii and New York.

IMPAX Pharmaceuticals30831 Huntwood AvenueHayward, CA 94544Phone: (510) 476-2000Fax: (510) 471-3200Website: www.impaxlabs.comBooth Number: 512

IMPAX Pharmaceuticals is dedicated to bring innovative treatmentto help physicians help their patients with neurological disorders.

Indiana University Medical & Molecular GeneticsPROGENI975 West Walnut Street, Suite 130Indianapolis, IN 46202Phone: (888) 830-5299 or (317) 274-5734Fax: (317) 278-4507Email: [email protected]: www.proeni.iu.eduBooth Number: 118

PROGENI is a national, NIH-funded genetic research project, enrollingfamilies with two or more living siblings with Parkinson’s disease.

In-Step Mobility Products8136 N. LawndaleSkokie, IL 60076Phone: (847) 676-1275Fax: (847) 676-1202Email: [email protected]: www.ustep.comBooth Number: 424

In-Step Mobility Products is a manufacturer of two Parkinsonproducts: U-Step walking stabilizer – an advanced and easy-to-usewalker which can be fitted with our laser module to reduce freezing.Laser Cane is for those seeking minor walking support with freeze-reduction technology.

Interactive Health3030 Walnut AvenueLong Beach, CA 90807Phone: (562) 426-8700Fax: (562) 426-9690Website: www.interhealth.comBooth Number: 320

Interactive Health designs, develops, manufactures and sellsinnovative, high-quality massage and lifestyle products that create abetter and healthier way of life.

17th International Congress on Parkinson’s Disease and Related DisordersPaulsborner Strasse 44D–14193 Berlin GermanyPhone: 030-30 06 69-0Fax: 030-30 57 391Email: [email protected] Number: 508

17th International Congress on Parkinson’s disease and RelatedDisorders will take place on December 9–13, 2007, in Amsterdam.This congress focus on the brain machinery enabling theorchestration of our behavior: the working brain visualized by MRI,PET and SPECT, MEG and ulrasonography. The spectrum of clinicaldisorders covered by the congress includes, but is not limited to,Parkinson’s disease and genetic/familial/vascular/traumatic/toxic/iatrogenic and otherwise induced parkinsonism, tardrivedyskinesia, dementia with Lewy bodies, restless legs syndrome,multiple system atrophy, progressive supranuclear palsy, cortico-basal-gangliadegeneration, frontotemporal dementia withparkinsonism, gait disorders, tremor, tic disorders and dystonia.

Karger Publishers26 West Avon RoadPO Box 529Farmington, CT 06085Phone: (860) 675-7834Fax: (860) 675-7302Email: [email protected]: www.karger.comBooth Number: 100

Publications on display include the monograph NeurologicalDisorders in Gerontology; Neurodegenerative Diseases;Neuroembryology and Aging; Neuroepidemiology;Neuropsychobiology; Neurosignals; and the book series Frontiers ofNeurology and Neuroscience.

76

EXHIBITOR DIRECTORY

Kyowa Hakko Kogyo Co., Ltd.1-6-1 Ohtemachi Chiyoda-KuTokyo, JAPAN 100-8185Phone: (81) 3-3782-0007Website: www.kyowa-kpi.comBooth Number: 301

Kyowa Hakko Kogyo Co., Ltd. is one of Japan’s foremostbiotechnology companies. Kyowa is pursuing internationaldevelopment of a number of NCE drug candidates.

Lewy Body Dementia AssociationP.O. Box 11390 Tempe, AZ 85284-0024Phone: (800) LEWYSOS (800-539-9767)Fax: (480) 422-5434Email: [email protected]: www.LewyBodyDementia.orgTable Number: 522 A

Through education and outreach, the Lewy Body DementiaAssociation supports those affected by Lewy body dementias andpromotes research for a cure.

Lippincott, Williams & Wilkins202 9th Street SEWashington, DC 20003Phone: (202) 543-8710Fax: (202) 543-8734Website: www.lww.comBooth Number: 514

Lippincott, Williams & Wilkins publishes medical books, journals andsoftware.

Luminaud, Inc.8688 Tyler RoadMentor, OH 44060Phone: (800) 255-3408Fax: (440) 255-2250Email: [email protected]: www.luminaud.comBooth Number: 426

PERSONAL VOICE AMPLIFIERS – A wide variety of amplifiers andmicrophones to suit all needs for increasing voice volume. Also voiceamplifying telephones and other communication devices. Switchesfor minimal movement capability to control battery and line powereddevices such as lights, fans, radios Tracheostoma covers and filters.

M. Yahr International Parkinson’s Disease Foundation1241 Flagler DriveMamaroneck, NY 10543Phone: (914) 698-7580Booth Number: 427 A

MYIPDF promotes excellence in neurological training, patient careand scientific research related to Parkinson's disease by offeringfinancial aid to residents, fellows and junior researchers forattending appropriate scientific meetings.

MDS Pharma ServicesThe Triad, 2200 Renaissance Boulevard, Suite 400King of Prussia, PA 19406-2755Phone: (610) 239-7900Fax: (610) 239-7111Email: [email protected]: www.mdsps.comBooth Number: 325

The MDS Pharma Services Pharmacology division offers anextensive selection of biochemical, cellular, tissue and organ andanimal assays used in profiling a compound’s efficacy, specificity,selectivity and toxicity. Parkinson’s Disease rodent models includeMPTP and 6-OHDA. View our online assay catalog of more than800 assays and services at www.mdsps.com

Medtronic, Inc.710 Medtronic ParkwayMinneapolis, MN 55632Phone: (763) 505-5000Website: www.medtronic.comBooth Number: 409

Activa® deep brain stimulation therapy from Medtronic representsan advancement in the treatment of the three most commonmovement disorders: Parkinson’s disease, Essential Tremor andDystonia. Activa® Therapy can dramatically improve the quality of“On” time for people with Parkinson’s disease. More than 30,000people worldwide have received Activa® Therapy.

Michael J. Fox Foundation for Parkinson’s ResearchGrand Central StationP.O. Box 4777New York, NY 10163Phone: (800) 708-7644Fax: (212) 509-2390Website: www.michaeljfox.orgBooth Number: 126

The Michael J. Fox Foundation is dedicated to finding a cure forParkinson’s disease within this decade and has funded over $70million for research.

77

EXHIBITOR DIRECTORY

Monitoring Force USA, Inc.888 Seventeenth Street NW Suite 640Washington, DC 20006Phone: (443) 321-3798Fax: (410) 295-3992Email: [email protected]: www.monitoring-force.comBooth Number: 102

Monitoring Force is a full-service CRO (Contract ResearchOrganization). We design, implement and manage global and localPhase I to IV clinical trials in all therapeutic areas through 13affiliate entities in 10 countries. We offer a comprehensive range ofclinical trial management services, with specific centers ofexcellence in our international organization.

Movement Disorder Society555 E. Wells Street, Suite 1100Milwaukee, WI 53202Phone: (414) 276-2145Fax: (414) 276-3349Email: [email protected]: www.movementdisorders.orgBooth Number: 106

The Movement Disorder Society (MDS) is an international,professional society of clinicians and scientists interested inParkinson’s disease and related neurodegenerative andneurodevelopmental disorders. The goals of the Society are todisseminate knowledge, facilitate research and promote training inMovement Disorders.

Movers & Shakers, Inc.15275 Collier Boulevard #201 Box 151Naples, FL 34119Phone/Fax: (239) 304-2241Email: [email protected]: www.pdadvocates.orgTable Number: 526

Movers and Shakers, Inc. is a national organization dedicated tosupport, advocacy, outreach and education of those with youngonset Parkinson’s and the community at large through programsand a network of partnering organizations.

Muhammad Ali Parkinson Center – Registry500 W. Thomas Road #720Phoenix, AZ 85013Phone: (602) 406-6315Fax: (602) 406-3434Email: [email protected]: www.maprc.comTable Number: 522 B

Enrollment and information about the PD Registry.

National Center for Complementary and Alternative MedicineBuilding 31, Room 2B11 National Institutes of HealthBethesda, MD 20892-2182Phone: (888)644-6226 or (301) 435-6826Fax: (301) 435-6549Email: [email protected]: http://www.nccam.nih.govBooth Number: 316

The National Center for Complementary and Alternative Medicine(NCCAM), part of the National Institutes of Health, is dedicated toexploring complementary and alternative healing practices in thecontext of rigorous science, training complementary and alternativemedicine (CAM) researchers and disseminating authoritativeinformation to the public and professionals.

National Parkinson Foundation1501 NW 9th AvenueMiami, FL 33136Phone: (305) 243-8145Fax: (305) 243-7851Email: [email protected]: www.parkinson.orgBooth Number: 319

The National Parkinson Foundation (NPF) is dedicated to supportingresearch and providing education, support advocacy and outreach to theParkinson community. NPF serves people with Parkinson disease andtheir families. NPF has a relationship with scientists conducting researchand practitioners offering services, support and outreach through NPFCenters of Excellence, NPF Outreach Centers and NPF chapters.

Neurotoxin Exposure Treatment Research ProgramHQ, USAMRMC; Attn: MCMR-ZBDRO (S.Grate)504 Scott StreetFt. Detricke, MD 21702Phone: (301) 619-6631Fax: (301) 619-2416Email: [email protected] Number: 124

Description of mission and function of Neurotoxin ExposureTreatment Research Program.

78

EXHIBITOR DIRECTORY

NextStep®

3227 Wellington CourtRaleigh, NC 27615Phone: (888) 344-7637Fax: (208) 275-6789Email: [email protected]: www.icanstep.comTable Number: 423

Win back your independence with the NextStep®. Called a“miraculous breakthrough” by leading neurologists, it’s a walking aidinvented by a Parkinson’s patient that liberates sufferers of“freezing” episodes with the use of the visual cue wand.

NIH/NINDS31 Center Drive, Building 31 Room 8A07Bethesda, MD 20892-2540Phone: (301) 496-5751Fax: (301) 402-2186Email: [email protected]: www.ninds.nih.govBooth Number: 218

The National Institute of Neurological Disorders and Stroke (NINDS)provides information about available research support and offersfree publications for patients and their families on Parkinson’sdisease and related disorders. Members of the NINDS staff will beavailable to assist you. Printed material is available.

Novartis Pharma AGLichstrasse 35WSJ 310.126Basel CH-4002SwitzerlandPhone: +41 61 324 6954Fax: +41 61 324 6652Website: www.Novartis.comBooth Number: 401

Novartis AG is a world leader in pharmaceuticals and consumerhealth, headquartered in Basel, Switzerland. Novartis researches,develops, manufactures and markets leading innovative prescriptiondrugs used to treat a number of diseases and conditions and hasbeen a leader in the Neuroscience area for more than 50 years.

Orion Corporation Orion PharmaOrionintie 1FI-02101 EspooFinlandTel: + 358 10 429 4701Fax: + 358 10 429 3815Website: www.orion.fi/englishBooth Number: 401

Orion Pharma, the pharmaceutical division of the Orion Group, is aNorth European R&D-based, business-driven pharmaceuticalscompany with special emphasis on developing innovative treatmentsfor global markets. The R&D and product strategies are focused oncentral nervous system disorders, cardiovascular diseases andintensive care and hormone therapies.

PAL Publishing Co.8 Carmine StreetChatham, NJ 07928Phone: (973) 635-7937Fax: (973) 635-8198Email: [email protected]: www.palpublishing.comBooth Number: 324

PAL Publishing is a conduit for the books written by Paul Luscombe.His books include: Play the Game Right, a biography on basketballcoach Butch van Breda Kolff, who had PD; Give Dad a Mulligan, ahumorous book about golf, with reflections on PD in the finalchapter; Howard Powerless, a history of the rise and fall of aprominent NJ savings bank; and Pills, Bills & Parkinson’s Diseasetackles his own personal battle with Parkinson’s.

Parkinson AllianceP.O. Box 308Kingston, NJ 08528Phone: (800) 579-8440Fax: (609) 688-0875Email: [email protected]: www.parkinsonalliance.orgTable Number: 524 A

The Parkinson Alliance is a national non-profit organizationdedicated to raising funds to help finance the most promisingresearch to find the cause and cure for PD. Through the support ofThe Tuchman Foundation and our numerous partnerships, weguarantee that 100% of all individual donations and net proceedsfrom events go directly to research.

79

EXHIBITOR DIRECTORY

Parkinson’s Association of LouisianaP.O. Box 10303New Orleans, LA 70181Phone: (504) 952-6659Email: [email protected]: www.parkinsonsla.orgBooth Number: 524 B

Information, literature, awareness pins, wristbands and car magnets.

Parkinson’s Disease Foundation1359 Broadway, Suite 1509New York, NY 10018Phone: (800) 457-6676 or (212) 923-4700Fax: (212) 923-4778Email: [email protected]: www.pdf.orgBooth Number: 214

The Parkinson’s Disease Foundation (PDF) is a leading nationalpresence in Parkinson’s disease research, patient education andpublic advocacy. PDF is working for the nearly one million people inthe U.S. living with Parkinson’s by funding promising scientificresearch and supporting people with Parkinson’s, their families andcaregivers through educational programs and support services.Since its founding in 1957, PDF has funded more than $50 millionworth of scientific research in Parkinson’s disease, supporting thework of leading scientists throughout the world.

Parkinson’s Institute1170 Morse AvenueSunnyvale, CA 94089Phone: (408) 734-2800Fax: (408) 734-8522Website: www.thepi.orgBooth Number: 121

The Parkinson’s Institute has programs in basic and clinicalresearch, operates a Movement Disorder Clinic, offers Speech andPhysical Therapy and provides outreach and education programs.

Parkinson Pipeline Project3914 Harrison Street NWWashington, DC 20015Phone: (202) 686-9430Email: [email protected]: www.pdpipeline.orgTable Number: 520 B

Information (print and electronic) on involvement of PWP in thetreatment, development and clinical trials processes. Introduction ofa trial participants’ Bill of Rights.

Parkinson Study Group1351 Mt. Hope Avenue Suite 223Rochester, NY 14620Phone: (585) 275-1068Fax: (585) 273-1074Email: [email protected]: www.parkinson-study-group.orgTable Number: 427 B

The Parkinson Study Grop (PGS) is a non-profit, cooperative group ofParkinson’s disease experts from medical centers in the UnitedStates and Canada who are dedicated to improving treatment forpersons affected by Parkinson’s disease through clinical andobservational research.

Schwarz Pharma, LLC6140 W. Executive DriveMequon, WI 53092Phone: (262) 238-9994Fax: (262) 238-0961Website: www.schwarzusa.comBooth Number: 313

SCHWARZ PHARMA develops therapies for neurology and urologyconditions. Current development projects include: Parkinson’sdisease, restless legs syndrome, epilepsy, neuropathic pain andoveractive bladder syndrome.

Signet Laboratories, Inc.180 Rustcraft Road Suite 140Dedham, MA 02026Phone: (800) 223-0796 or (781) 329-7919Fax: (781) 961-2456Email: [email protected]: www.signetlabs.comBooth Number: 318

Signet Laboratories, Inc. (Signet, Dedham, MA) is a leading medicaldiagnostics/research company specializing in the development ofmonoclonal antibodies and diagnostics assays for cancer, infectiousdisease and neurodegenerative disease. Signet was created in1989 as a commercial spinout of Johnson & Johnson’s CambridgeResearch Laboratories, Inc. (CRL, Cambridge, MA). Signet hasimplemented aggressive licensing and development programs,responsible for its broad patent and intellectual estate andexpansion into neurodegenerative diseases.

80

Solvay Pharmaceuticals GmbHHans-Boeckler-Allee 20Hannover 30173GermanyPhone: +49 511 857 3199Fax: +49 511 857 3319Email: [email protected] Number: 326

SOLVAY PHARMACEUTICALS, a research driven group ofpharmaceutical companies in Solvay that seeks to fulfill carefullyselected, unmet medical needs in the therapeutic areas ofneuroscience, cardio-metabolic, influenza vaccines, pancreaticenzymes, gastroenterology and men’s and women’s health. SolvayPharmaceuticals employs about 13,000 people worldwide after theacquisition of Fournier Pharma in July 2005.

Valeant Pharmaceuticals3300 Hyland AvenueCosta Mesa, CA 92626Phone: (714) 545-0100Fax: (714) 668-3239Website: www.valeant.comBooth Number: 101

Valeant Pharmaceuticals North America (NYSE:VRX) is a unique,global, research-based specialty pharmaceutical company thatdiscovers, develops, manufactures and markets pharmaceuticalproducts in three therapeutic areas: neurology, infectious diseaseand dermatology.

National VA Parkinson’s Disease ConsortiumPhiladelphia VA Medical CenterUniversity & Woodland Avenues (127)Philadelphia, PA 19104Phone: (215) 823-5394Fax: (215) 823-5815Website: www.parkinsons.va.govBooth Number: 122

The National Veterans Affairs Parkinson’s Disease Consortium wasestablished to encourage progressive Parkinson’s care, througheducation and training across the collective VA healthcare system.

VernalisOakdene CourtWinnershBerks RG41 5UAUnited KingdomPhone: +44 (0) 118 977 3133Fax: +44 (0) 118 989 9300Website: www.vernalis.comBooth Number: 307

Vernalis is a specialty pharmaceutical company focused on productsmarketed to specialist neurologists, with strong franchises inParkinson’s disease and pain. The company has two marketedproducts, frovatriptan and Apokyn®.

Vitaline Formulas825 Challenger DriveGreen Bay, WI 54311Phone: (800) 287-5972Fax: (888) 570-6460Email: [email protected]: www.vitalinecoq10.comBooth Number: 127

For more than 20 years, Vitaline has been involved in the study ofCoQ10’s effects on neurological health. More than 25 research-institute-sponsored clinical studies have used Vitaline CoQ10. VitalineCoQ10 has been designated an Orphan Drug and has severalpatent-pending files.

WE MOVE204 W. 84th StreetNew York, NY 10024Phone: (212) 875-8312Fax: (212) 875-8389Email: [email protected]: www.wemove.orgBooth Number: 220

WE MOVE is a not-for-profit organization providing movementdisorder education. Visit www.wemove.org for PD research news,diagnostic and treatment information, online CME and more.

EXHIBITOR DIRECTORY

81

MAP OF EXHIBITS

82

MAP OF CONGRESS FLOOR PLAN

FH

FH

FH

FH

FH

FH

FH

DO

CK

SR

AM

P

DO

CK

S

UP

TO

8'

HA

LL

EH

ALL D

TR

UC

KLO

AD

ING

DR

IVE

-IN

RA

MP

8'

8'

TR

UC

K

RA

MP

& R

EC

YC

LIN

G

CO

MP

AC

TO

R

RO

OM

RO

OM

CO

NC

OU

RS

E

21

0

RO

OM 2

09

B

CONCOURSE

209C

RO

OM

20

9A

BRIDGEL STREET

EN

TR

AN

CE

HA

LL D

CONCOURSE

SERVICE CORRIDOR

RO

OM

20

6

RO

OM

20

7A

20

7B

RO

OM

CO

NC

OU

RS

E

20

8B

20

8A

OP

EN

TO

BE

LO

W

RO

OM

RO

OM

RO

OM

LO

AD

ING

DO

CK

S

DR

IVE

-IN

RA

MP

CONCOURSE

CA

FE

SE

AT

ING

20

4A

204C

20

4B

RA

MP

TR

UC

K

RO

OM

20

5

CONCOURSE

20

2B

SERVICE CORRIDOR

20

3A

20

3B

CO

NC

OU

RS

E

RO

OM

RO

OM

RO

OM

RO

OM

20

2A

RO

OM

20

1

WC

C

ST

OR

AG

E

HA

LL E

EN

TR

AN

CE

Level Two

Exhibit Halls D

&E

Meeting R

ooms

83

MAP OF CONGRESS FLOOR PLAN

E E

30

33

02

30

1

30

43

05

FE

FE

BE

LO

W

HA

LL

D SE

RV

ICE

CO

RR

IDO

RF

EF

E

FE

FEUN

DE

R

CE

ILIN

G:

10' H

IGH

,

BA

LC

ON

Y

KIT

CH

EN

KIT

CH

EN

SERVICE CORRIDOR

EE

TO

OP

EN

BE

LO

W

PRE-FUNCTION

PRE-FUNCTION

BA

LL

RO

OM

B

BA

LL

RO

OM

C

FE

SERVICE CORRIDOR

FE

FE

BA

LC

ON

Y

10' H

IGH

,C

EIL

ING

:

UN

DE

R

30

6

TO

EE

BE

LO

W

OP

EN

SERVICE CORRIDOR

BA

LL

RO

OM

A

FE

E

CA

FE

HA

LL

E

OF

FIC

E

SH

OW

E

BE

LO

W

HA

LL

E

Level ThreeB

allrooms

The World Parkinson Congress would like to thank the following companies for their support:

84

ACKNOWLEDGEMENTS

The World Parkinson Congress would like to thank the following supporters for making this event possible.

Silver Level

Gold Level

Platinum Level

• Boston Life Sciences• FHC, Inc.• Georgetown University Hospital

• Impax Pharmaceuticals• Sharon Klein Graphic Design• Merck Research Laboratories

• MERZ• NeuroBiotec• Vernalis

85

ACKNOWLEDGEMENTS

The organizers of the World Parkinson Congress

wish to thank the following government of f ices, professional

associations, patient voluntary organizations and foundations

without whose grants and f inancial support this Congress

would not be possible:

• New Rhythms Foundation• Bob and Jane Wachsler• Society for Neuroscience • The Mary Duke Biddle Foundation

• James and Wanda HollensteinerFoundation

• Takako Asakawa Richards and PaulRichards Foundation

• VSA arts

• Parkinson Foundation of the NationalCapital Area

• Fondazione Grigioni per il Morbo diParkinson

Additional Supporters:

86

NOTES

87

NOTES

Join us in Paris, France for the nextWorld Parkinson Congress in June 2009!

world parkinson congress - cdn.ymaws.com€¦ · national institutes of neurological disorders and...

Documents